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                                                  ABSTRACT 
 
Neurofibrillary tangles consist of hyperphosphorylated tau, one of the 
pathological hallmarks of Alzheimer’s disease (AD). Alternative splicing of the 
tau pre-mRNA produces six tau isoforms with or without exon 10 (E10); tau4R or 
tau3R, microtubule binding repeats respectively. In normal human brains the ratio 
of 4R/3R tau is approximately one. Aberrant E10 splicing is also observed in 
some sporadic AD cases as well as Pick’s disease.  
 
The rationale for this study is that abnormal splicing may predispose to 
neurological diseases such as AD either through abnormal expression and/or 
activity of splicing factors that control tau alternative splicing. In particular, 
expression levels of splicing factors regulating tau pre-mRNA splicing may be 
altered in AD and contribute to pathogenesis. 
 
The AD model used was dependent on the presence or absence of TDP43 
inclusions because approximately 30 % of AD cases have inclusions of the RNA 
binding protein, TDP-43 which may contribute to the clinical phenotypes 
observed in these cases. However TDP-43 is an RNA binding protein known to 
regulate alternative splicing.  In addition, TDP-43 pathology has now been shown 
to co-occur with tau pathology in some tauopathies. Whether the TDP-43 
inclusions in AD is incidental or whether it contributes to more severe clinical 
phenotype remains unresolved. This model was used to determine if TDP43 
pathology in AD exacerbates the changes in splicing factor expression in AD 
cases with TDP43 pathology. 
 
Splicing factors including serine and arginine (SR) rich proteins that either repress 
or promote E10 inclusion and CELF proteins are of particular interest. The brain 
selective CELF3 promotes tau E10 inclusion in vitro by binding to an intronic 
element in tau pre-mRNA. The levels of expression of CELF proteins and SR 
proteins that modulate tau splicing were characterised in five brain regions 
(frontal cortex, temporal cortex, amygdala, hippocampus and cerebellum) using 
  5 
post-mortem brain tissue from AD patients. Tau E10 alternative splicing pattern 
was also analysed in these brain regions. 
 
We investigated the expression levels of CELF proteins (CELF1, CELF3 and 
CELF4) and SR proteins (SC35, SRp40, and SRp55) in AD cases with (+) and 
without (-) TDP-43 inclusions compared to aged-matched controls.  
 
Tau E10 alternative splicing pattern analysis revealed that tau4R was increased in 
the amygdala and hippocampus of AD brain. We found, by quantitative RT-PCR, 
that the expression level of CELF3 RNA is increased in the amygdala and frontal 
cortex of AD cases, regardless of TDP-43 inclusions. Interestingly, in the 
amygdala of ADTDP43- cases where an increase in tau4R is found, we also found 
an increased expression of CELF4, SRp40 and SRp55 RNA. Although CELF3, 
CELF4 and SRp40 promote tau E10 inclusion in vitro, SRp55 inhibits tau E10 
inclusion in vitro; whether this occurs in vivo is unknown. The association of 
abnormal expression of SR proteins and CELF proteins as well as aberrant tau 
E10 splicing in brain regions affected during AD pathogenesis may be a 
contributing factor to disease. 
 
Independent of the role of SR proteins and CELF proteins in sporadic AD, these 
tau splicing factors may be therapeutic targets to correct aberrant tau splicing in 
tauopathies. Future work will determine whether these splicing factors (CELF3, 
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Neurodegenerative diseases include a diverse range of neurological disorders 
characterised by the progressive loss of neuron structure and function, eventually 
leading to neuronal death. This occurs usually within areas of the cerebral cortex, 
basal ganglia, cerebellum, brain stem, motor systems and spinal cord; eventually 
leading to the progressive loss of motor, sensory and perceptual functions.  
 
Neurodegenerative diseases are characterised by both cognitive and functional 
impairments as well as behavioural symptoms. There are several well established 
features of neurodegenerative diseases and Alzheimer’s dementia (AD) in 
particular. These include inflammation; neurotoxicity caused by chemicals or 
other toxic events; increase in free radical species and oxidative damage; loss of 
nerve trophic factors (important in nerve physiology) and loss of nerve cell 
transmission; as well as altered metal ion homeostasis (Dyrks et al., 1993; Lovell 
et al., 1998). Most neurodegenerative diseases are associated with the presence of 
abnormal protein deposits. These protein aggregates can be in the form of 
extracellular deposits such as amyloid plaques or intracellular inclusions within 
the cell body and axons/dendrites of neurons such as tau filaments (Braak and 
Braak, 1992). How the chemistry of the afore-mentioned features that result in the 
generation of radical species contributes to the production of protein deposits and 
hallmarks of neurodegenerative diseases is yet to be fully understood. Moreover, 
understanding the molecular events that lead to dysfunction of usually ‘functional’ 
proteins is paramount to finding a cure to these diseases. 
 
Neurodegenerative diseases are considered as multifactorial conditions, some of 
which have well defined genetic factors as well as several possible environmental 
variables. A known cause of AD, is genetic mutations linked to early onset AD 
including the gene for amyloid precursor protein on chromosome 21 (Kang et al., 
Chapter 1. 
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1987), the gene for the presenilin 1 protein on chromosome 14 (Schellenberg et 
al., 1992) and the gene for the presenilin 2 protein on chromosome 1 (Levy-Lahad 
et al., 1995); all of which modify production of amyloid-beta peptide. However, 
the majority of AD cases are sporadic with clinical symptoms appearing mostly 
after the age of 65 while 5 - 10 % are familial AD (Blennow et al., 2006). Familial 
AD is rare and restricted to some families around the world with its prevalence 
being 0.1 % of the world population (Janssen et al., 2003). Hence, the prevalence 
of sporadic AD implies the important role that environmental (such as toxins, 
viruses and head trauma/ injury) and lifestyle factors play in the development of 
AD. In addition, the relative importance of each environmental factor may differ 
between patients for different neurodegenerative diseases. Better understanding 
and elucidation of these factors will provide preventive measures as well as 
effective pharmacological therapy.  
 
In addition, epidemiological studies have highlighted other provisional links to 
AD such as reduced brain size, reduced mental and physical activity during late 
life as well as limited educational and occupational attainment. AD is now one of 
the leading causes of death in developed countries in addition to cancer, stroke, 
cardiovascular diseases, obesity and diabetes (Blennow et al., 2006). 
 
Another prominent risk for development of AD is the presence of apolipoprotein 
E ε4 allele (APOE ε4) which increases susceptibility for AD (Corder et al., 1993; 
Poirier et al., 1993). Specifically, people with a first-degree relative with AD have 
10 - 30 % increased risk of developing the disorder (van Duijn et al., 1991). 
Furthermore, the presence of ApoE in neuritic plaques led to investigation of its 
role in plaque formation. ApoE has been implicated in the transport of cholesterol 
in the brain and recycling of other lipids. Also, ApoE is involved in neuronal 
repair and regeneration of dysfunctional connections between neurons (Poirier, 
1994). Hence, it is conceivable that ApoE production is increased in areas of the 
brain with Aβ as a result of neuronal damage. However, ApoE binds to Aβ 
(generated for APP breakdown) readily and so ApoE bound to beta amyloid is not 
free to repair neurons, creating the environment for plaque formation (Carter, 
Chapter 1. 
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2005; Holtzman et al., 2000). Therefore, the binding of ApoE to beta amyloid 
assists paque formation. 
Recently, the genome-wide association studies (GWAS) in AD have highlighted 
over a dozen novel genetic risk factors associated in AD. These include:  
• GAB2 encodes GRB2-associated binding protein 2 (Gab2) a scaffolding 
protein invoveld in signaling and transduction pathways and may 
influence glycogen synthase kinase 3 (GSK3)-dependent phosphorylation 
of tau (Bertram and Tanzi, 2009). 
• GALP encodes for galanin-like peptide (GALP) and increases the risk for 
AD by about 10 % (Grupe et al., 2007).  
• PGBD1 encodes for piggyBac transposable element derived 1 (PGBD1) 
and increases the risk for AD by about 20 % (Grupe et al., 2007),  
• CLU encodes clusterin (also known as apolipoprotein J), a glycoprotein 
expressed ubiquitously. Clusterin is proposed to enhance the transport of 
boluble Aβ from the plasma across the blood-brain barrier (Bertram and 
Tanzi, 2009; Eisenstein; Zlokovic et al., 1996). However, ApoE is 
proposed to transport Aβ in the reverse direction from the brain to the 
plasma (Tanzi et al., 2004). Hence, ApoE and clusterin may be important 
modifiers of Aβ with reference to its transport into and from the brain 
(Bertram and Tanzi, 2009). 
 
Most of these genes are proposed to increase the risk for AD by 10 – 20 % 
(Bertram and Tanzi, 2009; Eisenstein 2011) 
 
The importance of abnormal RNA processing in neurodegenerative disease, 
however, is becoming increasing clear (Anthony and Gallo, 2010). The following 
sections will review the importance of accurate alternative splicing and the 
function of RNA-binding proteins in neurodegeneration, paying particular 
attention to the role of aberrant splicing in tauopathies such as Alzheimer’s 
disease (AD). Essentially, we focus on the role of specific RNA-binding proteins 
involved in the regulation of tau splicing which are abnormally expressed and/or 





1.2 Alzheimer’s disease brain pathology  
 
Dementia is the gradual decline in the cognitive abilities of an individual, 
affecting their daily life due to a series of symptoms linked to diseases/damage of 
the brain (Blennow et al., 2006).  These symptoms include loss of cognitive 
functions including memory (memory loss that disrupts daily activities), thinking 
(challenges in planning and solving problems) and behaviour (changes in mood 
and personality; withdrawal fom work or social activities).  Although dementia is 
associated with aging, it is a deviation from the normal processes in the brain of 
the elderly. The most common type of dementia is Alzheimer’s disease (AD) 
affecting 1 in 20 people over the age of 65 and about 26 million worldwide 
(Blennow et al., 2006).  The prevalence of the disease is attributed to the increase 
in life expectancy in industrially developed countries. The World AD Report 2010 
recently estimated the cost of dementia worldwide to $640 billion (World 
Alzheimer’s Disease International World Alzheimer Report 2010; Prof Andres 
Wimo and Martin Prince). The large numbers affected combined with the high 
cost of care and treatment for sufferers makes it an active area of research.  
 
Alois Alzheimer was the German neuropsychiatrist who over 100 years ago 
(1906), described a condition of his patient, Auguste D as a disease of middle-
aged women with memory disturbances as well as cognitive deficits. After the 
death of Auguste D, autopsy of her brain revealed neuropathological hallmarks 
such as extracellular, miliary bodies (now known as amyloid plaques) and 
intracellular, dense bundles of fibrils (now known as tangles) (Figure 1.1). At 
present, diagnosis of AD is based on careful neurological and psychiatric 
examinations as well as neuropsychological testing. However, the only clear-cut 
diagnosis of AD is through post-mortem examination of the brain. Over a century 
after its discovery, a cure for AD is still elusive with current treatment being 
palliative, only slowing cognitive decline temporarily (Blennow et al., 2006).  
 
Biological changes observed in AD exist long before the onset of clinical 
symptoms (Bookheimer et al., 2000). Before the development of AD, some 








Figure 1.1. Amyloid plaques and neurofibrillary tangles in an AD brain 
(Blennow et al., 2006). Neurofibrillary tangles are intracellular aggregates 
consisting of the hyperphosphorylated form of the microtubule associated protein, 














impairment which may lead to AD development later (Flicker et al., 1991). 
During the progression of AD, symptoms observed include personality and 
behavioural changes in addition to problems recognising friends and family 
members.  
The distinctive pathological features of AD are accumulation of protein 
aggregates in the form of extracellular amyloid (neuritic plaques) and intracellular 
neurofibrillary tangles (NFTs) (Figure 1.1) as well as a remarkable decrease in 
brain volume due to neuronal loss (Blennow et al., 2006). Immunochemical and 
electron microscopic studies of extracellular plaques identified amyloid fibres as 
the core of amyloid plaques (Terry et al., 1964). Thereafter, the amyloid fibres 
were shown to consist of β-amyloid (Aβ) peptides (Glenner and Wong, 1984; 
Glenner et al., 1984) derived from the cleavage of the transmembrane 
glycoprotein amyloid precursor protein (APP) (Kang et al., 1987)). Insoluble Aβ 
accumulates in the extracellular matrix into amyloid deposits, surrounded by 
axonal and dendritic processes. In an AD patient’s brain, amyloid plaques are 
predominantly found throughout the cortex, including the isocortex, frontal, 
temporal and occipital lobes (Braak and Braak, 1991). 
 
NFT pathology progression during AD  
 
NFTs in AD are intracellular aggregates consisting of paired helical filaments 
(PHFs) (Kidd, 1963). Particularly, PHFs are made up of filaments twisted around 
each other and therefore referred to as ‘helical’. PHFs are made up of the 
microtubule-associated protein, tau in its hyperphosphorylated form (Grundke-
Iqbal et al., 1986).  
 
NFT pathology progresses in six stages with tangles first appearing in the 
pyramidal neurons of the transentorhinal cortex which then spread to the 
entorhinal cortex, the hippocampus and surrounding limbic regions such as the 
amygdala before reaching association areas of the cerebral cortex (Braak and 
Braak, 1991; Selkoe, 2001). This progression of NFT in brain regions is the basis 
of ‘Braak staging’. Brain regions including the motor cortex, basal ganglia and 




Plaques and tangles spread throughout the cortex as AD progresses (Braak and 
Braak, 1991, 1992). However, the speed of AD progression is diverse and 
depends on the age of onset and the presence of other health conditions. There are 
three prominent stages in AD progression: 
 
• Preclinical AD, Braak stages I - II – changes may start 20 years before 
diagnosis. However, from this stage, further decline is unavoidable. In the 
earliest stages, before symptoms can be detected, plaques and tangles are 
formed in areas of the brain involved in speaking and understanding 
(Braak and Braak, 1991).  
 
• Mild to moderate AD, Braak stages III - IV – this stage lasts between 2 
- 10 years. In these stages, brain regions essential in memory, thinking and 
planning develop more plaques and tangles than observed in the early 
stages. Hence, memory and thinking problems arise that are serious 
enough to interfere with work or social life. These individuals may also 
get confused, experience difficulty in articulating themselves or organizing 
their thoughts. Most AD patients are diagnosed at this stage (Braak and 
Braak, 1991). 
 
• Severe AD, Braak stages V - VI – this stage lasts from 1 - 5 years 
(www.alz.o. In advanced AD, most of the cortex including the occipital 
cortex is seriously damaged and the brain shrinks dramatically due to 
widespread neuronal death (Braak and Braak, 1991).  Individuals lose their 
ability to communicate, to recognize family and loved ones and to care for 
themselves. 
 
1.3 The microtubule-associated protein, tau 
 
The cytoskeleton is vital for the maintenance of cellular morphology, intracellular 
organisation as well as interaction with surrounding cells. It consists of three 
groups of filaments; microfilaments, intermediate filaments and microtubules. The 
microtubule is a cylindrical protein polymer made up of tubulin subunits (α- and 
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β-tubulin) (Kirschner and Mitchison, 1986). Stabilisation of the microtubule is 
dependent on accessory proteins referred to as microtubule associated proteins 
(MAPs) which structurally organise the microtubule in the cell when required 
(Ramirez et al., 1999). Microtubules form the transport machinery within cells. 
They are involved in the maintenance of neuronal morphology, formation of 
axonal and dendritic processes in addition to cellular trafficking (Hanger et al., 
2009; Matus et al., 1990). For example, microtubules determine the destination of 
cellular organelles as well as intracellular transport of proteins and vesicles from 
the cell body to the synapse of neurones.  
 
The microtubule associated protein, tau was discovered in 1975 after isolation 
from tubulin (Weingarten et al., 1975).  In the absence of tau in vitro, tubulin 
exists as a dimer of α- and β-tubulin subunits which did not assemble into 
microtubules (Weingarten et al., 1975). However, in the presence of tau, tubulin 
polymerises to form microtubules (Weingarten et al., 1975). Hence, tau acts as a 
connecting protein for microtubule subunits by binding through its microtubule-
binding domain (Figure 1.2) thereby promoting microtubule assembly and 
stability. Tau is predominantly localised in the axon of neurones. Tau exists in a 
dynamic balance between phosphorylated and dephosphorylated forms (Johnson 
and Stoothoff, 2004). Depending on its phosphorylation state, tau modulates 
microtubule assembly and stability which are essential for axonal growth and 
transport of proteins such as tubulin that makes up the axonal cytoskeletal 
polymers.  
 
Structure and alternative splicing of the MAPT gene 
 
The MAPT gene encodes human tau and spans 134 kb on chromosome 17 at 
position 17q21 (Neve et al., 1986). There are two haplotypes of the MAPT gene, 
H1 and H2 (Stefansson et al., 2005). H1 and H2 are identified by regions with 
linkage disequilibrium between several polymorphisms over the entire MAPT 
gene both of which do not recombine because of their opposing orientation to 
each other (Pittman et al., 2004). An invariant H2 haplotype differs from the H1 
haplotype by the presence of eight haplotype tagging single nucleotide 
polymorphisms (htSNP) which are variations at single positions in the DNA 
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sequence and a 238 bp deletion in intron 9 (Pittman et al., 2004). The H1 
haplotype is further divided into three sub-haplotypes; H1a, H1b and H1c due to 
the presence of further single nucleotide polymorphisms (SNPs) that are 
distinguished only on a H1 background (Pittman et al., 2005).  
The MAPT gene consists of sixteen exons with six alternative exons including 
exon 2, 3, 4a, 6, 10 and 13. The first and last exons, exon -1 and 14 are transcribed 
but not translated into protein (Figure 1.2) (Andreadis et al., 1992) (Andreadis, 
2005). Exons 2, 3 and 10 of the MAPT gene are alternatively spliced to produce 
six different isoforms of the tau protein in the adult human brain (Figure 1.2). Tau 
transcripts containing exons 2, 3 and 10 are present in different combinations as 
well as being regulated in a developmental- and tissue-specific manner 
(Andreadis, 2005). 
 
Alternative splicing of a gene is the joining of exons in different patterns.  It 
involves the inclusion or exclusion of an exon to generate different forms of the 
mRNA transcript from the same pre-mRNA.  For example, tau exon 10 may be 




Figure 1.2. Alternative splicing of the MAPT gene and the six tau isoforms 
(from (Gallo et al., 2007)). 
Alternative splicing of exons 2, 3 and 10 give rise to six isoforms from a single 
gene in the brain. The presence or absence of exons 2 and 3 in the N-terminus and 
exon 10 in the C-terminus generates different tau isoforms. Exon 10 inclusion 
produces tau isoforms containing four microtubule-binding repeats (4R tau) while 
its exclusion produces tau isoforms containing three microtubule-binding repeats 





1.3.1 Alternatively spliced tau exons  
1.3.1.1 Tau exon 2 and 3  
 
The amino-terminal of tau proteins contains a 29- or 58-amino acid insert encoded 
for by exon 2 alone (1 N-terminal insert) and exons 2 and 3 (2 N-terminal inserts) 
respectively (Goedert et al., 1989a) (Figure 1.2). These N- terminal inserts of tau 
are expressed in an adult-specific manner. Exon 2 can be expressed independently 
in the tau mRNA transcript; however exon 3 is never expressed independently (Li 
et al., 2003). By default, the expression of exon 3 is exclusion and dependent on 
the presence of exon 2 (Andreadis, 2005; Andreadis et al., 1995) while the default 
splicing pattern of exon 2 is inclusion (Andreadis et al., 1995). Tau interacts with 
neuronal plasma membrane through its N-terminal and is proposed to mediate the 
microtubule-plasma membrane interaction (Brandt et al., 1995). 
 
1.3.1.2 Tau exon 10  
At the carboxyl-terminal, tau contains either 4 or 3 microtubule-binding repeats 
(R) encoded for by exons 9 - 12 (Andreadis, 2005; Goedert et al., 1992b). 
Alternative splicing of tau exon 10 encodes for the second microtubule-binding 
repeat (R) of tau (Figure 1.2). This divides the six tau isoforms generated after 
alternative splicing into two groups, depending on the inclusion or exclusion of 
exon 10, designated as tau with four (4R) or three (3R) microtubule-binding 
repeats respectively (Figure 1.2). The expression of 4R and 3R tau containing 
transcripts is developmentally regulated with only 3R tau being expressed during 
embryonic development while 4R tau is expressed in an adult-specific manner 
(Goedert et al., 1989a). The 4R/3R ratio is approximately one in normal human 
adult brain (Hutton et al., 1998), while only 4R tau is expressed in the brain of 
adult rodents (Kosik et al., 1989). The presence or absence of tau exon 10 in the 
mRNA transcript modulates tau’s affinity for microtubules, an important role for 
tau in neurons. Also, the lack of exon 10 (3R tau) increases neuronal plasticity and 
reduces binding to microtubules which are essential during development (Goedert 





1.3.2 Tau function and distribution 
 
Translation of the six tau mRNA isoforms generates different tau proteins with 
several physiological roles in the cell. These include microtubule-dependent and 
microtubule-independent functions: 
 
• Polymerisation and stabilisation of microtubules. The C-terminal of the 
tau protein has three or four microtubule-binding repeats (Figure 1.2) that 
allow for interaction with tubulin subunits to promote assembly of 
microtubules, growth and nucleation (Brandt and Lee, 1993). The 
microtubule is in a state of dynamic instability, with alternating phases of 
growth and rapid shrinkage (Mitchison and Kirschner, 1984). Therefore, 
microtubules exist in a dynamic state of change between polymerisation 
and depolymerisation, depending on the cellular requirement (Kirschner 
and Mitchison, 1986). This regulates the trafficking of molecules 
including cellular organelles such as mitochondria along the microtubule 
cytoskeleton (Howard and Hyman, 2009). 
 
• Neurite outgrowth. The dynamic behaviour of microtubules is regulated 
differentially in different parts of the neuron. In neurons, tau is 
predominantly localised in the axons with the largest amounts found at the 
distal end, close to the growth cone, in developing neurons (Black et al., 
1996). Microtubules at the distal end of the axon as well as growth cones 
are the most dynamic (Ahmad et al., 1993). The involvement of tau during 
neurite outgrowth was demonstrated when PC12 cells treated with nerve 
growth factor (NGF), showed an increased expression of tau which 
correlated with neurite outgrowth (Drubin et al., 1985). However, 
treatment of PC12 cells with antisense tau oligonucleotides inhibits tau 
expression and revealed a reduction in neurite formation and the number 
of microtubules (Black et al., 1996; Caceres and Kosik, 1990; Caceres et 




• Signal transduction. Tau exons 2 and 3 may interact with specific 
membrane compartments involved in signal transduction (Brandt et al., 
1995). The src family of tyrosine kinases such as fyn have a src homology 
3 (SH3) domain which interacts with the proline-rich domain (pro-lys-ser-
pro sequence) of tau (Lee, 2005; Usardi et al., 2011). Tau was identified as 
a substrate of fyn through co-transfection experiments of tau and fyn in 
COS cells. Tau is phosphorylated by fyn at tyr18 in transfected cells in a 
manner that is independent of tau’s microtubule association properties 
(Lee, 2005; Usardi et al., 2011). Furthermore, tau-fyn complexes are 
located underneath the plasma membrane and associated with the actin 
cytoskeleton (Lee et al., 1998). Hence, tau may be important in src family 
tyrosine kinase signalling processes that modify cell shape through their 
activity on the actin cytoskeleton. Tyrosine phosphorylation of tau 
suggests its involvement in neuronal signal transduction (Usardi et al., 
2011). This may account for other functions of tau in cell signalling 
besides its main role in microtubule assembly (Lee, 2005). 
 
• Axonal transport. The transport of vesicles and organelles in the 
antetrograde direction, from the cell body to the synapse; and retrograde 
direction from the synapse to the cell body requires a stable axonal 
transport network that involves microtubules, stabilised by tau 
(Mandelkow et al., 2003). Tau competes with motor proteins involved in 
the transport of cargo along the microtubule tracks including kinesin and 
kinesin-like motors (Dixit et al., 2008). Overexpression of tau interferes 
with the binding of these motor proteins and inhibits kinesin dependent 
trafficking of mitochondria, endoplasmic reticulum and vesicles (Dixit et 
al., 2008) (Ebneth et al., 1998). In addition, high concentrations of tau 
inhibit kinesin dependent transport of filaments and Golgi-derived vesicles 
and peroxisomes (important for detoxification of H2O2) to neurites which 
makes them susceptible to oxidative stress (Stamer et al., 2002). 
Furthermore, increased expression of tau inhibits the transport of APP 




1.4 Tau pathology in neurodegeneration  
 
A group of neurodegenerative dementias and movement disorders called 
tauopathies have tau as the major component of neurofibrillary tangles (NFTs) in 
which tau is abnormally phosphorylated and assembled into filamentous 
aggregates. Tauopathies include: 
 
• Alzheimer’s Disease (AD) 
• Frontotemporal dementia with parkinsonism linked to chromosome 17,  
(FTDP-17) 
•  Pick’s Diseases (PiD) 
• Progressive Supranuclear Palsy (PSP) 
• Coritcobasal Degeneration (CBD) 
• Myotonic Dystrophy (DM) 
 
Tau aggregates in tauopathies may be in the form of intracellular filamentous 
deposits in the brain including NFTs, neuropil threads and glial tangles 
(Spillantini and Goedert, 1998). However, the morphology, tau content and 
localisation of the tau deposits are dependent on the specific tauopathy. These 
aggregates consist of paired helical filaments (PHFs) and straight filaments (SFs) 
(Crowther et al., 1992). Biochemically in AD, these deposits may consist of all six 
tau isoforms present in adult human brain (Goedert et al., 1989a). The H1 sub-
haplotypes, H1b and H1c have a high degree of association with CBD and PSP 
tauopathies (Myers et al., 2005; Myers et al., 2007; Pittman et al., 2005; Pittman 
et al., 2004) while the H1c haplotype is associated with an increased risk for AD 
(Myers et al., 2005).  
 
In these diseases, tau’s binding to microtubules is impaired which leads to 
destabilisation of neuronal microtubules and degeneration of dendrites, axons and 
synapses before cell death (Ballatore et al., 2007). The NFT pathology in these 
tauopathies correlates with neuronal loss and cognitive decline due to alterations 




Abnormal levels of tau phosphorylation are the most prominent hallmark of tau in 
tauopathies (Braak and Braak, 1992; Goedert and Spillantini, 1990). In addition, 
mutations in MAPT gene highlighted the direct link between tau and tauopathies 
(Hutton et al., 1998; Poorkaj et al., 1998; Spillantini and Goedert, 1998). 
Moreover, abnormal splicing of tau exon 10 is an important pathological event in 
FTDP-17. The complex regulation of tau exon 10 is detailed below. 
 
1.4.1 Tau phosphorylation 
 
Tau is usually phosphorylated in the cell but its activity is regulated by the degree 
of phosphorylation (Tanaka et al., 1998). Tau phosphorylation is achieved through 
the activity of several kinases and phosphatases. Amongst these are two 
prominent kinases, glycogen-synthase kinase 3 (GSK3) and cyclin-dependent 
kinase 5 (cdk5) (Hanger et al., 1992) (Hanger et al., 2009). Appropriate 
phosphorylation of tau enhances its physiological roles in the cell including 
neurite outgrowth, axonal transport and microtubule dynamics (Biernat and 
Mandelkow, 1999); (Tatebayashi et al., 2004); (Cho and Johnson, 2004).  
 
In pathological conditions such as AD, tau becomes hyperphosphorylated due to 
an imbalance in the activity of kinases that phosphorylate tau and phosphatases 
that de-phosphorylate tau. This results in a tendency of hyperphosphorylated tau 
to loose its microtubule association and form insoluble fibrils and tangles within 
neurons (Abraha et al., 2000; Jameson et al., 1980). Whether tau is 
phosphorylated in NFTs before or after aggregation is unknown. 
Hyperphosphorylated tau sequesters normal tau as well as other MAPs thereby 
causing depolymerisation of microtubules and impairing axonal transport which 
compromises synaptic function (Buee et al., 2000) and may even increase cell 
death (Fath et al., 2002). All six tau isoforms are present and hyperphosphorylated 
in AD brain and aggregate into PHFs in tangles (Goedert et al., 1992a; Goedert et 
al., 1989b). There are thirty-nine phosphorylation sites identified in PHFs by mass 
spectrometry in addition to six sites detected with phospho-specific antibodies 




1.4.2 Alternative splicing 
 
In eukaryotic cells, splicing is a well-defined RNA processing event. After 
transcription of a protein-coding gene, the mRNA transcript undergoes several 
post-transcriptional modifications including capping, splicing and polyadenylation 
which may occur co-transcriptionally or consecutively in the nucleus (Maniatis 
and Tasic, 2002).  
 
Splicing of pre-mRNA involves the accurate removal of non-coding sequences 
(introns) and the simultaneous ligation of coding sequences (exons) to form a 
mature messenger RNA (mRNA) transcript (Long and Caceres, 2009). 
Alternative splicing allows for the production of multiple mRNA from a single 
gene. As a result, the different mRNA are translated into different protein 
isoforms, with varying location and function (Andreadis et al., 1992; Douglas and 
Wood, 2011; Modrek and Lee, 2002). This also modulates the expression of 
different protein isoforms in a tissue- and developmental-dependent manner, 
depending on the requirements of the cell (Black et al., 1996; Ladd et al., 2004). 
 
1.4.2.1 Regulation of alternative splicing 
 
The spliceosome catalyses the splicing reaction to remove introns through 
accurate recognition of cis-acting elements as well as donor and acceptor sites   
(5’-, 3’-splice sites respectively) found at the intron-exon boundaries of pre-
mRNA (Figure 1.3) (Mount, 1982). Also present within the intron is the branch 
point (A) and polypyrimidine (polyY) tract which are important as early entry 
point of the spliceosome and removal of the intron (Figure 1.3). In addition to 
these splicing signals, splicing regulation involves regulatory cis-acting elements 
in both exons and introns. These are divided into four categories: exonic splicing 
enhancer (ESE), exonic splicing silencer (ESS), intronic splicing enhancer (ISE) 













Figure 1.3. Control elements regulating splicing. (from (Douglas and Wood, 
2011)). 
Complementary base pairing of U1 and U2 snRNPs to the 5’ splice site and 
branch point respectively occurs through their binding to loose consensus 
sequences. The polypyrimidine tract serves as a binding site for U2AF (U2 
auxillary factor). SR proteins bind to ESEs and exert a positive effect to increase 
splice site use, while hnRNPs bind to ESSs, exerting a negative effect on splice 










Cis-acting elements serve as binding sites for trans-acting factors (RNA-binding 
proteins/splicing factors) that promote or inhibit the inclusion of an alternative 
exon (Douglas and Wood, 2011). 
 
The alternative splicing reaction depicts that splicing factors bind to enhancer 
elements within the pre-mRNA to promote exon inclusion for instance, a group of 
proteins rich in serine and arginine residues (SR proteins) while splicing factors 
that repress exon inclusion bind to silencers; including members of the 
heterogeneous nuclear ribonucleoproteins family (hnRNPs) (Figure 1.3) (Douglas 
and Wood, 2011). Nevertheless, SR proteins and hnRNP proteins may repress or 
stimulate splicing respectively. For example, in the adenovirus infection, the SR 
protein, ASF/SF2, binds to an intronic repressor element near the branch point of 
the adenovirus IIIa pre-mRNA and inhibits the binding of a small nuclear 
ribonucleoprotein (snRNP), U2 snRNP (to prevents the use of the 3’ splice site) 
(Douglas and Wood, 2011; Kanopka et al., 1996). The presence of regulatory 
proteins including SR proteins and hnRNPs on splice site signals through their 
RNA- and protein-binding domains mediates alternative splicing (Douglas and 
Wood, 2011).  
 
Regulation of tau pre-mRNA alternative splicing 
 
The alternative splicing of tau exon 2, 3 and 10 is accurately regulated due to 
interaction between trans-acting factors (splicing factors) and cis regulatory 
elements.  Several studies have investigated the trans-acting factors involved in 
the regulation of tau splicing (Table 1.1). These include members of three splicing 
factor families: hnRNP proteins, SR proteins and and CELF {CUG-BP1 (CUG 
Binding Protein) and ETR-3 [(ELAV (Embryonic Lethal, Abnormal Vision) type 
RNA-binding protein] Like Factors} proteins. 
Although the default splicing pattern for exon 2 is inclusion, most of the splicing 
factors tested in vitro inhibit its inclusion (Table 1.1). For instance, SRp30c and 
SRp55 significantly inhibit exon 2 splicing while CELF4 activates it (Li et al., 
2003). Hence, exon 2 may be regulated primarily by inhibition (Andreadis, 2005). 
In contrast, the default splicing pattern of exon 3 is exclusion and never 
independent of exon 2 (Andreadis et al., 1995). 
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Table 1.1. Splicing factors influence on three tau alternative exons 2, 3 and 10 
(Andreadis, 2005);(Qian et al., 2011a) 
A=activator, I=inhibitor, N=no effect, ( ) =weak action, nd=not determined, 














2 3 10 
SRp20 N I (I) 
ASF N I (I) 
SRp30c I I I 
SC35 (I) I A 
SRp40 (I) * A 
9G8 N nd I 
SRp55 I A I 
SRp75 N A I 
U2AF N * I 
PTB I * I 
hnRNPA1 N I N 
hnRNPG N nd I 
Tra2-β I I A 
CELF3 (I) I? A 
CELF4 A I? A 
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Tau exon 10 is included in the tau mRNA transcript by default and its expression 
is highly regulated by its flanking exons; exons 9 and 11, which function to 
promote and inhibit exon 10 inclusion respectively (Gao et al., 2000). The 
regulation of tau exon 10 splicing involves ESE sequences at the 5’ and 3’ ends of 
exon 10 (Figure 1.4) (D'Souza and Schellenberg, 2005) as well as ESS sequences; 
both of which are indispensable for accurate splicing (D'Souza and Schellenberg, 
2002, 2005). In addition, there are well-characterised weak 5’ and 3’splice sites, a 
polyY tract and two separate branch point sequences in intron 9 and a bipartite 
regulatory element consisting of an intronic splicing silencer (ISS) and an intronic 
splicing modulator (ISM) in intron 10 (D'Souza and Schellenberg, 2002, 2005). 
ESEs present within exon 10 include: 
• SC35-like sequence 
• PPE (polypurine enhancer) element which enhances the 5’ and 3’ splice 
sites (D'Souza and Schellenberg, 2002). 
 
• A/C-rich (ACE) enhancer, that works with the PPE enhancer to neutralize 
an inhibitory ISS element in intron 10 (D'Souza and Schellenberg, 2002). 
 
• ESE element at the 3’ end of exon 10 between an 18 nucleotide ESS 
element and the 5’ splice site (D'Souza and Schellenberg, 2005). 
 
The regulation of exon 10 splicing is paramount for maintaining the appropriate 
4R/3R ratio in the adult human brain (Andreadis, 2005; Myers et al., 2007).  
There are two models for the regulation of tau exon 10 splicing: 
• In the linear model, different concentrations of splicing factors compete 
between the two ISS elements within intron 10 and the 5’ splice site 
(Figure 1.4) (D'Souza and Schellenberg, 2002). Although SR proteins are 
splicing enhancers, they can also act as repressors depending on where 
they bind in the pre-mRNA (Kanopka et al., 1996). For example, the SR 
protein, 9G8 binds to the ISS in intron 10 and inhibits exon 10 inclusion 
(Gao et al., 2007).  
• A putative stem loop structure is proposed to regulate exon 10 splicing 









Figure 1.4. Tau exon 10 splicing regulation (adapted from (D'Souza and 
Schellenberg, 2005)) 
Tau exon 10 alternative splicing is regulated by both positive (blue arrow) and 
negative (red arrow) interactions between trans-acting splicing factors and cis-
acting elements within the pre-mRNA. SR proteins bind to ESE elements in exon 
10 to stabilise the interaction between U1 and U2 snRNP with the 3’ and 5’ splice 
sites respectively. Several ESE elements counteract weak 3’ and 5’ splice sites to 
promote exon 10 inclusion.  
 
Key: 
A/C-rich enhancer (ACE);  
Polypurine enhancer (PPE);  
Exonic splicing silencer (ESS); Exonic splicing enhancer (ESE);  
Intronic splicing silencer (ISS);  











1.5 The importance of alternative splicing  
 
Alternative splicing occurs in over 90 % of human genes (Pan et al., 2008; Wahl 
et al., 2009). In addition to this, at least 15 % and probably 50 % of human genetic 
diseases are due to mutations in either the consensus splice sites or the variable 
cis-acting elements which results in aberrant splicing (Cartegni et al., 2002; 
Lopez-Bigas et al., 2005). Genome-wide analysis elucidated that most of the 
tissue-specific alternatively spliced isoforms are expressed in the brain (Shai et 
al., 2006). 
 
Splice sites are loosely conserved in the mammalian genome and mutations at 
these sites results in abnormal splicing either through exon skipping or the 
recognition of cryptic splice sites that are not usually used during splicing 
(Cartegni et al., 2002).  Moreover, disruption of the alternative splicing process 
can cause deficiency in cellular and tissue requirements, leading to disease.  
 
1.5.1 Aberrant splicing of tau results in FTDP-17 
 
In 1998, genetic studies on the MAPT gene provided the most convincing 
evidence for the involvement of tau in disease. Dominant mutations (alterations in 
the DNA sequence) in the MAPT gene were linked to the rare dementia, FTDP-17 
(Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998). FTDP-17 is an 
autosomal-dominant disease with variable clinical and neuropathological 
characteristics. Symptoms observed in patients can be behavioural (personality 
changes and reduced speech output), cognitive (loss of executive functions) and 
motor (bradykinesia) changes (Poorkaj et al., 1998).  
 
Neuropathologic changes in the brain are abundant in cortical and subcortical 
areas of FTDP-17 cases (Foster et al., 1997); including frontotemporal atrophy, 
occasionally with atrophy of the amygdala, basal ganglion, and substantia nigra 





To date, there are over 30 mutations in the MAPT gene associated with FTDP-17. 
Dominant mutations in the MAPT gene cause tau dysfunction through one or more 
distinct mechanisms (Foster et al., 1997; Hutton et al., 1998; Poorkaj et al., 1998; 
Spillantini et al., 1998). MAPT mutations that cause FTDP-17 are divided into two 
groups.  
 
• The first group includes missense (single amino acid substitutions), 
deletion, or silent mutations. Some missense mutations decrease the 
microtubule binding ability of tau to promote microtubule assembly 
(Hasegawa et al., 1998; Hong et al., 1998).  
 
• The second group includes splice site and intronic mutations located in or 
around the microtubule-binding domains of tau (Figure 1.5) (Hutton et al., 
1998). These mutations alter the regulation of tau exon 10 pre-mRNA 
splicing causing a change in the relative proportion of 4R and 3R tau 
isoforms and promote tau filament formation (Foster et al., 1997; Hong et 
al., 1998; Hutton et al., 1998; Poorkaj et al., 1998).  
 
 
1.5.1.1 Missense mutations in FTDP-17 
 
About 50 % of mutations in FTDP-17 are missense mutations. These mutations 
directly alter tau function and disrupt microtubule binding capacity (D'Souza and 
Schellenberg, 2005). The rationale behind this is that most missense mutations are 
in the C-terminal end of tau, within or around the microtubule-binding domain 
(Gallo et al., 2007). For instance, the missense mutation, P301L (substitution of 
proline to leucine within tau exon 10) causes the PGGG motif in this microtubule 
binding repeat to become LGGG (Hutton et al., 1998). The P301L mutation 
affects only tau transcripts containing exon 10, causing a 90 % reduction in the 
rate of tubulin polymerisation (Hasegawa et al., 1998). Furthermore, tau 
aggregates from patients with the P301L mutation mainly contain 4R tau isoforms 








Figure 1.5. Dominant MAPT mutations in FTDP-17 and elements regulating 
alternative splicing of exon 10 (from (Gallo et al., 2007)). 
Trans-acting factors and cis-acting elements regulating tau exon 10 splicing are 
shown with the predicted stem loop structure at the exon 10/intron 10 boundary 
(uppercase is exonic sequences, lowercase is intronic sequences). MAPT 
mutations implicated in FTDP-17 which change tau 4R/3R isoform are indicated. 
Most of these mutations are present within the predicted stem loop structure or 















1.5.1.2 Intronic and splice site mutations in FTDP-17 
 
Mutations within the exon 10/intron 10 junction of the MAPT gene destabilize the 
putative stem loop structure credited with the regulation of tau exon 10 alternative 
splicing (Figure 1.5) (D'Souza et al., 1999; Grover et al., 1999; Hutton et al., 
1998). Although silent and intronic mutations of FTDP-17 do not affect the 
amino-acid sequence of the tau protein, they eventually affect exon 10 splicing 
and tau function (D'Souza and Schellenberg, 2005). 
 
Silent or intronic mutations alter tau splicing by disrupting either the use of the 5’ 
splice site or exonic sequences (PPE, ACE or ESS) in exon 10. This results in 
alteration of the 4R/3R tau ratio in FTDP-17 to favour 4R tau (at a 2-3 to 1 ratio 
of 4R/3R) as opposed to 1 in normal adult human brain (Hutton et al., 1998; 
Poorkaj et al., 1998; Spillantini et al., 1998). The fact that this alteration of the 
normal 4R/3R tau ratio was sufficient to cause FTDP-17 shows the importance of 
correct alternative splicing regulation of tau in the human brain (Andreadis, 2005; 
Hutton et al., 1998; Spillantini et al., 1998). In addition, RT-PCR analysis of four 
FTDP-17 brains from patients with 5’ splice site mutations revealed a two-six fold 
increase in 4R tau transcripts compared to controls (Hutton et al., 1998). 
Similarly, the 4R/3R tau ratio in the frontal and temporal lobe was increased by 
up to six-fold in FTDP-17 patients with intronic mutation at position +16 (Connell 
et al., 2005). Hence, intronic and/ splice site mutations result in aberrant 
alternative splicing pattern of tau exon 10 causing disease. 
 
1.5.1.3 Exonic mutations in FTDP-17 
 
There are several exonic mutations within the ESE sequences of tau exon 10 
which enhance splicing of exon 10 rather than reduce microtubule assembly 
(Hasegawa et al., 1999). Exonic mutations that affect tau exon 10 splicing include, 
N279K and Del280K associated with FTDP-17 which disrupts the PPE splicing 
enhancer in exon 10 by adding or removing an AAG motif in the normal sequence 
of PPE respectively (Figure 1.5) (D'Souza and Schellenberg, 2005; Jiang et al., 
2003). The N279K mutation strengthens the PPE while the Del280K mutation 
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abolishes it (Kondo et al., 2004). The SR-related protein tra2β (transformer 2 β) 
which regulates tau exon 10 splicing has a higher affinity for PPE with N279K 
mutation and promotes exon 10 inclusion while Del280K reduces exon 10 
inclusion (D'Souza and Schellenberg, 2005; Kondo et al., 2004).   
 
Maintaining the 4R/3R tau ratio is paramount for normal tau function because 
tauopathies with aberrant tau exon 10 splicing such as CBD and PSP have 4R tau 
as the main component of the tangles (Chambers et al., 1999; Hutton et al., 1998; 
Myers et al., 2007; Takanashi et al., 2002). Conversely, investigations into the 
relative abundance of alternatively spliced tau isoforms in sporadic AD have 
revealed conflicting results (Boutajangout et al., 2004; Chambers et al., 1999; 
Connell et al., 2005; Glatz et al., 2006; Ingelsson et al., 2006; Yasojima et al., 
1999). However, two pre-mRNA encoding proteins that regulate tau exon 10 
splicing, tra2β and clk2 kinase, which phosphorylates tra2β, showed altered 
splicing pattern in the temporal cortex of some sporadic AD patients which also 
had increased tau exon 10 inclusion (Glatz et al., 2006). Furthermore, the H1c 
haplotype of the MAPT gene associated with increased susceptibility for AD 
correlates with an increase in levels of tau transcripts containing exon 10 (Myers 
et al., 2005; Myers et al., 2007).  
 
Additionally, the MAPT  H1 haplotype is  associated with tauopathies that show 
altered tau exon 10 splicing with increased 4R/3R tau ratio (PSP and CBD) 
(Baker et al., 1999; Houlden et al., 2001). On the other hand, in Pick’s disease, 
aggregated intracellular insoluble tau consists mainly of 3R tau (Mailliot et al., 
1998). These suggest that aberrant alternative splicing may contribute to the 










1.6 RNA binding proteins regulating alternative splicing  
 
A key question in splicing and an obvious point in regulation is how external 
factors or proteins regulate alternative splicing. Several studies have reported the 
synergistic interaction between trans-acting factors which bind to cis-acting 
elements within the pre-mRNA transcript to regulate alternative splicing 
(Andreadis, 2005; Caceres et al., 1994; Kralovicova and Vorechovsky, 2007). 
Splicing factors are RNA-binding proteins that may be expressed ubiquitously or 
in a tissue-specific or developmentally controlled manner to regulate alternative 
splicing of specific pre-mRNAs transcripts.   
 
Several families of RNA binding proteins are grouped on the basis of structural 
homology between family members, function and conservation between members 
or species. The following sections describe three important families of RNA 
binding proteins involved in the regulation of tau splicing: hnRNP proteins, SR 
proteins and CELF {CUG-BP1 (CUG Binding Protein) and ETR-3 [(ELAV 




1.6.1 The heterogeneous nuclear ribonucleoproteins (hnRNP) family 
 
Mammalian splicing regulators include the family of hnRNPs which consist of a 
diverse group of proteins that share a modular structure and RNA-binding motifs 
and are expressed exclusively in the nucleus (Gorlach et al., 1993; Hanamura et 
al., 1998). Members of the hnRNP family have three RNA-binding domains: 
 
• RNA recognition motif (RRM)  
 
• RGG Domain – containing tripeptide arginine-glycine-glycine repeats 




• KH Domain – ‘K homology’ domain discovered in the hnRNP K protein 
contains a central IGXXG motif that spans about 40 residues (Gorlach et 
al., 1993). 
 
In the past, hnRNP proteins were seen as inhibitors of splicing activity; prominent 
examples include hnRNP A1, hnRNP I and PTB (polypyrimidine tract-binding 
protein) which interfere with the binding of U1 snRNP and U2AF to pre-mRNA 
(Gorlach et al., 1993; Martinez-Contreras et al., 2007). hnRNP proteins 
characteristically inhibit alternative splicing by antagonising the binding of SR 
proteins to pre-mRNA (Hanamura et al., 1998). hnRNP A1 interferes with the 
interaction of SR proteins to regulate the alternative splicing of c-src exon N1 
(Rooke et al., 2003). However, it recently emerged that hnRNPs both inhibit and 
promote alternative splicing (Martinez-Contreras et al., 2007). Additionally, 
hnRNP proteins have been implicated in several roles during RNA metabolism 
such as pre-mRNA transport, transcription, RNA stabilisation and RNA editing 





















1.6.2 SR proteins 
 
Serine and arginine-rich (SR) proteins are a group of closely related RNA-binding 
proteins classified based on their structural features (Roth et al., 1991). SR 
proteins are part of the spliceosome and are actively involved in the regulation of 
mammalian alternative splicing (Twyffels et al., 2011; Zahler et al., 1992). There 
are nine human SR proteins encoded by nine genes with regions of similarity 
(Table 1.2) (Figure 1.6) (Kramer, 1996; Long and Caceres, 2009) based on the 
following criteria; 
 
• The presence of at least one RNA recognition motifs (RRM) at the N-
terminal which binds to RNA (Query et al., 1989). In some SR proteins, a 
second RRM-like domain with RRM homology (RRMH) is present. The 
only exception is the SR protein, 9G8 which has a zinc knuckle motif, 
thought to bind to RNA (Cavaloc et al., 1994) (Figure 1.6). 
 
• A signature RS domain enriched in serine/arginine repeats at the C-
terminal (Figure 1.6). 
 
 
The RRMs have a structure which enhances their interaction with multiple RNA 
contacts as well as being vital in determining RNA-binding specificity (Maris et 
al., 2005). Conversely, the RS domain, rich in alternating arginine and serine 
residues contributes to the varying lengths of the different members of the SR 
family (Caceres et al., 1994; Kramer, 1996; Manley and Tacke, 1996) (Figure 
1.6). The RS domain was detected in other RNA-binding proteins referred to as 
SR-like proteins such as Tra2β (D'Souza and Schellenberg, 2005; Kramer, 1996). 
This domain is important for mediating protein-protein interactions, splicing and 
the  nucleocytoplasmic shuttling of individual SR proteins, acting as a nuclear 





Table 1.2. The nine human SR proteins family members and their encoding 
genes (from (Shepard and Hertel, 2009)). 
Name SR protein Chromosomal location 
SFRS1 ASF/SF2/SRp30a 17q21.3-q22 
SFRS2 SC35/SRp30b 17q25.1 
SFRS3 SRp20 6p21.31 
SFRS4 SRp75 1p35.3 
SFRS5 SRp40 14q24.2 
SFRS6 SRp55 20q13.11 
SFRS7 9G8 2p22.1 
SFRS9 SRp30c 12q24.23 
SFRS11 SRp54 1p31.1 
 
Figure 1.6. Modular structure of the nine human SR proteins (from (Shepard 
and Hertel, 2009)). 
The nine human SR proteins are encoded by nine genes (Table 1.2). All SR 
proteins contain at least one RRM (orange) and an RS domain (lim.e green). Only 
one SR protein, 9G8 has a zinc knuckle domain (Zn) (purple). Five SR protein 




1.6.2.1 Functions of SR proteins 
 
SR proteins have multiple roles in RNA processing including constitutive and 
alternative splicing (Andreadis, 2005; Zahler et al., 1992). They mediate their 
function either by binding directly to pre-mRNA or indirectly to components in 
the spliceosome during splicing to enhancer or repress nearby splice sites (Roth et 
al., 1991). SR proteins were first identified by their intrinsic ability to activate 
splicing through complementation assays with cytoplasmic S100 splicing-
deficient extracts from HeLa cells containing all splicing machinery except SR 
proteins (Zahler et al., 1992). 
 
1.6.2.2 Splicing and SR proteins 
 
SR proteins are amongst the first components that interact with the pre-mRNA 
transcript during splicing. They have an essential role during alternative splicing, 
acting as regulators of mRNA metabolism (Kramer, 1996; Long and Caceres, 
2009). SR proteins promote exon inclusion by binding to ESE motifs on pre-
mRNA through their RRM. They bind almost exclusively to exonic regions, 
probably because of their role in the recruitment of other splicing factors that may 
stabilize their interaction with the pre-mRNA (Lin et al., 2005). The binding of 
SR proteins to ESE motifs enhances spliceosome assembly and promotes exon 
inclusion in two ways: 
 
1. SR proteins recruit spliceosome components such as small nuclear 
ribonucleoproteins (snRNPs); for example U1 snRNP at the 5’ 
splice site (Zhu et al., 2001) and U2AF at the 3’ splice site (Wang 
and Manley, 1995) through the RS domain which mediates protein-
protein interactions. 
 
2. Competitive binding with other RNA-binding proteins for example 
hnRNP proteins to ESS motifs (Zhu et al., 2001). Also, two SR 
proteins that recognise the same ESE may compete with each other 
(Sanford et al., 2005a). 
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1.6.2.3 Role of SR proteins during splicing 
 
SR proteins regulate alternative splicing of many pre-mRNA transcripts, by  
promoting the use of proximal 5’ splice sites which  is counteracted by hnRNP A1 
and related proteins, that usually favour the use of distal 5’ splice sites (Hanamura 
et al., 1998). Hence, SR proteins and hnRNPs play an important role in the 
selection of 5’ splice sites in vitro and therefore the regulation of several pre-
mRNA transcripts in vivo. The relative abundance of SR proteins may vary 
depending on the cell type, splicing condition or stage of development (Caceres et 
al., 1998).  
 
Changes in SR proteins activity can lead to specific disease phenotypes or 
developmental defects (Long and Caceres, 2009). However, functional 
redundancy between members of the SR protein family is likely and can 
compensate for any deficiency. For example, when a single SR protein, SRp30a 
was knocked down in A549 cells, there was no overall consequence on cell-wide 
splicing events (Massiello and Chalfant, 2006). Similarly, in Caenorhabiditis 
elegans, gene inactivation using RNA interference of single SR proteins (except 
for ASF which is essential for nematode development) did not alter neuronal 
viability (Twyffels et al., 2011).  
 
SR proteins ASF, SRp30c and Tra2β bind to the same ESE on tau exon 10, a PPE 
(Kondo et al., 2004; Lynch and Maniatis, 1995).  Some exons including tau exon 
10 contain more than one ESE recognised by different SR proteins with one 
having a stronger effect than the others (Lynch and Maniatis, 1995). In this case, 
knocking down one of the SR proteins would probably have little or no effect on 
splicing of the particular exon. RNAi knock down of six different SR proteins in 
C. elegans showed no phenotype. Conversely, developmental defects or death 
were observed when multiple SR proteins were targeted simultaneously 
(Longman et al., 2000). Deletion of a Drosophila melanogaster orthologue of 
human SRp55 was found to be embryonic lethal (Ring and Lis, 1994). These 




Other SR proteins that regulate tau exon 10 splicing in vitro include SC35, SRp40 
and SRp55 (Andreadis, 2005). In tau alternative splicing, SC35 binds to a SC35-
like enhancer element in exon 10 to promote tau exon 10 inclusion (Qian et al.) 
while SRp40 binds to a PPE element in tau exon 10 to promote tau exon 10 
inclusion (Jiang et al., 2003; Kondo et al., 2004). In contrast, SRp55 binds to an 
ESS to inhibit tau exon 10 inclusion in vitro (Andreadis, 2005; Gao et al., 2000; 
Wang et al., 2005).  
 
1.6.2.4 SR protein expression is developmentally regulated 
 
SR proteins are known to be the limiting factor in alternative splicing and show 
changes in their expression levels during development (Stamm et al., 1994; Zahler 
et al., 1992; Zahler et al., 1993). SR proteins are localised and enriched in nuclear 
speckles (Fu, 1995). Nuclear speckles are storage compartments for splicing 
factors, which respond to the level of transcription by RNA polymerase II (Misteli 
et al., 1997). The RS domains of SR proteins act as a localisation signal into 
nuclear speckles before they are recruited to splicing sites during constitutive or 
alternative splicing (Hedley et al., 1995).  
 
A gradual decline of the SR protein, ASF was observed from embryonic stages to 
adult rat brain (Daoud et al., 1999). In addition, the level of tra2-β1 decreased 
from embryonic rat brain (E14, E16, E18, and E20) to postnatal stages (P5, P15 
and P20) and adult rat brain (Daoud et al., 1999).  
1.6.2.5 Phosphorylation regulates splicing activity of SR proteins 
 
Serine residues within the RS domain are phosphorylation sites for kinases which 
modify the splicing activity of SR proteins in two ways: 
 
1. Control of SR proteins subcellular localisation. 
 
2. Control of protein-protein interactions of SR proteins with other 
RNA-binding proteins such as SR-related proteins. 
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All SR proteins are phosphorylated in vivo at their RS domain, recognised in cells, 
and tissues of different invertebrates and vertebrate species by a monoclonal 
antibody 104, mAb104 (Gui et al., 1994b; Hanamura et al., 1998; Kramer, 1996; 
Roth et al., 1991; Zahler et al., 1992). Several families of kinases phosphorylate 
SR proteins including the SR protein kinases 1 (SRPK1) (Gui et al., 1994a; Gui et 
al., 1994b), Clk/Sty family kinases (Colwill et al., 1996) and cdc2-like kinases 
(CLK) (Hartmann et al., 2001). The splicing activity of SR proteins is regulated 
throughout development by their phosphorylation state (Sanford et al., 2005b).  
However, hypo- and hyper-phosphorylated SR proteins are inactive during 
splicing while moderately phosphorylated SR proteins partake in splicing (Gui et 
al., 1994a) (Sanford and Bruzik, 2001).  
 
SR proteins ASF, SRp20 and 9G8 constantly shuttle between the nucleus and the 
cytoplasm depending on their phosphorylation state. SR protein shuttling, 
implicates them in the export of mRNA to the cytoplasm from the nucleus 
(Graveley, 2000; Sanford et al., 2005a). The evidence for this comes first from the 
fact that both RS domain and RMMs are phosphorylated in shuttling SR proteins 
(Caceres et al., 1998) which may increase the association of mRNA and SR 
proteins. Secondly, SR proteins remain in close proximity to mRNA transcripts 
after intron removal. Furthermore, a protein involved in nuclear export, Tip-
associated protein (TAP), interacts with 9G8 and ASF during the “hand-over” of 
mRNA (Hautbergue et al., 2008). SR protein kinases present in the cytoplasm 
phosphorylate SR proteins and activates their re-shuttling back to the nucleus 
(Ding et al., 2006). 
 
1.6.3 CELF family of RNA-binding proteins 
 
The CELF {CUG-BP1 (CUG Binding Protein) and ETR-3 [(ELAV (Embryonic 
Lethal, Abnormal Vision) type RNA-binding protein] Like Factors} proteins are a 
family of RNA binding proteins that are expressed in a developmental and tissue 
specific manner (Ladd et al., 2001). The tissue distribution of CELF proteins is 


















Hyperphosphorylated and stabilised in DM1 patients 
resulting in increased activity (Kuyumcu-Martinez et al., 
2007). 
 
Down-regulated in DM1 brain at RNA (Leroy et al., 2006) 





Ubiquitously Expressed  
 
Enriched in Skeletal Muscle and Brain  
 
Up-regulated in muscle of SMA patients and interacts with 
SMN (Anderson et al., 2004). 
 
CELF2 is down-regulated three-fold in SCA3 transgenic 
mice compared to wild type mice (Menzies et al., 2010). 
 
Down-regulated in DM1 brain at RNA (Leroy et al., 2006) 
and protein level (Dhaenens et al., 2011). 
 
SNPs in CELF2 gene are associated with late-onset AD in 














Enriched in Skeletal Muscle 
 
CELF4 k/o mice have a seizure phenotype (Yang et al., 
2007). 
 
Unc-75 (CELF3, 4 and 5 orthologue) knock-out in C. 
elegans results in an uncoordinated movement phenotype 
rescued by human CELF4 (Loria et al., 2003). 
 























CELF protein family members were identified after screening human expression 
sequence tag (EST) database for paralogs of CUG-binding protein, CUG-BP (also 
known as CELF1). There are six members of the CELF family in human ranging 
from CELF1 to CELF6; within the family, CELF proteins are divided into two 
groups, depending on sequence similarity and functional difference. The first 
group includes CELF1 and CELF2 (78 % identical) and the second group consists 
of CELF3 to CELF6 all of which have a similarity of approximately 67 % (and 
43.8 % similarity to CUG-BP) (Figure 1.7) (Singh et al., 2004).  
 
CELF1 was the first member of the CELF protein family to be discovered during 
investigations into molecular mechanisms of a muscle wasting disease, myotonic 
dystrophy (DM1). CUG-BP/CELF1 as the name suggests was found by its 
sequence specific binding of RNA containing CUG repeats in intronic elements or 
3’-UTR (untranslated region) of pre-mRNA (Ladd et al., 2001). The second 
member, ETR-3, was identified from genes expressed in human foetal heart (Ladd 
et al., 2001). An independent search for human homologues to the Xenopus laevis 
protein BrunoL-1 identified the same six proteins, leading to the alternative 
classification - the ‘Bruno-like’ (BRUNOL) family of proteins (Good et al., 
2000). Some CELF proteins are also known by specific names other than their 
CELF or BRUNOL nomenclature, which are summarised in Table 1.4. CELF1 
and CELF2 are used interchangeably as CUG-BP1 and ETR-3 respectively (Ladd 
et al., 2001); (Ladd et al., 2004). The CELF nomenclature is used throughout in 
this thesis.  
 
All CELF proteins have similar structures to CELF1 (Figure 1.8) (Ladd et al., 
2001; Ladd et al., 2004).  CELF proteins have a unique structure with two N-
terminal RNA recognition motifs (RRM) domains and one C-terminal RRM 
separated from the N-terminal RRM by a non-conserved divergent domain whose 
function is unknown (Ladd et al., 2001). The structure and size of the six known 
members of the CELF family of proteins is shown in Figure 1.8. All CELF 
proteins have multiple phosphorylation sites for protein kinase C (PKC) and 
casein kinase II (Ladd et al., 2001). The primary sequence analysis of the 
divergent domain in CELF1, revealed a serine-rich region, phosphorylated by 




Figure 1.7. CELF proteins family and their phylogenic relationship (from 
(Ladd et al., 2004)). 
The CELF family can be split into two sub-families based on their sequence 
similarity and splicing activity. The first subfamily contains CELF1 and CELF2, 
and the second contains CELF3, CELF4, CELF5 and CELF6. 
 
 
Table 1.4. Members of the CELF family of RNA binding proteins and their 
different nomenclatures 
CELF BRUNOL OTHER 
CELF1 BRUNOL2 CUG-BP1 
CELF2 BRUNOL3 ETR-3, CUG-BP2, NAPOR 
CELF3 BRUNOL1 TNRC4, CAGH4 
CELF4 BRUNOL4  
CELF5 BRUNOL5  












Figure 1.8. Modular structure of the human CELF protein family members 
(from (Gallo and Spickett, 2010)). 
All members of CELF family of proteins have a similar structure that consists of 
three conserved RRMs, two at the N terminus, RRM1 and RRM2 (red and green), 
separated from the third, RRM3 (blue) at the C terminus by a divergent domain. 
The divergent domains of CELF1, CELF3 and CELF4 have distinctive 
differences within them. CELF1 has a serine rich region; CELF3 has a 
polyglutamine region and CELF4 has specific regions in the divergent domain 







1.6.3.1 Functions of CELF proteins 
 
Members of CELF protein family are involved in several post-transcriptional 
events including: regulation of alternative splicing, translation and mRNA 
localisation (Vermersch et al., 1996) (Sergeant et al., 2001) (Gallo and Spickett, 
2010; Ladd et al., 2005).  
 
The divergent domain of CELF4 is implicated in splicing activity of some specific 
pre-mRNA targets. These include promotion of cardiac troponin T (cTNT) exon 5 
inclusion, PTB exon 11 inclusion and NDMA R1 (N-Methyl-D-aspartate receptor 
1) exon 5 exclusion (Singh et al., 2004). Similarly, the divergent domain of 
CELF2 plays a role in alternative splicing of CFTR (cystic-fibrosis trans-
membrane conductance regulator) exon 9 (Dujardin et al., 2010). CELF3 is a 
unique CELF protein with a 15-18 polyglutamine (polyQ) repeat in its divergent 
domain encoded by variable CAG repeats (Figure 1.10) (Chapple et al., 2007; 
Gallo and Spickett, 2010; Margolis et al., 1997).  CELF3 was originally identified 
by a screen of candidate disease genes in cDNA libraries containing CAG repeats 
encoding long polyQ tracts (Margolis et al., 1997). As a result of this polyQ tract, 
CELF3 is also known as TNRC4 (tri-nucleotide repeat containing 4).  
 
Some neurological disorders caused by CAG repeat expansion, include 
Huntington’s disease (HD) and spinocerebellar ataxia type 1 (SCA1) (Rubinsztein 
and Carmichael, 2003) (Suzuki et al., 2008). It is unlikely that the polyQ tract in 
CELF3 tract will be the subject to pathogenic expansion, because it does not have 
a high degree of variation within the human population (Butland et al., 2007). As 
a result, CELF3 is not associated with any polyglutamine expansion disorders. 
This is because proteins with repeat CAG lengths of about 40 or more are 
sequestered into aggregates (Ross and Tabrizi, 2011). For instance in HD, CAG 
triplet repeat expansion in Huntingtin (HTT) gene leads to pathogenic expanded 
polyQ stretch in HTT protein (Lee et al., 2004; Ross and Tabrizi, 2011). 
Moreover, co-expressed CELF3 was not recruited into cytoplasmic huntingtin 
aggregates or nuclear aggregates of ataxin-1 in CHO cells (Chapple et al., 2007). 
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1.6.3.2 Expression of CELF proteins  
 
The expression of CELF proteins is developmentally regulated in the heart and 
striated muscle (Ladd et al., 2001).  All CELF proteins are expressed in adult and 
foetal brain (Ladd et al., 2004). In all tissues examined, there is expression of at 
least one or more CELF protein with the exception of CELF3 and CELF5 whose 
expression are restricted to the brain while CELF2 and CELF4 are 
developmentally regulated in striated muscle and heart (Ladd et al., 2001); (Ladd 
et al., 2004); (Ladd et al., 2005) (Table 1.3).  
 
CELF proteins are localised in the nucleus and cytoplasm, conforming to their 
role as multifunctional proteins. CELF1 has multiple roles including regulation of 
alternative splicing in the nucleus; as well as mRNA translation (through its 
activity at the 5’ end) and mRNA degradation (at the 3’ end in the cytoplasm) 
(Timchenko et al., 1996) (Barreau et al., 2006; Paillard et al., 2003). CELF 
proteins are localised to the nucleus by their NLS sequences at the C-terminal, 
within RRM3 (Chapple et al., 2007; Ladd et al., 2001). This NLS motif located 
within RRM3 is conserved in all members of the CELF family; with the basic 
amino acid sequence KRXK.  
 
CELF proteins bind specifically to CUG repeats in intronic elements or in the 3’-
UTR (untranslated region) of pre-mRNA and mRNA transcripts (Faustino and 
Cooper, 2005; Ladd et al., 2001). Several CELF proteins have been implicated in 
the regulation of tau alternative splicing including CELF2, CELF3 and CELF4 
(Chapple et al., 2007; Leroy et al., 2006; Wang et al., 2004). During alternative 
splicing of the MAPT gene, CELF proteins bind to intronic elements around 
alternative exons including exon 2 and 10 to govern their inclusion or exclusion in 
the mature tau mRNA (Andreadis, 2005). It is therefore paramount that the 
expression levels of these splicing factors in response to cellular stimuli is 
accurate to ensure precise alternative splicing of tau transcripts as well as their 





1.6.3.3 Functional redundancy among CELF protein family members 
 
A prominent splicing target for CELF proteins is Cardiac troponin T (cTNT). The 
alternative splicing pattern of cTNT is developmentally regulated and conserved 
from birds to mammals (Ladd et al., 2001). The alternative cTNT exon 5 which is 
normally included in the embryo of cardiac and skeletal muscle is skipped in adult 
cardiac muscle mRNA (Ladd et al., 2001) (Barreau et al., 2006).  
 
Alternative splicing of cTNT exon 5 generates isoforms with different contractive 
properties important during muscle development (Cooper and Ordahl, 1985). All 
CELF proteins bind to conserved intronic elements called muscle-specific splicing 
enhancer elements (MSEs) which contains a CUG repeat to promote exon 5 
inclusion (Ladd et al., 2001). Although this splicing event is dependent on 
different intronic splicing enhancer (ISE) elements, CELF3 and CELF6 promote 
exon 5 inclusion in the presence of a muscle-specific ISE element (MSE2) found 
at the proximal region flanking exon 5 while other CELF proteins require several 
MSE elements (Ladd et al., 2001).  
 
Furthermore, all regions within CELF proteins are implicated in the splicing 
regulation of cTNT exon 5.  These include sequences within RRM1 and RRM2 of 
CELF2 as well as regions within the divergent domain and RRM1 of CELF4 
(Singh et al., 2004). Altogether, these findings suggest that different ISE elements 
in addition to domains within CELF proteins are indispensable for splicing 
activity of the same exon which indicates functional redundancy among CELF 
family members.  
 
An orthologue of CELF3, 4 and 5 in Caenorhabditis elegans, unc-75, is neuron 
specific and involved in neurotransmission where it regulates neuron-specific 
alternative splicing (Loria et al., 2003). unc-75 null mutants have a motor 
phenotype that is rescued by human CELF4 (Loria et al., 2003).  These studies 





Similarly, the generation of mouse models deficient in specific CELF proteins, 
has helped to elucidate the role of members of the CELF family during alternative 
splicing. In mice lacking CELF1, growth is retarded; there is impaired viability 
and reduced fertility due to disruption of spermatogenesis (Kress et al., 2007). 
CELF3 knock-out mice did not show any reduction in fertility but similar to 
CELF1 knock-out mice, they have reduced spermatogenesis (Dev et al., 2007). 
This may be the result of the compensatory effect of other members of the CELF 
family. The expression of CELF3 is restricted to the mouse brain and testis 
although it is exclusively expressed in human brain (Dev et al., 2007). CELF4 
knock-out mice have similar phenotype as the frequent flyer mouse model, whose 
celf4 gene is disrupted resulting in a complex seizure phenotype (Yang et al., 
2007). CELF4 regulates the expression of genes essential for neuronal viability, 
which are subsequently down-regulated in mutant mice, two (Htr2c and Syn2) 
that cause seizures when knocked-out in mice (Yang et al., 2007). Hence, 
disruption of the CELF4 gene results in a disease phenotype probably due to its 
impaired function. 
 
1.7 RNA binding proteins in disease 
 
Mutations that disrupt alternative splicing can lead to cellular dysfunction and 
disease as explained with FTDP-17 mutations. Furthermore, misregulation of the 
activity of RNA-binding proteins can also result in aberrant splicing of their target 
pre-mRNA transcripts. The regulation of alternative splicing is complex, 
depending on loosely conserved cis-acting regulatory sequence elements, trans-
acting protein factors as well as cellular responses dependent on environmental 
conditions. The following sections describe the role of misregulated RNA-binding 
proteins in neurological disorders. 
 
Several trans-acting factors/splicing factors interact with regulatory elements in 
the MAPT gene during tau exon 10 splicing as explained above. They include 
members of the SR proteins family and CELF family of RNA-binding proteins 





1.7.1 SR proteins in disease 
 
The identification of SR proteins as essential factors in the control of alternative 
splicing and cell growth make them potential candidates for specific disease 
conditions when they are misregulated either through post-translational 
modifications or expression. SR proteins exhibit their function in disease in 
several ways as follows. 
 
1.7.1.1 Gene transcripts regulated by SR proteins are implicated in disease   
 
SR proteins regulate some gene transcripts implicated in disease; these include 
oncogens and tumour suppressor genes. A typical example of this is that ASF 
regulates the alternative splicing of Ron proto-oncogene (a tyrosine kinase 
receptor for a macrophage protein which stimulates proliferation while inhibiting 
apoptosis). A mutant auto-activating form of Ron confers high metastatic potential 
leading to production of a protein product that is directly involved in the invasive 
characteristic of tumour cells. Since SR proteins exert their function in a dose 
dependent manner (Karni et al., 2007), it is conceivable that altering their 
expression may cause noticeable changes in activity. For instance, cellular deficits 
may occur during proliferation and differentiation (Karni et al., 2007). Indeed, 
altering the alternative splicing pattern of target genes (such as CD44 gene), by 
SR proteins has been reported in ovarian and breast cancers where Tra2β and 
SRp55 were increased in primary tumours (Fischer et al., 2004).  
 
1.7.1.2 Recognition of point and deletion mutations by SR proteins 
 
SR proteins have the ability to recognise point and deletion mutations in disease-
causing genes. For example, in spinal muscular atrophy (SMA), aberrant 
alternative splicing results in disease phenotype.  SMA is a recessive disorder in 
humans and a prevalent cause of infant mortality. It is a form of motor neuron 
disease caused by deletion mutations of a functional SMN1 gene that encodes for 
the survival motor neurone (SMN) protein. Ubiquitously expressed SMN is a 
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splicing factor required for the synthesis and assembly of snRNP to form the 
SMN complex (Gubitz et al., 2004). SMN associates with mRNA binding 
proteins, such as HuD and transports poly (A) mRNA, in the axons of motor 
neurons (Fallini et al., 2011). A loss of SMN function results in 
neurodegeneration of motor neurons especially common in the spinal cord.  
 
SMA is considered a general splicing disease. Loss of function of SMN1 cannot 
be compensated for by its almost identical gene, SMN2. SMN2 has a silent C > T 
substitution in the sixth nucleotide of exon 7 which results in exon 7 skipping and 
the production of a non-functional, truncated SMN protein, SMN2 (Coovert et al., 
1997; Le et al., 2005; Monani, 2005). This SMN2 mutation causes a loss of an 
ESE by abolishing the binding site for the SR protein, SF2/ASF and creation of an 
ESS to which the hnRNP A1 binds (Cartegni et al., 2002). Furthermore, the SR-
related protein, Tra2β promotes SMN2 exon 7 inclusion. Therefore, modulation of 
Tra2β may be an avenue to therapeutically correct aberrant SMN2 splicing 
(Hofmann et al., 2000). 
 
1.7.1.3 Phosphorylation of SR proteins is misregulation in tauopathies  
 
Glycogen synthase kinase 3 (GSK-3β) is one of the kinases that phosphorylates 
tau protein in vitro to an extent where its characteristics resembles PHF-tau in AD 
(Hanger et al., 1992; Lovestone et al., 1994). GSK-3β inhibition in rat cortical 
neurons causes an increase in the expression of the SR protein, SC35 in nuclear 
speckles, which leads to an increase in tau exon 10 inclusion (Hernandez et al., 
2004). Hence, misregulation of GSK-3β activity may alter tau exon 10 splicing 
through SC35 phosphorylation-dependent changes in localisation and activity, 
which may contribute to the aggregation of tau in NFTs observed in AD. 
 
Another kinase that phosphorylates the SR protein, ASF, is Dyrk1a kinase which 
has been implicated in Down’s syndrome (DS) tauopathy. There is an extra copy 
of chromosome 21 in DS patients as well as early onset of AD like tau pathology 
(Wisniewski et al., 1985a; Wisniewski et al., 1985b). ASF plays a very important 
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role in promoting tau exon 10 inclusion. Dyrk1a kinase phosphorylates ASF and 
regulates its role in tau splicing (Shi et al., 2008). Phosphorylation of ASF by 
Dyrk1a results in its localisation into nuclear speckles. This prevents ASF 
promotion of tau exon 10 inclusion causing an increase in tau transcripts with 
only three microtubule binding repeats (3R tau) and may contribute to early onset 
of tauopathy in DS patients (Shi et al., 2008).  
1.7.1.4 Misregulation of SR proteins during splicing in tauopathies 
 
Several SR proteins have been implicated in the regulation of tau alternative 
splicing including Tra2β which activates tau exon 10 splicing by binding to a 
purine-rich enhance (PPE) element in exon 10 (Kondo et al., 2004; Wang et al., 
2005). The expression levels of Tra2β (therefore its activity) was significantly 
increased in the temporal cortex of AD cases (Glatz et al., 2006).  
 
1.7.2 Molecular pathology of myotonic dystrophy (DM)  
 
Disruption of alternative splicing regulation leads to diseases such as myotonic 
dystrophy (DM).  DM1 is an autosomal dominant disease characterised by 
delayed relaxation of muscle contractions (myotonia), progressive myopathy, 
cardiac conduction abnormalities and cataracts (Ladd et al., 2001). In DM, 
pathogenic mutations occur due to unstable repeat expansion which leads to 
altered RNA function and consequently, the increased expression of non-coding 
and non-translated repeats. In DM, there is an expansion of the CUG or CCUG 
repeats in the 3’-UTR of dystrophia myotonica protein kinase (DMPK) mRNA  
and  in intron 1 of ZNF9 pre-mRNA resulting in DM1 and DM2 respectively 
(Fuger et al., 1995; Ho et al., 2005; Mahadevan et al., 1992). Pathogenesis of DM 
is due to altered alternative splicing caused by the sequestration of RNA-binding 
proteins (such as muscleblind, MBNL1) which results in abnormal splicing 





1.7.2.1 Tau pathology in myotonic dystrophy (DM) 
 
Although DM1 is a muscle wasting disease, elderly patients show signs of 
neurodegeneration (de Leon and Cisneros, 2008). Neurodegeneration in DM1 is 
noticeable as AD-like aggregated tau pathology in the cortical areas including the 
hippocampus, entorhinal cortex and temporal areas of aged patients similar to that 
observed in AD (Sergeant et al., 2001; Vermersch et al., 1996). In the cortical 
neurons of DM1 patients, a decrease in tau isoforms containing exon 2, 3 and 10 
was detected (Jiang et al., 2004; Sergeant et al., 2001; Vermersch et al., 1996). 
CELF3 and CELF4 promote the inclusion of tau exon 10 in vitro (Andreadis, 
2005; Wang et al., 2004). It is likely that deficient CELF protein activity in DM1 
brain for example, CELF4 (Leroy et al., 2006) may contribute to the expression of 
tau transcripts without exon 10 (Andreadis, 2005; Wang et al., 2004). 
 
1.7.2.2 CELF proteins in myotonic dystrophy 
 
In the brain of DM1 patients, CELF protein expression is misregulated and thus, 
their activity is altered. A prominent decrease in the expression of CELF1, CELF2 
and CELF4 transcripts was observed at RNA level in DM1 brain although CELF1 
is up-regulated in the skeletal muscle of DM1 patients (Leroy et al., 2006). Hence, 
these deficiencies of CELF protein expression at RNA level in DM1 brain may 
contribute to the decrease of tau exon 10 transcripts (Dhaenens et al., 2011).  
 
The important role of CELF1 in the pathogenesis of DM1 was highlighted by the 
altered splicing of its pre-mRNA targets. CELF1 has a high affinity for CUG or 
CCUG repeats (Ladd et al., 2001) (Douglas and Wood, 2011). DMPK transcripts 
containing expanded CUG repeats are aggregated in the 3’ UTR of the pre-mRNA 
causes a gain of function mutation of CELF1. The expanded CUG repeats 
increases the activity of PKC for which CELF1 is a downstream target. Increased 
phosphorylation of CELF1 stabilises it, resulting in up-regulation of its activity 
(Kuyumcu-Martinez et al., 2007). This causes abnormal splicing of CELF1 
downstream transcripts seen to be abnormally expressed in DM1 patients (Philips 
et al., 1998; Ranum and Cooper, 2006). For example, the insulin receptor (IR) 
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showed increased exon 11 exclusion which causes insulin resistance (Savkur et 
al., 2001) while increase in cardiac troponin T (cTNT) exon 5 inclusion results in 
cardiac muscle defects. In addition, muscle-specific chloride channel gene 
(CLNC-1) had increased inclusion of intron 2 as well as two pseudo exons 
between exons 6 and 7. This produced premature stop codons which cause non-
sense mediated decay of CLNC-1 transcripts and reduced expression of CLNC-1 
and abnormal chloride conductance in muscle causing myotonia (Charlet et al., 
2002). 
 
1.7.3 Amyotrophic Lateral Sclerosis  
 
Amyotrophic Lateral Sclerosis (ALS) is a progressive adult-onset 
neurodegenerative disorder characterised by the loss of motor neurons in the brain 
and spinal cord resulting in cell death and progressive muscle weakness (Shaw, 
2001).  Approximately 10 % of all ALS cases are familial (FALS) while the rest 
are sporadic (SALS). 20 % of these FALS are due to mutations in Cu/Zn 
superoxide dismutase 1 (SOD1) and 1 % of all sporadic (SALS) cases (Pasinelli 
and Brown, 2006; Rosen, 1993). Another mutation that causes ALS is in the 
RNA/DNA-binding FUS/TLS (fused in sarcoma/translocated in liposarcoma) 
gene which causes some familial ALS (Kwiatkowski et al., 2009; Vance et al., 
2009). 
 
ALS is characterised by the presence of polyubiquitinated inclusions (UBIs) in the 
soma and proximal axon of surviving motor neurons (Leigh et al., 1991). 
Furthermore, FTLD-U (frontotemporal lobar degeneration with ubiquitin-positive 
inclusions), a tau negative and ubiquitin positive frontotemporal lobar dementia 
also have pathological UBIs in the cortical neurons of both the frontal and 
temporal lobes of patients (Lipton et al., 2004).  
The identification of TDP-43 (see below) as a major constituent of both ALS and 
FTLD-U led to them been grouped as ‘TDP-43 proteinopathies’ because of their 
similar clinico-pathological phenotype (Arai et al., 2006; Cairns et al., 2007; 




1.7.3.1 TDP-43 in ALS 
 
 TDP-43 (TAR DNA binding protein 43) is a DNA and RNA binding protein 
implicated in alternative splicing regulation and mRNA transport. TDP-43 was 
identified through a search for proteins binding UG repeat regions (Buratti et al., 
2001). TDP-43 binds to UG repeats in intron 8 of CFTR pre-mRNA and regulates 
of exon 9 splicing (promotes exon 9 skipping) (Buratti et al., 2001). TDP-43 
mediates splicing activity through its glycine-rich C-terminal, necessary for CFTR 
exon 9 splicing (Buratti and Baralle, 2008). Structurally, TDP-43 is similar to 
members of the hnRNP family, with two RRMs flanked by N- and C-terminal 
domains (Figure 1.9). RRM1 is implicated in the RNA and DNA binding 
properties of the protein (Buratti and Baralle, 2008; Ou et al., 1995).  
 
TDP-43 disease associated mutations were recognized by several groups in a 
subset of FALS cases and some SALS cases through direct sequencing (Gitcho et 
al., 2008; Kabashi et al., 2008; Kuhnlein et al., 2008; Sreedharan et al., 2008; Van 
Deerlin et al., 2008). The glycine-rich C-terminal of TDP-43 harbours majority of 
the disease-related mutations (accountable for protein-protein interactions with 
members of the hnRNP family) except for D169G found within RRM1 (Buratti et 
al., 2001). Most of these mutations are missense mutations except for Y374X, 
which causes C-terminal truncation (Daoud et al., 2009). The disturbance of TDP-
43 interaction with other splicing factors, such as hnRNP A2 does not alter protein 
function, but may contribute to pathogenesis of disease through aggregate 
formation (D'Ambrogio et al., 2009). 
 
In ALS and FTDL-U, TDP-43, is mislocalised to the cytoplasm from the nucleus 
where it is ubiquitinated, hyperphosphorylated, and cleaved, producing C-terminal 
fragments (Arai et al., 2006; Neumann et al., 2006; Sreedharan et al., 2008). The 
TDP-43 pathology in these diseases coincides with cytoplasmic aggregation 
(Kwong et al., 2007; Van Deerlin et al., 2008). This may occur due to 













Figure 1.9. Structural domains and disease causing mutations of TDP-43 
(from (Lagier-Tourenne and Cleveland, 2009)). 
TDP-43 is an RNA and DNA binding protein with two conserved RRMs and a 
well defined C terminal glycine rich domain. The majority of disease-causing 
mutations are found within the C-terminal domain with the exception of D169G 
















The loss of TDP-43 from the nucleus implies that its functional properties in the 
nucleus during RNA metabolism are lost and may contribute to pathology 
(Lagier-Tourenne et al., 2010; Neumann et al., 2006; Sreedharan et al., 2008). The 
depletion of TDP-43 using antisense oligonucleotides in adult mouse brain 
revealed a decrease in the expression levels of about 1000 RNAs with very long 
introns having binding sites for TDP-43 (Polymenidou et al., 2011). The 
expression of the long mRNAs in the brain recognises their neuronal 
susceptibility to TDP-43 depletion (Polymenidou et al., 2011). Furthermore, 
iCLIP (individual nucleotide-recognition cross-linking immunoprecipitation) was 
used to identify the relationship between TDP-43 and long intronic regions 
containing UG-rich sequences in vivo (Tollervey et al., 2011). RNA-protein 
interactions of TDP-43 were identified in FTLD patients having characteristic 
TDP-43 inclusions. FTLD patients showed strong interaction between TDP-43 
and small nucleolar RNAs, small nuclear RNAs as well as ribosomal RNAs 
(Tollervey et al., 2011).  In addition, knockdown of TDP-43 in neuroblastoma 
cells revealed that 158 alternative exons were down-regulated including genes 
involved in neuronal development (Tollervey et al., 2011). 
 
TDP-43 positive inclusions have been increasingly recognised in other 
neurodegenerative conditions, referred to as secondary TDP-43 proteinopathies. A 
prominent member of this is AD with TDP-43 pathology (Amador-Ortiz et al., 
2007b). 
 
1.7.3.2 TDP-43 in AD 
 
TDP-43 inclusions frequently accompany the pathological hallmarks observed in 
AD (Amador-Ortiz et al., 2007b; Josephs et al., 2008; Uryu et al., 2008). These 
TDP-43 inclusions are present in the neurons and glia of roughly 20 – 30 % of 
sporadic AD cases (Amador-Ortiz et al., 2007b; Uryu et al., 2008) and about 14 % 
in familial AD (Lippa et al., 2009). However, TDP-43 pathology in AD is 
restricted to the limbic regions of the brain including the hippocampus, amygdala 











Figure 1.10. TDP-43 inclusions in AD with hippocampal sclerosis (from 
(Amador-Ortiz et al., 2007b)).  
AD case with hippocampal sclerosis showing TDP-43 positive cytoplasmic 

















Moreover, TDP-43 pathology in AD shows an overlap with tau pathology 
distribution (neuropil threads and NFTs) (Fujishiro et al., 2009) which bears 
resemblance with those in FTLD-TDP including the presence of neuronal 
cytoplasmic and intranuclear inclusions; particularly in neurons susceptible to 
NFTs. Immunochemical analysis of AD brain using specific antibodies to 
pathogenic forms of TDP-43 including C-terminal epitopes and phospho-epitopes 
were correlated with the presence of abnormal TDP-43 (Arai et al., 2009).  
 
These studies propose that TDP-43 inclusions in AD cases may contribute to 
pathogenesis of disease associated with greater brain atrophy principally in the 
hippocampus as well as severe clinical phenotype (Josephs et al., 2008). This is in 
agreement with the finding that hippocampal atrophy present in AD cases with 
TDP-43 pathology is more prominent than in AD cases without TDP-43 
pathology (Josephs et al., 2008).  
 
1.7.3.3 TDP-43 and its interacting RNA binding proteins  
 
Several RNA-binding proteins that regulate RNA metabolism show extensive 
interaction with TDP-43 (Freibaum et al., 2010; Ling et al., 2010). Some of the 
splicing factors interacting with TDP-43 depend on the N-terminal RRM1 to 
mediate RNA-protein functions of TDP-43 (Freibaum et al., 2010). The 
interactions of TDP-43 with splicing factors are in two distinct clusters: 
 
• A nuclear/splicing cluster. A group of nuclear proteins that control RNA 
splicing as well as other nuclear RNA metabolism were found in this 
cluster. They include many hnRNPs, SR proteins, snRNPs, and nuclear 
RNA export factors. These proteins are all implicated in nuclear RNA 
metabolism (mainly RNA splicing and mRNA export to the cytoplasm) 
(Freibaum et al., 2010; Ling et al., 2010). 
 
• A cytoplasmic/translation cluster.  This includes a group of cytoplasmic 
proteins that regulate mRNA translation. Members of this cluster include 




This is in accordance with the suggestion that TDP-43 has numerous functions in 
RNA metabolism in the nucleus and cytoplasm. Proteins interacting with TDP-43 
include some members of CELF proteins and SR proteins family (Freibaum et al., 
2010 660). These splicing factors may be under the influence of TDP-43 to 
mediate activities other than splicing such as control of mRNA export, 
localisation and stabilisation. 
 
Two members of the SR family of proteins were found in the nuclear splicing 
cluster of TDP-43 including 9G8 and SRp55 (Freibaum et al., 2010). However, 
the only CELF protein identified as an interactor of TDP-43 is CELF1 (Ling et al., 
2010); (Freibaum et al., 2010). TDP-43 (like CELF2) regulates CFTR exon 9 
skipping by binding an ISE motif at the end of intron 8 (Dujardin et al., 2010). 
Whilst CELF1 binds to this same ISE motif, it does not promote CFTR exon 9 
skipping (Dujardin et al., 2010). 
 
There are potential similarities between DM1 and TDP-43 proteinopathies. In 
TDP-43 proteinopathies, TDP-43 is sequestered into cytoplasmic aggregates in 
neurons while in DM1, there is gain of function of splicing factors (CELF1) in the 
nucleus. In both diseases, the splicing pattern of their downstream pre-mRNA 
targets is altered. Although, the exact relationship between mis-splicing of mRNA 
targets and neurodegeneration in DM1 is not known; it is plausible that in TDP-43 
proteinopathies (such as AD with TDP-43 pathology), RNA-binding proteins may 













1.8 Drugs targeting SR rich proteins 
 
The inhibition of splicing regulators either directly or indirectly by small 
chemicals could correct abnormal splicing (Douglas and Wood, 2011; Soret et al., 
2005). Splicing factors that rely entirely on the use of ESE sequences can be 
specifically inhibited to correct abnormal splicing. These drugs show highly 
selective inhibition of splicing processes mediated by ESE sequences (Soret et al., 
2005). For example the C77 and C83 drugs inhibit the activity of members of the 
SR family that are essential for spliceosome assembly through direct interaction 
with them (Soret et al., 2005).  
 
1.8.1 Kinases as a therapeutic target 
 
In terms of alternative splicing of pre-mRNAs, the phosphorylation state of 
splicing factors may determine if an exon is skipped or included in mRNA. The 
phosphorylation state of splicing factors has been implicated in AD where 
regulators of tau exon 10 alternative splicing were altered (Glatz et al., 2006).  
Analysis of the splicing patterns of exon 10 in the temporal cortex of sporadic AD 
brain showed decrease in Clk2 activity (a kinase, that phosphorylates tra2β1), 
increase human tra2β-1 mRNA, and increased exon 10 containing tau mRNA 
(Glatz et al., 2006). However, a decreased expression of htra2β-1 protein was 
reported in sporadic AD cases (Conrad et al., 2007). This suggests that defects in 
pre-mRNA processing contribute to sporadic AD and altering the phosphorylation 
state of splicing factors may be beneficial. However, modulation of the 
phosphorylation state of splicing factors in therapy may propose an obstacle 
because kinases or phosphatases have more than one downstream target thereby 
modulating SR-mediated splicing events. Therefore, altering the activity or 
expression of an enzyme may not have just the desired local effects but exert their 








1.8.2 Potential of gene therapy 
 
Generation of therapies that can reverse or restore mis-regulated splicing events 
linked to several human genetic disorders is essential for correcting abnormal 
splicing. To correct abnormal alternative splicing, direct intervention at the RNA 
level is required. Mutated sequences in regions of a gene such as splice sites or 
regulatory sequences that cause the production of dysfunctional proteins are 
targets for techniques used to correct aberrant splicing. 
 
A more efficient approach compared to altering the phosphorylation state of 
splicing factors may be the viral delivery of splicing factors to promote exon 
skipping or inclusion.  
 
1.8.2.1 Antisense oligonucleotides 
 
Antisense oligonucleotides modulate splicing in a target-specific manner. 
Oligonucleotides that are complementary to a specific RNA sequence can be 
synthesised to target splice sites, enhancer or silence elements within a RNA 
transcript (Douglas and Wood, 2011). This allows manipulation of the splicing 
machinery in a precise manner. Oligonucleotides binding to tau exon 10 splice 
junctions have been used to decrease the expression of exon 10 in PC12 cells 
(Kalbfuss et al., 2001). This application of antisense oligonucleotides directed 
against tau exon 10 splice junctions suppresses inclusion of tau exon 10 by 
forming a stable pre-mRNA-oligonucleotide hybrid, which blocks access of the 
splicing machinery to the pre-mRNA. The advantage of this technique is that the 
modified transcript’s expression pattern is the same as the endogenous transcript. 
This is because the modified RNA transcript is expressed under the influence of 
the gene’s transcriptional control (Douglas and Wood, 2011). Furthermore, the 
synthesis of antisense oligonucleotides that binds to CUG repeats in DM1 will 
prevent the binding and sequestration of splicing factors such as MBNL1 to 





1.8.2.2 RNA interference (RNAi) 
 
Eukaryotes modulate gene expression by RNAi at pre- and post-transcriptional 
levels (Gaur, 2006). RNAi mediated gene silencing is induced by small 
interference RNA (siRNA) produced from small hairpin RNA (shRNA) by Pol III 
promoter and transfer RNA (tRNA) promoters (Gaur, 2006). After transcription, 
intrinsic RNAse III processes shRNAs into siRNA duplexes followed by 
incorporation of the siRNA strand into the RNA-induced silencing complex 
(RISC). siRNA selectivity is paramount in silencing disease causing mRNA 
without affecting the levels of wild-type allele or an isoform that has a vital 
function (Gaur, 2006).  
 
1.8.2.3 Correcting abnormal alternative splicing using SMARTTM  
 
With SMARTTM, a chimaeric mRNA is created by trans-splicing where the 
spliceosome catalyses the reaction between the 5’ splice site of a natural target 
pre-mRNA and the 3’ splice site of an exogenous delivered pre-trans-splicing 
molecules (PTM) RNA molecule (Gallo et al., 2007; Puttaraju et al., 1999). The 
reprogramming of tau pre-mRNA using spliceosome-mediated RNA trans-
splicing (SMARTTM) can correct aberrant alternative splicing. SMARTTM corrects 
abnormal splicing at the RNA level such that the correct transcript is expressed 
and the mutant form of the transcript is down-regulated concurrently (Gallo et al., 
2007). SMART adequately modulates exon 10 splicing of tau pre-mRNA. Using 
SMARTTM, exclusion of exon 10 was achieved with 30 % efficiency (Rodriguez-
Martin et al., 2005) (Rodriguez-Martin et al., 2009). In the context of tauopathies 
with increased expression of tau exon 10 mRNA such as some FTDP-17 
mutations,   SMARTTM can be used to create a chimeric mature transcript to 
correct abnormal tau isoform ratio (Rodriguez-Martin et al., 2005). Treatment of 
diseases caused as a result of defective alternative splicing by directly interfering 
with the RNA requires the delivery of the PTM through viral vectors. This avoids 
the obstacles of the blood brain barrier as well as decreasing the possibility of 






The dynamic regulation of alternative splicing by a stringent combination of 
trans-acting factors and cis-acting elements is important for the proper 
functioning of neurons. Misregulation of alternative splicing can result in diseases 
due to alteration in the levels of mature transcripts and therefore protein isoforms 
as explained in this Chapter. This review has highlighted the important roles that 
RNA-binding proteins particularly, SR proteins and CELF proteins play in RNA 
processing, and suggests that they may contribute to pathogenesis of sporadic AD. 
This could occur due to misregulation of the activity of these RNA-binding 
proteins that govern the activity of cis-acting elements during tau exon 10 
alternative splicing. The misregulation of RNA-binding proteins such as SR 
proteins and CELF proteins in neurodegenerative disease makes them potential 
targets of therapeutic intervention in the treatment of these diseases. Direct 
modulation of splicing factors through their expression and/or phosphorylation 
state provides a means by which their splicing activity can be manipulated with 
drugs to correct aberrant alternative splicing events. For instance, modulating the 
phosphorylation state of the SR protein, SC35 (which promotes tau exon 10 
inclusion) through the activity of the kinase, GSK-3β (Hernandez et al., 2004) 
using drugs that directly inhibit it may provide therapeutic benefit. Furthermore, 
manipulating the machinery that controls splicing to repair misregulated 















1.10 Aim of thesis 
 
The rationale of this study is that the activity of splicing factors that associate with 
tau pre-mRNA transcript during RNA processing may be misregulated in sporadic 
tauopathies (for example, changes in expression level), which could lead to their 
identification as novel therapeutic targets. Potential targets include CELF1 and 
CELF2 implicated in the pathogenesis of DM1; as well as CELF3 and CELF4, 
implicated in tau alternative splicing. Also, SC35, SRp40 and SRp55 are 
modulators of tau alternative splicing.  
 
The specific aim of this project is: 
 
To investigate whether expression of splicing factors that modulate tau splicing is 
correlated with tau exon 10 splicing in brain regions affected in AD.  
 
The specific objectives of this thesis are: 
 
• To determine total levels of specific CELF proteins by quantitative 
western blotting in brain regions affected in AD (temporal cortex, 
amygdala and hippocampus) using human post-mortem brain tissue from 
AD patients (with (+) and without (-) TDP-43 inclusions) and age-matched 
controls. 
 
• To determine, the levels of transcripts encoding specific CELF proteins 
(CELF1, CELF3 and CELF4) and SR proteins (SRp55, SRp40 and SC35) 
using quantitative reverse transcription polymerase chain reaction (RT-
qPCR). Affected and unaffected areas from human post-mortem brain 
tissue of AD patients (with (+) and without (-) TDP-43 inclusions) and 
age-matched controls were analysed.  
 
• To correlate the expression levels of CELF proteins and SR proteins with 




The comparison of the levels of expression of the splicing factors in normal and 
diseased brain will give an insight to whether the expression of splicing factors 
changes in sporadic AD.  This will elucidate their importance in 
neurodegeneration. Understanding the mechanisms by which splicing factors 
regulate alternative splicing of tau in normal and diseased human brain will 
provide another avenue with which to therapeutically intervene in these 
dementias.  




2 Materials and methods 
 
2.1 Materials  
 
Molecular biology, microbiology and cell culture reagents were purchased 
from Invitrogen Ltd. (Paisley, UK), unless otherwise stated.  All other 
chemicals were purchased from Sigma-Aldrich Company limited (Dorset, 
UK) except where indicated. Ultrapure water from an Elga Maxima water 
purification system was used to prepare stock and buffer solutions. 
 
2.1.1 General reagents and stock solutions 
 
• Albumin, bovine (1mg/ml), BSA in ultra-pure water) 
• Agarose  
• Ammonium persulphate (APS), 10 % (w/v) (National Diagnostics 
Ltd., Yorkshire, UK)  
• Ampicillin, 100 mg/ml in ultra-pure water 
• Bromophenol blue, 0.5 % (w/v)  
• Dithiothreitol (DTT) 
• Ethanol, ~99.9 % (v/v) (Merck Biosciences, Hertfordshire, UK) 
• Ethidium bromide (10 mg/ml) 
• Ethylenediaminetetra-acetic acid (EDTA) (Merck Biosciences, 
Hertfordshire, UK) 
• Foetal bovine serum (FBS) (Sera Laboratories International, West 
Sussex, UK) 
• Hoechst 33258  
• Isopropyl-beta-D-thiogalactopyranoside (IPTG) 
• L-glutamine 
• Glycerol ~98 % (v/v) 
• Isopropanol (Merck Biosciences, Hertfordshire, UK) 
• Beta-mercaptoethanol (Merck Biosciences, Hertfordshire, UK) 
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• Methanol, 100 % (v/v) (Merck Biosciences, Hertfordshire, UK) 
• Orange G 
• Penicillin/ Streptomycin 
• Polyoxyethylene sorbitan monolaurate (Tween 20) 
• Sodium dodecyl sulphate (SDS) (National Diagnostics Ltd.) 
• SYBR Green I (Roche Diagnostics) 
• N,N,N’,N’-tetra-methylethylenediamine(TEMED)(National 
Diagnostics Ltd.) 
• TRIS (hydroxymethyl) aminomethane acetate salt 
• TRIS (hydroxymethyl) aminomethane hydrochloride   
• Triton X-100, 10 % (v/v) 
• Trizol® reagent (Invitrogen) 
• Trypsin-EDTA 
• X-gal (50mg/ml) (Promega) 
 
 
2.1.2 Bacterial strains 
Escherichia coli (E.coli) host strain, JM109 (Promega, Southampton, UK) 
was used to amplify plasmids. 
 
2.1.3 Bacteria culture media and reagents 
 
2.1.3.1 Luria-Bertani (LB) broth base 
 
A pre-mixed powder consisting of (per one litre): 1 % (w/v) SELECT 
Peptone 140, 0.5 % (w/v) NaCl and 0.5 % (w/v) SELECT yeast extract, 
pH 7.0 was purchased.  A 2 % (w/v) solution was prepared in 1 litre 
culture flasks and autoclaved at 121°C for 15 min. To achieve adequate 
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2.1.3.2 LB ampicillin (LB-amp) medium 
 
A Nalgene syringe filter, 0.2 µm pore size was used to prepare filter-
sterilised stock solution of ampicillin, 100 mg/ml in ultra-pure water. A 




A pre-mixed powder consisting of 1.2 % (w/v) SELECT-agar in LB was 
purchased. A 3.2 % (w/v) solution of LB-agar was prepared in ultra-pure 
water and autoclaved at 121°C for 15 min prior to use.  
2.1.3.4 LB-amp agar 
 
Ampicillin stock solution was added to cooled, autoclaved LB-agar to give 
a final concentration of 100 µg/ml.  LB-amp agar was poured into 10 cm 
diameter sterile Petri dishes two-thirds to the top and allowed to cool. 
 




All solutions were purchased as part of a QIAprep® Spin Miniprep Kit 
(Qiagen, West Sussex, UK). 
 
2.1.5 DNA analysis solutions 
2.1.5.1 Tris-acetate-EDTA (TAE) 50× 
2M Tris-acetate (pH 8.0) 
50 mM EDTA 
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2.1.5.2 Agarose gel loading solution 6× 
0.25 % (w/v) orange G 
40 % (w/v) sucrose  
 
2.1.5.3 DNA size markers 
 
Quick-load™ 1kb DNA ladder (New England BioLabs, Hertfordshire, 
UK): 10002, 8001, 6001, 5001, 4001, 3001, 2000, 1500, 1000, 517 and 
500 bp fragments.  The 3001 bp fragment is of a higher concentration for 
easy identification. 
 
Quick-load™ 100 bp DNA ladder (New England BioLabs): 1517, 1200, 
1000, 900, 800, 700, 600, 500, 517, 400, 300, 200, 100 bp fragments.  The 
1000 and 500 bp fragments are of a higher concentration for easy 
identification. 
 
2.1.5.4 QIAquick gel extraction/reaction cleanup kit  
 
QIAquick kit (Qiagen) was used to extract and purify DNA from agarose 
gels. 
 
2.1.6 RNA analysis solutions 
 
2.1.6.1 RNA extraction 
 
RNA was extracted from cells using Trizol® reagent, a solution of phenol 
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2.1.7 Reverse transcription solutions 
 
Reverse transcription (RT) was performed using a kit (Applied 
Biosystems, Cheshire, UK).  The reagents are listed as final concentrations 
with stock concentrations in brackets.  Non-DEPC treated, nuclease free 
water was purchased from Ambion Ltd. (Cheshire, UK). 
 
• 1× RT buffer  (10× RT buffer: 500 mM KCl, 100 mM Tris-HCl, pH 
8.3) 
• 55 mM magnesium chloride (25 mM) 
• 500 µM of each deoxyNTPs (dNTPs) (dNTP mixture containing 2.5 
mM of dATP, dCTP, dGTP and dTTP) 
• 25 µM oligo-dT (dT16) (50 µM in 10 mM Tris-HCl pH 8.3) 
• 0.4 U/µl RNase inhibitor (20 U/µl in 20 mM HEPES-KOH, pH 7.6, 50 
mM KCl, 8 mM DTT, 50 % (v/v) glycerol) 
• 1.25 U/µl MultiScribe Reverse Transcriptase (50 U/µl) 
 
2.1.8 PCR Solutions 
2.3.1.1 Taq DNA polymerase in storage buffer B 
 
PCR was carried out using Taq DNA polymerase in storage buffer B 
(Promega).  Taq DNA polymerase is a thermostable enzyme that replicates 
DNA at 74 ºC and exhibits a half-life of 40 min at 95 ºC. Taq catalyses the 
polymerisation of nucleotides into duplex DNA in the 5’-3’ direction in 
the presence of magnesium.   
2.3.1.2 Taq DNA polymerase 5× buffer 
 
Containing (working concentration 1:10) 
• 50 mM KCl 
• 10 mM Tris-HCl pH 9.0 
• 1.5 mM MgCl2 
• % (v/v) Triton X-100 
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2.3.1.3 2’-Deoxynucleoside 5’-triphosphates (dNTPs) 
 
Each nucleotide (Amersham Pharmacia Biotech UK Ltd., 
Buckinghamshire, UK) was supplied as a 100 mM solution in sterile ultra-
pure water (pH 7.5).  A 12.5× stock solution containing 2.5 mM of each 
dNTP was prepared by mixing 5 μl of dATP, dCTP, dGTP and dTTP with 




Primers were synthesised by MWG-Biotech and diluted to a working stock 
solution of 2 µM.  The melting temperature (Tm) is defined as the 
temperature at which half of the strands are in the double-helical state and 
half are in the “random-coil” state. Different formulas for calculating Tm 
have been described in the literature; consequently, Tm varies according to 
the formula chosen for their calculation.  In the present work, Tm were 
calculated by MWG-Biotech and provided with each oligonucleotide 
synthesis report (Tm = 69.3 + 0.41 x GC % - 650/length of sequence).  
The primers used in this work are described in Table 2.1.   
 
 
2.3.1.5 Quantitative reverse transcription polymerase chain reaction 
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Table 2.1. Primers used  
 Name Location Sequence      Product(s) 
      Size (bp) 
GAPDH G1 
 
Exon 4 5’-GCCCAATACGACCAA ATCC-3’ 
 







Exon 5 5’-CCAGAGGCGTACAGG GATAG-3’           97 
βA2 
 
Exon 6 5’-CCAACCGCGAGAAGATGA-3’ 
Tau 9-13 
(Figure 2.1) 







274 E13 Exon 13 5’-TGGTCTGTCTTGGCTTTGGC-3’ 
 
Total  Tau TF Exon 8 5’- GATTGGGTCCCTGGACAATA -3’ 
 
          106 
TR Exon 9 5’- GTGGTCTGTCTTGGCTTTGG -3’ 
 
SC35 35F Exon 3 5’-CTACAGCCGCTCGAAGTCTC -3’ 
 
         171 
35R Exon 3 5’- GATTCCCTCTTGGACACTGG-3’ 
 
SRp40 40F Exon 6 5’-GGAAGTAACGTTTGCGGATG-3’ 
 
         177 
40R Exon 8 5’- GGATCGAGACCTGCTTCTTG -3’ 
 
SRp55 55F Exon 4 5’-CACAAGCCATAGGCGATCTT-3’ 
 
         172 




Exon 8 5’-TCCTCTGGAACCTCAACAC-3’         236 
C1R 
 
Exon 10 5’-AGGGCCCAAGTGAGGCTAT-3’ 
CELF3 C3F 
 
Exon 8 5’-CTGCCCCTGATGCTCTGTAT-3’         209 
C3R 
 
Exon 10 5’-CTGCTGCTGTTGAGGTGG-3’ 
CELF4 C4F 
 
Exon 7 5’-CACCTATGACCCCAACCTCA-3’        236 
C4R 
 
Exon 9 ACCTGCATACTGCTGCACTC -3’ 




2.3.2 Nuclease free water 
 
2.3.3 TURBO DNase (2 U/µl) 
• pTRI-Xef, 0.5 mg/ml (Control Template) 
• Ammonium acetate stop solution, 5 M ammonium acetate, 100 mM 
EDTA 
• Lithium chloride precipitation solution, 7.5 M lithium chloride, 50 mM 
EDTA 
• 10× Reaction buffer 
• ATP solution, 75 mM 
• CTP solution, 75 mM 
• GTP solution, 75 mM 
 
2.3.4 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) solutions 
2.1.11.1 Laemmli sample buffer (2×) 
• 125 mM TRIS-HCl pH 6.8 
• 4 % (w/v) SDS 
• 5 % (v/v) β-mercaptoethanol  
• 20 % (v/v) glycerol 
• 0.05 % (v/v) bromophenol blue 
2.1.11.2 Acrylamide working stock 
 
Acrylamide stock was purchased as ProtoGelTM solution (National 
Diagnostics Ltd.) and consists of: 
• 30 % (w/v) acrylamide 
• 0.8 % (w/v) bis-acrylamide (37.5:1) 
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2.1.11.3 Tris-HCl SDS stock buffers 
 
The Tris-HCl SDS stock buffers used for the preparation of the resolving 
and stacking gels were purchased from National Diagnostics Ltd.  
ProtoGelTM Resolving Buffer solution consisted of 1.5 M Tris-HCl (pH 
8.8) and 0.1 % (w/v) SDS, whereas ProtoGelTM Stacking Buffer consisted 
of 0.5M Tris-HCl (pH 6.8) and 0.1 % (w/v) SDS. 
 
2.1.11.4 Resolving gel, pH 8.8 
• 10 % (w/v) bis-acrylamide 
• 25 % (v/v) resolving buffer 
• % (w/v) APS  
• % (v/v) TEMED  
2.1.11.5 Stacking gel, pH 6.8 
• 4 % (w/v) bis-acrylamide  
• 25 % (v/v) stacking buffer  
• 0.075 % (w/v) APS  
• 0.15 % (v/v) TEMED 
2.1.11.6 Running buffer (10×), pH 8.3  
• 0.25 M Tris-HCl 
• 1.92 M glycine 
• 1 % (w/v) SDS 
 
2.1.12 Protein molecular weight markers 
 
Precision Plus Protein Standards (All Blue) were purchased from Bio-Rad 
Laboratories Ltd. and contained ten proteins of 10 kDa, 15 kDa, 20 kDa, 
25 kDa, 37 kDa, 50 kDa, 75 kDa, 100 kDa, 150 kDa and 250 kDa.  The 25 
kDa, 50 kDa and 75 kDa proteins serve as reference bands because they 
are three times as intense as the other bands.  
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2.1.13 Western blotting and immunodetection solutions 
2.1.13.1 Electroblotting transfer buffer 
• 25 mM Tris-HCl (pH 8.3)  
• 192 mM glycine  
• 20 % (v/v) methanol 
2.1.13.2 Blocking solution 
5 % (w/v) skimmed milk powder in PBS-Tween-20 [0.1 % (w/v)]  
2.1.13.3 Primary antibody incubation solution 
 5 % (w/v) skimmed milk powder in PBS-Tween-20 [0.1 % (w/v)]  
2.1.13.4 Secondary antibody incubation solution 
 PBS-Tween-20 [0.1 % (w/v)] 
 
2.1.14 Immunofluorescence solutions 
2.1.14.1 Fixative 
4 % paraformaldehyde (PFA) in PBS  
2.1.14.2 Blocking and permeabilising solution 
Dissolved in PBS: 
0.1 % (v/v) Triton X-100 
 5 % PBS 
2.1.14.3 Antibody diluent  
Dissolved in PBS: 
 10 % blocking solution 
 
2.1.15 Antibodies 
Primary antibodies and secondary antibodies used are listed in tables 2.2 
and 2.3 respectively. 
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Table 2.2. Primary antibodies used for immunofluorescence and western 
blotting (WB) 


















ATCC® 1/10 - 
GAPDH  Mouse 
monoclonal 
 Sigma-Aldrich  1/1000 - 
β-actin Mouse  
monoclonal 
 Sigma-Aldrich 1/500 - 
 
 
Table 2.3. Secondary antibodies used for immunofluorescence and WB 
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2.1.16 Cell culture 
 
All medium used for the culture of cell lines was supplemented with: 
 2 mM L-glutamine 
 Penicillin (100 units/ml) 
 Streptomycin (100 µg/ml) 
2.1.16.1 Medium for Chinese hamster ovary (CHO) cells 
Nutrient mixture Ham’s F-12 (HAM)  
 10 % (v/v) FBS 
2.1.16.2 Medium for SH-SY5Y cells 
 DMEM/nut mix F-12 
 15 % (v/v) FBS 
2.1.16.3 Medium for HeLa cells 
DMEM 4.5 g/l glucose 
10 % FBS 
2.1.16.4 Hank’s balanced salt solution (HBSS) 
HBSS was purchased from Invitrogen Ltd. as a 1× solution without 
calcium chloride, magnesium chloride or magnesium sulphate.  This 
solution was used to maintain cells for short periods of time during 
passage and washing before tryptinisation. 
2.1.16.5 Trypsin solution 
Trypsin-EDTA (TE) was purchased from Invitrogen Ltd. as a solution 
containing 0.05 % (w/v) TE in PBS. 
2.1.16.6 OPTIMEM™ solution 
Optimem was purchased from Invitrogen as a 1× solution containing: 
 HEPES buffer 
 2.4 g/l sodium bicarbonate 
 Hypoxanthine 
 Thymidine 
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 Sodium pyruvate 
 L-glutamine 
 Growth factors 
 Phenol red reduced to 1.1 mg/l 
2.1.16.7 Tranfection reagents 
Transfection was performed with Lipofectamine and Plus reagent 
(Invitrogen).  
 
2.1.17 Miscellaneous stock solutions 
2.1.17.1 PBS 
PBS tablets were purchased from Sigma-Aldrich Co. Ltd.  One tablet was 
dissolved in 200 ml of ddH2O to give a final concentration of: 
0.01 M phosphate buffer pH 7.4 
0.0027 M potassium chloride 
0.137 M sodium chloride 
 
2.1.18 Human brain tissue 
 
Frozen human brain tissue was obtained post-mortem from neurologically normal 
(controls) and individuals with moderate/severe AD (Braak stages V- VI) from 
the London Neurodegenerative Diseases MRC Brain Bank, Institute of 
Psychiatry, King’s College London (Ethical Committee Protocol #: 174/02). Brain 
tissue was dissected from subjects with AD; with and without TDP-43 inclusions. 
Staging of AD cases and definitive diagnosis for AD cases with and without TDP-
43 inclusions were made according to established clinical criteria and 
neuropathological criteria by pathologists and neuropathologists at the MRC 
Brain Bank. Dissection was carried out by Dr Tibor Hortobágyi and Dr Claire 
Troakes. Five brain regions were dissected where possible. 
 
Five brain areas from each case were selected for study. Brain regions selected 
include Frontal lobe BA 8/9, Temporal lobe BA 21, Amygdala, Hippocampus and 
Cerebellum. These brain regions develop neurofibrillary tangles (NFTs) during 
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the early stages of disease are heavily affected with tangles and plaques (Braak 
and Braak, 1995). The cerebellum is used as a control region from affected 
individuals because it is largely unaffected in AD with fewer occurrences of NFTs 
and functional damage in AD (Braak and Braak, 1995). Tissue was collected and 
stored in tubes containing 200 mg and 100 mg brain tissue from 31 human brains 
and stored at -70 °C until use. 100 mg of tissue was put directly into matrix 
lysing-D tubes (Qbiogene) for RNA extraction using the FastPrep sample 
preparation system (RNA extraction from human post-mortem brain tissue is 
listed in Table 2.4).  
 
A significant factor that affects RNA quality from post-mortem human brain 
tissue is the pH of the tissue (Kingsbury et al., 1995). The pH is accepted as an 
indicator for the duration and severity of the agonal state and the simulataneous 
hypoxia leading to acidiosis. An exteneded period of agonal state (which causes 
hypoxia) may lead to reduced RNA and protein integrity and content (Chevyreva 
et al., 2007).  All our brain samples had a pH within the acceptable range (pH 6.1 
– 7.0) reported for the obtainement of good quality RNA (Bahn et al., 2001) 
(Figure 2.4). Tissues with low or acidic pH (pH < 6.0) produce fragmented RNA 
reported to have a strong correlation with tissue pH and RNA quality. This is true 
for both control and pathological brain tissue (Bahn et al., 2001).  
 
Eight controls (age range 66 – 81, mean ± STDEV. 73.5 ± 13.29), fifteen 
ADTDP43- cases (age range 69 – 97, ± 8.50) and eight ADTDP43+ cases (age 
range 73-97, ± 7.88) (Table 2.4). Control samples analysed were void of any 
pathology seen in AD brain such as tau aggregates or amyloid plaques or 
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Age sex PMD (hours) pH 
A249/07 ADTDP43+  74 M 69 6.77 
A190/07 ADTDP43+ 88 F 73 6.98 
A221/07 ADTDP43+ 86 F 47 6.67 
A205/07 ADTDP43+ 73 M 24.5 6.37 
A349/08 ADTDP43+ 86 F 14 6.56 
A348/07 ADTDP43+ 85 M 16 6.4 
A063/09 ADTDP43+ 89 M 62 6.82 
A076/09 ADTDP43+ 97 M 16.5 6.18 
A037/04 ADTDP43- 96 F 39 6.62 
A039/02 ADTDP43- 90 F 4 6.63 
A331/07 ADTDP43- 80 F 12.5 6.48 
A098/04 ADTDP43- 84 M 73 6.86 
A191/07 ADTDP43- 69 F 16.3 7.43 
A192/07 ADTDP43- 96 F 19 6.57 
A210/05 ADTDP43- 84 F <24 6.57 
A240/06 ADTDP43- 97 F 12 6.9 
A141/07 ADTDP43- 80 M 41 6.33 
A050/04 ADTDP43- 91 F 28.5 6.64 
A058/07 ADTDP43- 81 M 74 6.76 
A160/06 ADTDP43- 71 M 32 6.42 
A187/07 ADTDP43- 82 F 69 6.67 
A122/04 ADTDP43- 86 M 24 6.72 
A065/04 ADTDP43- 91 F 28.5 6.19 
A140/07 Control 81 F 16.5 6.1 
A239/03 Control 78 M 9.5 6.63 
A359/08 Control 80 F 3 6.4 
A308/09 Control 66 M 52 6.66 
A292/09 Control 43 F 43           6.66 
A123/09 Control 78 M 24           6.28 
A113/09 Control 18 M 24.5 6.44 
A048/09 Control 81 M 18 6.72 
BB case no. Brain Bank case number; PM diagnosis Post mortem diagnosis; Age = age at death; (data from Medical 
Research Council Genetic Resource for Late-onset AD); PMD Post mortem delay; ADTDP43+ Alzheimer’s disease with 
TDP-43 inclusions;ADTDP43-,Alzheimer’s disease without TDP-43 inclusions. 








2.2.1 RNA extraction 
2.2.1.1 RNA extraction from postmortem human brain  
 
All RNA methods were carried out with RNase free plasticware and RNase free 
non-DEPC treated water (Ambion). 
 
Total RNA was isolated from frozen blocks of human brain. Samples were 
homogenised in matrix lysing-D tubes in conjunction with the Qbiogene FastPrep 
sample preparation system. Total RNA was extracted from the homogenised 
samples using the Qiagen RNeasy lipid tissue kit according to the manufacturer’s 
protocol. RNase-free tubes (for storage of RNA at -70 oC), lysis solution, buffers 
and RNase free water (for elution) are provided with the Qiagen RNeasy lipid 
tissue kit. 
 
Briefly, 1 ml of 4 °C Qiazol lysis solution (containing phenol and guanidine 
thiocyanate) was added to approximately 100 mg of brain tissue inside lysing 
matrix-D tubes (Qbiogene). Matrix D tubes contain ceramic beads that 
homogenize the tissue when used in conjunction with the FastPrep 24 machine. 
This machine is a high-speed bench top homogenising device that disrupts tissues. 
RNA was eluted in 40 μl of RNase-free water. Isolated RNA was stored at -70 oC 
until use.  
2.2.1.2 RNA isolation from rat brain tissue 
 
Total RNA was isolated from frozen blocks of rat brain (snap frozen in liquid 
nitrogen) using the Qiagen RNeasy lipid tissue kit using the same protocol as for 
the human brain samples. However, we used a mortar and pestle instead of the 
matrix lysing-D tubes for homogenisation of these samples. Approximately 100 
mg of brain tissue (kept on dry ice before use) was homogenised in 1 ml of 4 °C 
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Qiazol lysis solution. The brain tissue was homogenised with approximately 20 
strokes, on ice and RNA extracted as for the human samples.  
2.2.1.3 Total RNA isolation from HeLa and SHSY5Y cells 
 
HeLa and SHSY5Y cells were grown in a monolayer in 6-well plates and lysed 
with 1 ml of Trizol® reagent (Invitrogen Ltd.) added directly onto each well. Cell 
lysis was achieved by passing the cells through a pipette several times. 
Homogenised cells were incubated at room temperature for 5 min to break nucleic 
acid-protein complexes in the cells. 200 μl chloroform was added to the 
homogenate and vortexed for 15 s. Thereafter, centrifugation of the homogenate 
was carried out at 12, 500 rpm for 15 min at 4 oC. The clear layer at the top phase 
containing RNA was transferred into a new tube while avoiding the protein-
containing interphase. RNA was precipitated with 500 μl isopropanol by 
incubating for 15 min at room temperature.  The resultant RNA pellet obtained 
after centrifugation at 12, 500 rpm for 15 min at room temperature was washed 
three times with 1 ml 75 % (v/v) ethanol before resuspension in 50 μl of RNase-
free water. The isolated RNA was stored at -70 oC. 
2.2.1.4 Quantification and DNase treatment of RNA 
 
DNase treatment of isolated RNA removed genomic contaminant DNA from the 
RNA sample. DNA-free™ kit (Applied Biosystems) was used to treat RNA 
according to the manufacturer’s instructions. Briefly, 5 μl of 10× DNase buffer 
and 1 μl rDNase were added to the RNA and mixed gently. The mixture was then 
incubated at 37 oC for 30 min. To stop the reaction, 5 μl of DNase inactivation 
reagent was added while gently mixing and incubating for 2 min at room 
temperature. The DNase and inactivation reagents were removed by 
centrifugation (10, 000 g for 1.5 min) and the resultant RNA was transferred to a 
new tube. RNA concentration was determined with Nanodrop spectrophotometer 
(Thermo Scientific) using the manufacturer’s software. The pedestal was first 
cleaned using lint-free cloth. The machine was self-caliberated after each use and 
zeroed using appropriate buffer in which the nucleic acid is stored. 1.5µl of each 
undiluted total RNA samples was analysed, recording the concentration in ng/µl. 
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Also, the OD260/OD280 readings were between 1.8 and 2.1 meaning that there is 
little or no protein contamination in a RNA sample. 
2.2.1.5 RNA integrity 
 
RNA integrity number (RIN) was measured with the Agilent RNA 6000 Pico kit 
using the Agilent 2100 Bioanalyser. Chips were prepared for all human brain 
RNA according to the manufacturer’s instructions. The RNA samples and ladder 
were prepared and kept on ice until use. RIN was measured recorded in Table 2.5. 
RIN number less than ~ 5 was excluded from data analysis because it is below the 
acceptable range for good RNA quality. 
 
Briefly, 550 μl of the RNA 6000 Pico gel matrix was placed on a spin filter, and 
centrifuged at 1, 500 g for 10 min at room temperature. This was then divided into 
65 μl aliquots. After the addition of 1 μl of the RNA 6000 Pico dye concentrate to 
the 65 ul aliquot of filtered gel, the gel-dye mix was vortexed and centrifuged at 
13, 000 g for 10 min. A RNA ladder consisting of a mixture of RNA with known 
concentration was run after the addition of 5 μl marker to the ladder and sample 
wells. 1 μl (3 ng/μl) RNA of each RNA sample was added in the 11 designated 
sample wells, followed by the addition of 1 μl of diluted RNA 6000 ladder in the 
ladder well. The kit consists of interconnected microchannels that separate RNA 
fragments (18S and 28S for eukaryotic RNA) based on their size when driven 
electrophoretically. The eukaryotic 18S and 28S RNA are detected and plotted on 
an electropherogram graph.  
 
To determine the RIN number, the area under the RNA electropherogram is 
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        Table 2.5. RNA integrity (RIN) from brain regions of human brain.  













A249/07 T2 6.8 7.4 4.3 4.8 7.8 
A190/07     T3 2.3 2.4 2.2 2.6 2.2 
A221/07 T4 2.3 2.3 2.8 2.4 4.9 
A205/07 T5 4.5 3.8 5.9 4.8 6.4 
A349/08 T6 5 5.7 3.1 3.6 6.4 
A348/07 T7 7 7.6 6.5 6.3 5.2 
A063/09 T8 5.3 5.5 5 3.2 6 









A037/04 A1 6.7 7.7 5.5 3.1 5 
A039/02 A2 4.7 4.6 4.3 3.6 6.4 
A331/07 A3 6.8 4.3 6.1 4.7 6.9 
A098/04 A4 5.3 4.2 4.7 3.8 6.7 
A191/07 A5 7.6 6.9 7.4 6.6 8.5 
A192/07 A6 5.2 4.5 5.6 5.2 5.8 
A210/05 A7 4.2 2.5 4.6 2.7 5.3 
A240/06 A8 6.1 5 4.3 4.4 2.7 
A141/07 A9 5.9 4.3 5.4 5.5 6.9 
A050/04 A10 5.2 5.4 5.9 1.1 6.1 
A058/07 A11 4.9 4.7 2.6 3 7 
A160/06 A12 3.7 4.3  5.8 7.3 
A187/07 A13 5 3.1 3.4 4.3 5.4 
A122/04 A14 6 5.6  4.1 7.8 





A140/07  C1 2.4 2.3 2.1 2.4 2.3 
A239/03 C2 4.2 5.2 4.7 6 6.8 
A359/08 C3 7.8 5.8 7.4 7.1 7.2 
A308/09 C4 4.3 4.5 2.6 3.8 4.8 
A292/09 C5 6.7 7.8 7 6.9 8.4 
A123/09 C6 4.9 5.8 4.8 5.6 3.2 
A113/09 C7 2.5 2.6 3.6 3.4 3 
A048/09 C8 4.5 6.1 4.8 4.8 7.2 
RIN FC= Frontal cortex; RIN TC= Temporal cortex; RIN A= Amygdala; RIN H= Hippocampus; RIN C= 
Cerebellum. RIN is measured in arbitrary units from 0-10 with 10 being RNA of high integrity. Missing 
values indicate where no tissue was available. 
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2.2.1.6 Reverse transcription of RNA 
 
Reverse transcription (RT) was performed using reagents from Taqman RT Kit 
(GE Heathcare).  0.5 μg of total RNA was reverse transcribed in a total volume of 
10 μl. Master mixes for each reaction are as follows: 
 
Reagent Volume (µl) Final Concentration 
10× Buffer 1 1/10 dilution 
MgCl2 (25 mM) 2.2 5.5 mM 
dNTP mix 2 500 µM of each dNTP 
Oligo-dT 0.5 2.5 µM 
RNase inhibitor 0.2 0.4 U/µl 
Reverse transcriptase (50 U/µl) 0.25 1.25 U/µl 
 
A G-storm GS1 thermal cycler was used to perform the RT reaction with 
conditions as follows: 
25 °C for 10 minutes – oligo-dT hybridization 
48 °C for 30 minutes – reverse transcription 
95 °C for 5 minutes – denature reverse transcriptase 
4 °C for storage 
 
2.2.1.7 Polymerase chain reaction  
 
Polymerase chain reaction (PCR) was performed with GoTaq polymerase 
reagents (Promega) using primers listed in Table 2.1. Master mixes for multiple 
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Reagent Volume (µl) Final Concentration 
5× Buffer 10 1/5 dilution 
dNTP mix (2.5 mM) 4 200 µM 
Forward primer 5 200 µM 
Reverse primer 5 200 µM 
H2O 15.5 n/a 
Taq polymerase 0.5 0.05 U/µl 
 
40 μl of the PCR mix was mixed with 10 μl of the RT reaction. PCR controls 
without RNA (no template condition) and/or without RT (no RT condition) as 
well as water controls were routinely carried out to detect DNA contamination in 
the RT-PCR reaction. The PCR products are analysed at the end of the reaction 
hence the name ‘end-point PCR’ in contrast to real-time PCR. Gel electrophoresis 
was used to access the presence of PCR products according to their size. The PCR 
reaction was performed with the G-Storm GS1 thermal cycler according to 




1 cycle Denaturation 95 °C for 5 min 
28 cycles 
Denaturation 94 °C for 30 s 
Annealing 62 °C for 30 s 
Extension 72 °C for 1 min 
1 cycle Extension 72 °C for 10 min 
1 cycle Storage 4 °C for storage 
 
β-actin primers 
1 cycle Denaturation 95 °C for 5 min 
28 cycles 
Denaturation 95 °C for 30 s 
Annealing 55 °C for 30 s 
Extension 72 °C for 45 s 
1 cycle Extension 72 °C for 10 min 
1 cycle Storage 4 °C for storage 
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SC35  primers  
1 cycle Denaturation 95 °C for 2 min 
40 cycles 
Denaturation 94 °C for 30 s 
Annealing 65 °C for 30 s 
Extension 72 °C for 1 min 
1 cycle Extension 72 °C for 10 min 
1 cycle Storage 4 °C for storage 
 
SRp40  primers  
1 cycle Denaturation 95 °C for 5 min 
28 cycles 
Denaturation 94 °C for 30 s 
Annealing 62 °C for 30 s 
Extension 72 °C for 1 min 
1 cycle Extension 72 °C for 10 min 
1 cycle Storage 4 °C for storage 
 
SRp55  primers 
1 cycle Denaturation 95 °C for 5 min 
28 cycles 
Denaturation 94 °C for 30 s 
Annealing 62 °C for 30 s 
Extension 72 °C for 1 min 
1 cycle Extension 72 °C for 10 min 
1 cycle Storage 4 °C for storage 
 
Endogenous tau exon 10 primers 
1 cycle Denaturation 95 °C for 2 min 
35 cycles 
Denaturation 94 °C for 30 s 
Annealing 65 °C for 30 s 
Extension 72 °C for 20 s 
1 cycle Extension 72 °C for 10 min 
1 cycle Storage 4 °C for storage 
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CELF1 primers  
1 cycle Denaturation 95 °C for 6 min 
35 cycles 
Denaturation 95 °C for 30 s 
Annealing 57.4 °C for 30 s 
Extension 72 °C for 1 min 
1 cycle Storage 4 °C for storage 
 
CELF3 primers  
1 cycle Denaturation 95 °C for 6 min 
35 cycles 
Denaturation 94 °C for 30 s 
Annealing 57.1 °C for 30 s 
Extension 72 °C for 1 min 
1 cycle Storage 4 °C for storage 
 
CELF4 primers  
1 cycle Denaturation 95 °C for 5 min 
35 cycles 
Denaturation 95 °C for 30 s 
Annealing 57.4 °C for 30 s 
Extension 72 °C for 1 min 
1 cycle Storage 4 °C for storage 
 
2.2.1.8 Quantitative RT-PCR 
 
Taqman RT Kit (GE Healthcare) was used to synthesize the first strand cDNA as 
described above. In contrast to ‘end-point’ PCR, the principle of quantitative 
reverse transcription polymerase chain reaction (RT-qPCR) also known as real-
time RT-PCR allows the amplification and fluorescent detection step to be 
performed in one machine, in a single tube while recording the data. This is 
usually done after each PCR cycle. The Chromo 4TM (Bio-Rad) which supports 
the Opticon MonitorTM version 3.1 system was used to measure accumulation of  
PCR products during amplification with fluorescent dyes. The fluorophore used in 
this study was SYBR Green I (Roche Diagnostics). 
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Briefly, the sequence-independent detection assay we used works with the 
principle that SYBR Green I bind to all double-stranded DNA (dsDNA) 
molecules irrespective of the sequence.  The Chromo 4TM machine detects SYBR 
Green I fluorescence. SYBR Green I does not fluoresce when free in solution but 
after binding to dsDNA, its fluorescence emission is enhanced as a result of 
conformational changes in the dye. Hence, the increase in SYBR Green I signal 
(measured at 530 nm) was correlated with the amount of PCR products amplified 
during the reaction.  
 
 RT-qPCR was performed on 20 ng template cDNA with The Chromo 4TM 
machine using the FastStart SYBR Green Master (Rox) (Roche Diagnostics) 
according to the manufacturer’s manual. The RT reaction was performed as 
described above (Section 2.2.1.6). For each cDNA template, primers for GAPDH 
and β-actin were loaded in different wells on the same plate. For example, SC35 
had one 10 µl reaction and a separate one for GAPDH and β-actin on the same 96 
well plate. Master mixes for multiple reactions were prepared to avoid variability. 
For one reaction, the RT-qPCR mix was as follows: 
 
Reagent Volume (µl) Final Concentration 
Fast start SYBR green (Roche)        5 1× 
Forward primer 0.5 10 µM 
Reverse primer 0.5 10 µM 
H2O 2 N/A 
cDNA 2 10 ng/µl 
 
8 μl of the PCR mix was mixed with 2 μl of the cDNA solution. Two PCR 
controls without cDNA (with water) are performed for each transcript as well as 
each house-keeping gene to detect contamination in the RT-qPCR reaction. For 
each specific transcript, the PCR conditions were 3 min at 95 °C, 40 cycles of 20 s 
at 95 °C, 30 s at 60 °C, and melting curves from 60 to 90 °C every 0.5 °C. 
Amplification of the single gene transcript was confirmed by monitoring the 
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dissociation curve. Suitable baseline range and threshold levels were set after 
visual inspection of the amplification curves. All measurements were performed 
in duplicates. GAPDH and β-actin RNA levels were used for normalisation. The 
relative quantification method was employed for quantification of target 
molecules, in which the ratio between the amount of target molecule and the 
house-keeping gene molecule within the same sample was calculated.  
2.2.1.9 Data Analysis 
Quantification of RT-PCR and RT-qPCR products 
 
Data were expressed as percentage mean ± standard error of mean (SEM) unless 
otherwise specified of 4R tau amplicon in total tau (4R + 3R tau). Differences 
between two groups for 4R tau expression were determined by unpaired Student’s 
t test. For RT-qPCR products, data were expressed as mean ± S.E.M. Differences 
between controls, ADTDP43- and ADTDP43+ groups were examined for 
statistical significance using one-way analysis of variance (ANOVA) followed by 
Tukey’s post hoc test. A P-value less than 0.05 denoted statistically significant 
difference. 
2.2.1.10 PCR primers validation 
 
The primers used for RT-qPCR for all genes of interest in human brain were 
designed on the basis of the GenBank cDNA sequence using the primer designing 
program Primer3. The primers used are listed in Table 2.1. Each primer was tested 
for specificity using the NCBI Blast program and all were shown to be gene-
specific and free of non-specific homology. The primers were then tested using 
‘end-point’ PCR amplification protocol to amplify a product from a human cDNA 
template. In all cases, a single product of the expected size was amplified (see 
results section Chapters four and five). In addition, 100 % match was detected 
after sequencing for all transcripts according to Ensemble database. Finally, the 
primers were tested under the RT-qPCR protocol and in all cases; a single melting 
temperature curve was produced which indicates that only a single amplification 
product is present (Figure 2.1 and appendix 1.2). 
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Figure 2.1. A typical RT-qPCR melting curve 
 
 
2.2.2 DNA agarose gel electrophoresis 
 
1 and 2 % (w/v) agarose gels were prepared using electrophoresis grade agarose 
(Sigma). Agarose was melted in 100 ml 1× TAE buffer using a microwave oven.  
The DNA intercalator, ethidium bromide, (Sigma, 5 μl of 10 mg/ml) was added to 
the agarose gel prior to cooling. Melted gel was allowed to set in a horizontal 
casting tray with a suitable well comb. Set gels were placed in a Hybaid 
horizontal electrophoresis tank (Thermo Scientific) containing 1× TAE buffer. 
PCR samples were loaded into the wells and run with appropriate DNA markers. 
The electrophoresis reaction was performed at 125 V until the dye front had 
reached the bottom of the gel.  
 
2.2.2.1 DNA extraction from agarose gels 
 
DNA bands were excised from the gel using a clean scalpel blade and purified 
using the QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s 
instructions. The principle of action is based on a DNA absorption membrane 
with DNA eluted from high salt conditions using a low salt buffer.  
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2.2.2.2 Acquisition of agarose gel images  
 
Images were acquired from the UVP BioDoc-ItTM transilluminator with a digital 
camera. Gels were viewed at a wavelength of 302 nm. 
2.2.2.3 Acquisition of agarose gel images and analysis with the Odyssey imager  
 
Images were acquired by scanning whole DNA gels with the Odyssey scanner to 
upload images of DNA fragments containing the infrared-dye (IRD 700) (MWG 
Biotech) labelled primers (Figure 2.2) visible by scanning with the 700 nm 
channel. To quantify alternatively spliced tau isoforms accurately, our laboratory 
developed a sensitive method where alternatively spliced variants were visualised 
and measured using the Odyssey infrared imaging system. This method was 
employed because visualisation of DNA fragments using ethidium bromide can 
prove to be problematic for quantifying small differences between alternatively 
spliced isoforms. Ethidium bromide is a DNA intercalator that only measures the 
mass of DNA rather than the number of molecules. This therefore makes it 
difficult to compare relative molecular abundances of DNA fragments with 
different sizes. For instance, a DNA fragment containing an alternative exon will 
have more ethidium bromide staining compared to one without the alternative 
exon. This makes measurements of isoform ratio incorrect for investigating 
changes in alternatively spliced isoforms. In contrast, using the labelled primers 
accurately measures changes in isoform ratio compared to DNA intercalators. 
With this method, the signal intensity detected from the primer label is 
independent of the size of the DNA. 
 
Existing tau 9 – 13 primers were modified by attaching a fluorophore at the 5’ end 
of the forward primer (Figure 2.2) (Table 2.1). The IR-700 labelled primers were 
incorporated into DNA fragments using existing PCR protocols that were 
optimised to account for the proportion of labelled to unlabelled forward primer. 
The intensity of the DNA bands was quantified using the LiCor manufacturer’s 
software. Analysis was performed in triplicate and significant differences were 
analysed by unpaired Student’s t test. 
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Figure 2.2. Position of tau  9 – 13 primer in the MAPT gene. 
Schematic structure of MAPT gene comprising of tau exons 9-10-11-12-13 and 
full-length introns 9, 10, 11 and 12. The structure of the gene products after 
alternative splicing are schematically indicated (4R and 3R). Forward and reverse 
primers are indicated with blue arrows. The Forward primer in exon 9 has a 





















Ligation of cDNA insert (extracted PCR product) and vector was performed 
overnight on slush ice with 1 µl T4 ligase and 1 µl ligase buffer (Promega) in a 
total volume of 10 µl. 100 ng of vector DNA was used and the amount of insert 
DNA calculated as follows: 
 
 ng of vector × kb size of insert             molar ratio of  insert 
                       Kb size of vector                                    vector 
 
The six PCR products resulting from primer sets SC35, SRp40, SRp55, CELF1, 
CELF3 and CELF4 were validated (Tau 9-13, Total Tau, GAPDH and β-actin 
primers have previously been validated). PCR products were cut out of 2 % 
agarose gels; DNA was extracted from agarose and purified using the QIAquick 
gel extraction kit (Qiagen) (section 2.2.2.1). The DNA was ligated into pGEM-T 
easy vectors (Promega). 
 
2.2.4 Transformation of E.coli cells 
 
20 ng of plasmid DNA was transformed into 50 µl of competent JM109 
Escherichia coli (E. coli) cells (Promega) and incubated on ice for 20 min. The 
E.coli cells were subsequently heat-shocked at exactly 42 °C for 45 s and returned 
to ice for 2 min. 950 µl of sterile LB medium without antibiotic was added to the 
bacterial suspension and incubated at 37 °C for 1 hour to allow for antibiotic 
resistance gene expression. Bacteria were centrifuged for 5 min at 8000 rpm and 
re-suspended in 50 µl LB broth. Cells were streaked out onto LB agar plates         
(LB/ampicillin/IPTG/X-Gal) and placed in an incubator overnight at 37 °C to 
isolate individual colonies. 
 
IPTG/X-Gal allows colonies containing the DNA insert to be selected by 
blue/white selection. The pGEM-T easy vector contains a LacZ gene that codes 
× 
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for the production of an enzyme beta-galactosidase. Within the LacZ gene there 
are multiple cloning sites where the plasmid is cut and the DNA insert is added. 
This produces a plasmid with foreign DNA located within the LacZ gene. When 
the LacZ gene with the foreign DNA insert is translated into an enzyme, the 
translated protein product is disrupted and a non-functioning enzyme is produced, 
hence a white colony. White colonies containing the DNA insert were selected 
and grown in 5 ml of LB broth/ampicillin in a Unitron Infors AG shaker, shaking 
225 rpm, 37 °C overnight. 
 
2.2.5 Plasmid DNA digestion by restriction endonucleases 
 
The presence of the cDNA insert was confirmed with small-scale restriction 
enzyme analytical digest and agarose gel electrophoresis before sequencing. 1 µl 
of 1 unit/µl restriction enzyme, EcoR1 (Promega) was used to digest cDNA 
inserts from 1 µg of plasmid DNA with 2 µl 10× buffer with ultra-pure water to 
produce a final volume of 20 µl. Reactions were performed at 37 °C for 2 h to 
allow for complete digestion of plasmid DNA followed by a denaturation step at 
65 °C for 10 min. Digested DNA was then run in a 2 % agarose gel 
electrophoresis to confirm the presence of the cDNA insert in the purified plasmid 
DNA (Section 2.2.2). 
 
Correct orientation of cDNA insert was confirmed by sequencing (MWG) in 
addition, to further confirm successful cloning. The insert DNA sequence was 
compared and validated with cDNA sequences downloaded from Ensemble 
database.  
 
2.2.6 Cell culture 
 
All materials used for cell culture were purchased sterile or sterilised by 
autoclaving at 121 °C for 15 minutes. Monthly tested of cells were performed to 
detect mycoplasma contamination. All procedures were performed in class II 
microbiological safety cabinets. 
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2.2.6.1 Cell  lines 
 
Throughout this study, cell lines of human origin were used. The following cell 
lines were used in this study: 
 
• SH-SY5Y - A third generation human neuroblastoma cell line originated 
from the SK-N-SH line derived from a bone marrow biopsy in 1970 
(Biedler et al., 1973; Ross et al., 1983) 
 
• HEK-293 - Human cell line of embryonic kidney origin originated by the 
transformation of normal human embryonic kidney cells with sheared 
adenovirus 5 DNA. 
 
• HeLa – A human cancer cell line of cervical cancer origin. 
 
• The mA104 hybridoma cells were used to produce mAb104 antibody.  
 
2.2.6.2 Culture of cell lines 
 
Cell lines were cultured in medium supplemented with FBS, glutamine and 
penicillin/streptomycin. All cell lines were maintained in humidified atmosphere 
containing 5 % CO2/ 95 % air were used to maintain cells in a Heraeus Hera-cell 
incubator at 37 °C. SH-SY5Y and HEK293 cells were passaged at a sub-confluent 
stage and disposed off after passage 35. HeLa cells were maintained indefinitely.  
 
The mA104 hybridoma cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 20 % (v/v) FBS.  After collection of the antibody, 
the cell pellets were resuspended in the appropriate volume of medium for further 
antibody production at approximately 106 cells/ml. The growth medium was 
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2.2.6.3 Passaging of cell lines 
 
Cells were maintained by passaging when approximately 80 % confluent. Culture 
medium was aspirated and the cells washed with HBSS. Cells were then 
trypsinised by the addition of Trypsin-EDTA solution and incubating at 37 °C 
until cells were fully detached.  Cells were then re-suspended in culture medium 
to inactivate the trypsin. Cells were then recovered by centrifugation at room 
temperature at 1000 rpm for 5 minutes using a Sorvall® Legend T centrifuge, re-
suspended in 10 ml of fresh medium and reseeded at 1/10 dilution. 
 
2.2.6.4 Production of mAb104 
 
Mouse hybridoma cells which produce the monoclonal antibody 104 (mAb104) 
were purchased from ATCC (ATCC ®). The antibody was harvested, when the 
growth medium was yellow, the cell suspension was collected in 50 ml centrifuge 
containers by spinning down at 1, 000 g for 20 min at room temperature. The 
supernatant was then transferred to fresh tubes prior to addition of 0.01 % sodium 
azide to prevent bacterial growth. mAb104 was then frozen at -20 oC until use. 
2.2.6.5 Transfection of cell lines  
Lipofectamine and Plus Reagent transfection 
 
HeLa cells were transfected with Lipofectamine Plus™ reagent (Invitrogen Ltd.) 
in 6-well plates. Two solutions were made in sterile microcentrifuge tubes:  
 
Solution A: For each transfection, 2 μg DNA (plasmid), 150 µl OPTIMEM™  and 
12 µl Lipofectamine plus reagent were mixed together and incubated for 20 min at 
room temperature. 
Solution B: For each transfection, 6 μl Lipofectamine was diluted in 1.2 ml 
serum-free Optimem. 
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The two solutions (A and B) were mixed gently, and incubated at room 
temperature for 20 min. The cells were washed once with 2 ml serum-free 
medium.  
For each transfection, 1 ml serum-free medium was added to each tube containing 
the lipid-DNA complexes. The solution was gently mixed and the diluted complex 
solution was spread over the surface of the washed cells. The cells were incubated 
for 3 h at 37 °C/ 5 % CO2. After 3 hours the transfection mixture was removed 
and replaced with the normal volume of fresh medium and incubated for 24 h. 
Cells were harvested 24 h after transfection to extract RNA.  
 
2.2.7 Immunofluorescence  
 
HeLa cells were washed with 1× PBS at 37 °C and fixed using 4 % PFA in PBS 
for 10 min at room temperature. Cells were then washed three times with 1× PBS 
followed by permeabilising with 1× PBS containing 0.1 % Triton X-100 for 30 
min at room temperature. Coverslips were removed from the plastic wells and 
inverted onto primary antibody (3B1 and anti-SR protein antibody, 104) for 1 h at 
room temperature. Coverslips were then washed three times with 1× PBS before 
being incubated with a species-specific secondary antibody at room temperature 
in the dark. Coverslips were washed again three times with 1× PBS with the final 
wash containing Hoechst 33258 (180 mM). Finally coverslips were mounted onto 
glass slides using Dako-Cytomation fluorescent mounting medium. Slides were 
viewed with a Zeiss axioskop fluorescence microscope with appropriate filters 
and imaged using the Metamorph software package (Molecular Devices, 
Sunnyvale CA).  
 
2.2.8 Protein extraction from cell lines 
 
Cell lysates were prepared from 6-well plates when 85 % confluent. 
The cells were kept on ice and washed three times with ice-cold PBS. Cells were 
then scrapped into 1× Laemmli sample buffer at 100 °C. The cell lysates were 
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then boiled for 5 min at 100 °C and centrifuged for 5 min at 1,300 g at room 
temperature before analysis by SDS-PAGE.  
 
2.2.9 Preparation of rat brain homogenate 
 
A female rat was sacrificed by overdose of CO2 followed by severing of the 
spinal cord. The brain was then removed and was quickly snap frozen in liquid 
nitrogen. Whole brain was homogenised in 1 × sample buffer containing protease 
inhibitors using a pre-chilled glass homogeniser with approximately 20 strokes. 
Brain homogenate was aliquoted into 1.5 ml tubes and kept on ice for 5 min.  
 
Brain homogenate was then transferred to pre-chilled centrifuge tubes and 
centrifuged 37,000 g for 1 h at 4 °C using a Beckman-Coulter Optima TLX 
Ultracentrifuge. The pellet was discarded and the clear supernatant was used as 
the starting material. Samples were then boiled for 5 min and centrifuged before 
analysis by SDS-PAGE. 
 
2.2.10 Preparation of Human brain homogenate 
 
Brain tissue was obtained from the London Neurodegenerative Diseases Brain 
Bank, Institute of Psychiatry, King’s College London (temporal cortex of normal 
control groups: no tau deposits n=3). Ethical approval was obtained from the local 
Ethics Committee. 
 
Human brain samples were kept on dry ice before use. 100 mg of frozen human 
brain tissue was homogenised using a microcentrifuge tube and microcentrifuge 
pestle (20 strokes) in 5ml of boiling (100 oC) 1× Laemmli sample buffer. The 
homogenate was centrifuged for 1 h at 47, 000 g at 4 oC using a Beckman-Coulter 
Optima TLX Ultracentrifuge. The clear layer in the middle (supernatant) was then 
transferred to a new tube.  
 
Due to the presence of high concentrations of SDS and β-mercaptoethanol, protein 
assays (BCA and Bradford) could not be carried out. A GAPDH (a classical 
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standard for loading control) antibody was as a protein loading measure. The 
brain homogenates were prepared for western blotting as follows. 0.0125 % (w/v) 
bromophenol blue was dissolved in ddH2O and added to the homogenised brain 
samples to make the final concentration of sample buffer, 1×. For SDS-PAGE, the 
brain homogenates were heated at 100°C for 5 min prior to centrifugation for 5 
min at 1, 300 g at room temperature prior to loading.  
 
2.2.11 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Proteins were separated on one-dimensional gels using the Mini-Protean Tetra-
cell gel system (Bio-Rad Laboratories Ltd.) based on the method of Laemmli 
(1970). 10 % (w/v) bis-acrylamide resolving gel was prepared and following 
polymerisation a 4 % (w/v) bis-acrylamide stacking gel was poured on top of the 
resolving gel. An appropriate well comb was inserted and the gel allowed to 
polymerise. Unless otherwise stated 10 µl of samples were loaded onto the gels 
and run in 1× SDS-PAGE running buffer at 150 V until the bromophenol blue dye 
front had reached the bottom of the gel. An appropriate molecular weight protein 
ladder was run in parallel.  
 
2.2.12 Western blotting (WB) 
 
Protein separated on SDS-PAGE gels were transferred to a 0.45 µm pore size 
nitrocellulose membrane (Whatman® Protran®) using a Trans-Blot Semi-Dry 
Transfer Cell™ (Bio-Rad Laboratories Ltd.). Nitrocellulose and filter paper were 
pre-soaked in electroblotting transfer buffer. The gel was carefully placed onto a 
nitrocellulose sheet and then sandwiched between two layers of 10 filter papers 
and electroblotted at 15 V for 30 min. 
 
Prevention of non-specific antibody binding was achieved by blocking 
nitrocellulose membranes overnight at 4 °C or 1 h at room temperature in 
appropriate blocking solution; typically 5 % milk-PBS-T or BSA for mAb104. 
Appropriate primary antibody was diluted according to Table 2.2 and incubated 
for 1 h at room temperature (or overnight for mAb104). Membranes were washed 
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three times in PBS-T for 5 min. This was followed by species-specific secondary 
antibody (Table 2.3) incubation for 1 h at room temperature, in the dark after 
which the nitrocellulose membrane was washed in twice in PBS-T for 5 min. 
Membranes were stored in PBS before being analysed. Immunoreactivity was 
detected using the LI-COR Odyssey® infrared imaging (LI-COR Biosciences, 
Lincoln, NE, USA) by scanning at 700 and 800 nm. Scan intensity was adjusted 























3 Tau expression in brain regions affected in Alzheimer’s disease. 
 
TDP-43 (transactive response (TAR) DNA-binding protein 43) is an RNA-
binding protein involved in RNA splicing. The discovery of TDP-43 as the major 
constituent of pathological hallmarks present in some neurodegenerative disorders 
including amyotropic lateral sclerosis (ALS) and frontotemporal lobar 
degeneration with ubiquitin inclusions (FTLD-U) came about in the last five years 
(Arai et al., 2006); Neumann et al., 2006). In these TDP-43 proteinopathies, TDP-
43 is mis-localised from the nucleus to the cytoplasm forming aggregates (TDP-
43 inclusions). Interestingly, 20 – 30 % of AD patients, have the characteristic 
TDP-43 pathology seen in FTLD-U and ALS. The TDP-43 inclusions found in 
these AD cases are limited to the limbic system including the amygdala and 
hippocampus as explained in Chapter One. TDP-43 pathology observed in these 
AD patients may contribute to severe clinical symptoms and neuropathology seen 
in these patients (Amador-Ortiz et al., 2007b; Josephs et al., 2008; Kadokura et 
al., 2009; Wilson et al.). However, from the pathological report documented in 
appendix 1.1, there was no observed pathology in the majority of the cerebellar 
samples used in this study. 
 
We hypothesise that in sporadic AD cases; abnormal tau exon 10 splicing may 
occur and alter the 4R/3R tau ratio in regions affected in AD. It is possible that tau 
exon 10 inclusion is increased in AD cases similar to that observed in other 
tauopathies such as CBD and PSP to cause abnormal neuronal function as well as 
FTDP-17 where there is confirmed abnormal tau exon 10 splicing. This increased 
expression of tau exon 10 which will increase the 4R/3R tau ratio. TDP-43 
pathology in a subset of these AD cases may either exascerbate or ameliorate this 
abnormal splicing. Hence, TDP-43 inclusions may be protective whilst being 
detrimental to the proper functioning of a neuron. This might explain the severe 
clinical pathologies in AD cases with TDP-43 inclusions (Amador-Ortiz et al., 
2007b) in regards to tau splicing. 
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In this chapter, RT-PCR analysis was performed by Mr Michael Niblock to 
investigate the tau exon 10 splicing pattern of tau mRNA isoforms in AD cases 
with and without TDP-43 pathology. Also, total tau expression levels were 
investigated in AD patients with and without TDP-43 pathology in different brain 
regions of sporadic AD brain. Furthermore, we investigated whether the presence 
of TDP-43, influences tau alternative splicing or the total tau expression in 
sporadic AD. From here on AD cases with TDP43 inclusions will be referred to as 
ADTDP43+ and AD cases without TDP43 inclusions as ADTDP43-. For this we 
first performed RNA extraction of the different brain regions and analysed the tau 
4R and 3R isoforms profile by RT-PCR. Secondly, we have examined the total 
levels of tau by quantitative reverse transcription polymerase chain reaction (RT-
qPCR) in the different AD groups; Eight controls, fifteen ADTDP43- cases and 
eight ADTDP43+ cases were examined. Five brain areas from each case were 
selected for this study. They include four areas known to be heavily affected with 
NFTs in AD (frontal cortex, temporal cortex, amygdala and hippocampus) and 
one area only slightly affected or unaffected (cerebellum). These brain regions 
have varying involvement of NFT pathology during the stages of disease 
development (Braak and Braak, 1995; Chambers et al., 1999; Yasojima et al., 
1999). The cerebellum is used as a control region from affected individuals 
because it is largely unaffected in AD with fewer occurrences of NFTs and 
functional damage in AD (Braak and Braak, 1995).  
 
For all subsequent experiments, we considered the following criteria:   a) control 
cases analysed were void of any pathology such as tau aggregates or amyloid 
plaques or symptoms and b) AD cases are all sporadic cases with advanced 
disease (Braak and Braak stages V-VI). 
 
3.1 Tau exon 10 alternative splicing in brain regions affected in AD. 
 
We used RT-PCR analysis to determine tau mRNA isoforms expression in 
ADTDP43-, ADTDP43+ and age-matched control cases. Total RNA extracted 
from the frontal cortex, temporal cortex, amygdala, hippocampus and cerebellum 
of ADTDP43-, ADTDP43+ cases and age-matched controls was reverse 
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transcribed to produce cDNA. Tau 9 – 13 primers previously designed by Dr 
Teresa Rodriguez Martin (King’s College London) (Rodriguez-Martin et al., 
2005) allowed the amplification of both 4R tau and 3R tau sequences 
simultaneously by PCR. The forward primer is adapted by the presence of a 5’ 
infra-red label (IRD 700) as detailed in the methods section.   
 
These primers are predicted to amplify a product of 367 base pairs for the cDNA 
containing exon 10 (4R tau) and 274 base pairs for the cDNA without exon 10 
(3R tau). The intensity of tau spliced products; 4R and 3R tau bands were 
measured using the Li-Cor odyssey scanner and quantified using the 
manufacturer’s software. 4R tau is quantified as mean percentage of exon 10 
inclusion relative to total tau transcripts (mean percentage ± SEM). Statistical 
analysis was performed using Student’s unpaired t-test.  
 
 
3.1.1 Tau exon 10 splicing in frontal cortex of AD brain. 
 
The frontal cortex, which is involved in the control of skilled movements, mood 
and planning, is one of the brain regions affected in the later stages of AD 
(Tamminga and Buchsbaum, 2004). To investigate whether the frontal cortex with 
NFT pathology has altered pattern of tau alternative splicing, we analysed the 4R 
and 3R tau expression in the frontal cortex of AD brain compared to controls.  
 
In the frontal cortex of ADTDP43- and ADTDP43+ cases as well as age-matched 
controls, we found expression of two transcripts; an upper band corresponding to 
4R tau and a lower band corresponding to 3R tau (Figure 3.1A).  
 
In controls, the 4R/3R tau ratio is 1.03, similar to expected levels in normal 
human brain (Figure 3.1B). The 4R/3R tau ratio in ADTDP43- (1.30) and 
ADTDP43+ (1.46) were statistically similar to that found in age-matched controls 
(Figure 3.1B). Although the frontal cortex is one of the areas affected in AD with 
characteristic hallmarks including neurofibrillary tangles, the tau isoforms ratio is 
not significantly different to that observed in normal human brain regions. 
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3.1.2 Tau exon 10 splicing in temporal cortex of AD brain 
 
The temporal cortex, involved in the control of hearing, memory and language 
functions; is also one of the regions affected in AD brain. We analysed the 
alternative splicing pattern of tau exon 10 in the temporal cortex of AD patients, 
which develops neurofibrillary tangles at the early stages of AD.  
 
In all samples from ADTDP43- and ADTDP43+ cases and age-matched controls, 
tau transcripts including (4R) or excluding (3R) exon 10 were produced (Figure 
3.2 A). In controls, the 4R/3R tau ratio was 0.83, which is approximately 1 as 
expected in normal human brain (Figure 3.2 B). The 4R/3R tau ratio in 
ADTDP43- was 1.40 and in ADTDP43+ was 1.22; both of which were not 
significantly different from that observed in compared to controls (Figure 3.2 B).  
 
Hence, regardless of TDP-43 inclusions, AD cases did not show any difference in 
the 4R/3R tau alternative splicing pattern compared to age-matched individuals 
not suffering from AD. 
 
3.1.3 Tau exon 10 splicing in amygdala of AD brain 
 
The amygdala controls many brain functions including emotions, learning and 
memory. It also controls reflective emotions such as fear and anxiety.  
 
We investigated the alternative splicing of tau exon 10 in the amygdala of AD 
brain which has characteristic neurofibrillary tangles. In all samples from 
ADTDP43- and ADTDP43+ cases and age-matched controls, we detected tau 
transcripts with both exon 10 inclusion (4R) and exon 10 exclusion (3R) (Figure 
3.3 A).  
 
In controls, the 4R/3R tau ratio was 0.85 (Figure 3.3 B). The 4R/3R tau ratio in 
ADTDP43- was 1.52 and was significantly increased by 78.8 % compared to 
controls (1.52 % ± 0.08 vs. 0.85 ± 0.09, P<0.005) (Figure 3.3 B). However, the 
4R/3R tau ratio in ADTDP43+ was 1.50 and was not statistically different from 
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that observed in controls. The 4R/3R tau ratio in the amygdala was significantly 






3.1.4 Tau exon 10 splicing in the hippocampus of AD brain 
 
One of the areas first affected in AD is the hippocampus which is involved in the 
formation of long term memory; as the disease progresses, pathology spreads to 
the surrounding lobes.  
We next analysed the alternative splicing of tau exon 10 in the hippocampus of 
AD patients.  
 
In all samples from ADTDP43- and ADTDP43+ cases and age-matched controls, 
we detected tau transcripts with exon 10 (4R) and without exon 10 (3R) (Figure 
3.4 A).  
 
In controls, the 4R/3R tau ratio was 1.15 (Figure 3.4 B). The 4R/3R tau ratio in 
ADTDP43- and ADTDP43+ was 2.00 and 2.11 respectively. 4R/3R tau ratio in 
ADTDP43- was significantly increased by 73.9 % (2.00 ± 0.26 vs. 1.15 ± 0.22, 
P<0.05) but not in ADTDP4+ (2.11 ± 0.58 vs. 1.15 ± 0.22) compared to controls 
(Figure 3.4 B).  
 
3.1.5 Tau exon 10 splicing in the cerebellum of AD brain 
 
The cerebellum is involved in the control of movement and posture. This brain 
region is usually unaffected in AD. The alternative splicing of tau exon 10 in the 
cerebellum of AD patients was next analysed.  
 
In all samples from ADTDP43- and ADTDP43+ cases and controls, we detected 
tau transcripts with exon 10 (4R) and without exon 10 (3R) (Figure 3.5 A).  
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In controls, the 4R/3R tau ratio was 1.04 (Figure 3.5 B). The 4R/3R tau ratio in 
ADTDP43- and ADTDP43+ was 1.54 and 1.47 respectively. 4R/3R tau ratio in 
ADTDP43- was significantly increased by 48 % (1.54 ± 0.11 vs. 1.04 ± 0.17, 
P<0.05) but not in ADTDP4+ (1.47 ± 0.16 vs. 1.04 ± 0.17) compared to controls 
(Figure 3.5 B).  
 
3.2 Total tau expression in brain regions affected in AD. 
 
To gain insight into whether the expression ratios of 4R tau and 3R tau reflects a 
corresponding change in total tau levels in brain regions affected in sporadic AD 
cases, the total tau expression levels in the amygdala and hippocampus of AD 
patients as well as other brain regions affected in AD including the frontal cortex 
and temporal cortex were investigated. The cerebellum was used as a control brain 
region because it is largely unaffected in AD. Total RNA extracted from the 
frontal cortex, temporal cortex, amygdala, hippocampus and cerebellum of fifteen 
ADTDP43-, eight ADTDP43+ and eight age-matched normal control subjects was 
analysed by RT-qPCR. For all experiments in each brain region, we considered 
the following criteria:   
 
a) The control cases analysed were void of any pathology such as tau 
aggregates or amyloid plaques;  
 
b)  Only cases with similar expression of GAPDH and β–actin were selected 
for analysis because of variability between samples such as post mortem 
delay and RNA quality. GAPDH and β–actin house-keeping genes were 
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Figure 3.1. Tau exon 10 splicing in frontal cortex of Alzheimer’s disease and 
control brain. 
(A) Representative agarose gel of RT-PCR products obtained from RNA of 
frontal cortex from AD (ADTDP43- and ADTDP43+) brain and age-matched 
controls. 4R/3R tau spliced products were detected using infrared labelled primers 
that amplified tau between exons 9 and 13. A prominent band was detected 
around 367 bp corresponding to tau with 4 repeats (4R, tau) and a smaller band 
was detected at 274 bp corresponding to tau with 3 repeats (3R, tau) in control, 
ADTDP43- and ADTDP43+ cases. (B) The the 4R/3R tau ratio in controls is at 
1.03. The the 4R/3R tau ratio in ADTDP43- and ADTDP43+ cases is similar to 
controls, showing no significant difference between the groups. Significance was 
set at P<0.05, Student’s unpaired t test; n, control = 4, ADTDP43- = 7, 
ADTDP43+ = 6 
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RT-qPCR revealed that the total tau RNA level in the amygdala was 1.4-fold 
higher in ADTDP43- (2.37 ± 0.14 vs. 1.00 ± 0.62, P < 0.05) and 2.2-fold higher in 
ADTDP43+ (3.24 ± 0.14 vs. 1.00 ± 0.62, P < 0.05) compared to age-matched 
controls (Figure 3.6). However, in the frontal cortex of ADTDP43- and 
ADTDP43+ cases compared to age-matched controls, there was no significant 
difference in the level of total tau RNA (Figure 3.6).  Similarly, in the temporal 
cortex of ADTDP43- and ADTDP43+ cases compared to age-matched controls, 
there was no significant difference in the level of total tau RNA expression 
(Figure 3.6). Likewise, there was no significant difference in of total tau RNA 
levels in the hippocampus and cerebellum of ADTDP43- and ADTDP43+ cases 
compared to age-matched controls (Figure 3.6).  
 
   Chapter 4 
 123 
Figure 3.2. Tau exon 10 splicing in temporal cortex of control and AD brain. 
(A) Representative agarose gel of RT-PCR products obtained from RNA of 
temporal cortex from AD (ADTDP43- and ADTDP43+) brain and age-matched 
controls using infrared labelled primers, tau 9 - 13. (B) The 4R/3R tau ratio in 
ADTDP43- and ADTDP43+ cases was not statistically different from controls, 
showing no difference between the groups. Significance was set at P<0.05, 









igure 3.3. Tau exon 10 splicing in the amygdala of control and AD brain. 
(A) Representative agarose gel of RT-PCR products obtained from RNA of 
amygdala from AD (ADTDP43- and ADTDP43+) brain and age-matched controls 
using infrared labelled primers, tau 9 - 13. (B) The 4R/3R tau ratio in ADTDP43- 
cases is significantly increased by 78.8 % compared to controls. The 4R/3R tau 
ratio in ADTDP43+ cases is similar to controls, showing no significant difference 
between the groups. *, P<0.05, Student’s unpaired t test; n, Control = 5, 
ADTDP43- = 8, ADTDP43+ = 3. 





Figure 3.4. Tau exon 10 splicing in the hippocampus of control and AD brain. 
(A) Representative agarose gel of RT-PCR products obtained from RNA of 
hippocampus from AD (ADTDP43- and ADTDP43+) brain and age-matched 
controls using infrared labelled primers, tau 9 - 13. (B) The 4R/3R tau ratio in 
ADTDP43- was significantly increased by 73.9 % compared to controls. The 
4R/3R tau ratio in ADTDP43+ cases is similar to controls, showing no significant 
difference between the groups. *, P<0.05, Student’s unpaired t test; n, control = 5, 
ADTDP43- = 8, ADTDP43+ = 4. 
 





Figure 3.5. Tau exon 10 splicing in cerebellum of control and AD brain. 
(A) Representative agarose gel of RT-PCR products obtained from RNA of 
cerebellum from AD (ADTDP43- and ADTDP43+) brain and age-matched 
controls using infrared labelled primers, tau 9 - 13. (B) The 4R/3R tau ratio in 
ADTDP43- was significantly increased by 48 % compared to controls. The 4R/3R 
tau ratio in ADTDP43+ cases is similar to controls, showing no significant 
difference between the groups. *, P<0.05, Student’s unpaired t test; n, control = 5, 
ADTDP43- = 11, ADTDP43+ = 7. 
 
 






Figure 3.6. Total tau expression in control and Alzheimer’s disease (AD) 
brain.  
Total RNA was extracted from four brain regions affected in AD (frontal cortex, 
temporal cortex, amygdala and hippocampus) and one region largely unaffected in 
AD, the cerebellum. AD brain with (ADTDP43 +) and without (ADTDP43 -) 
TDP-43 inclusions and age-matched controls were analysed. In the frontal cortex 
temporal cortex, hippocampus and cerebellum, there was no significant change in 
the levels of expression of total tau in ADTDP43- and ADTDP43+ cases 
compared to controls. However, total tau expression was significantly increased in 
the amygdala of ADTDP43- and ADTDP43+ cases compared to controls. Data 
are normalised mean values with error bars indicating ± SEM of two independent 
experiments. One way ANOVA; *, P< 0.05. Newman-Keuls Multiple 
Comparison Test. n, control = 4, ADTDP43- = 6, ADTDP43+ =3. 
 




Although an increase in the expression of 4R tau in affected regions of AD has 
been previously shown, this is the first time that the pattern of tau exon 10 
splicing as well as total tau levels in AD cases with and without TDP-43 
inclusions are examined.  
 
The results presented in this chapter have demonstrated that: 
 
• There is a significant increase in levels of 4R tau in selectively vulnerable 
brain regions affected in AD including the temporal cortex, amygdala and 
hippocampus. 
 
• We found a significant increase in 4R tau levels in the temporal cortex and 
amygdala of ADTDP43- cases but not in ADTDP43+ cases. 
 
• In the hippocampus, we found an increased expression of 4R tau in AD 
cases irrespective of TDP-43 inclusions. 
 
• We also found an increase in 4R tau isoform in the cerebellum, a region 
with no NFT pathology in AD, irrespective of TDP-43 inclusions. 
 
• The total tau levels were increased only in the amygdala of AD cases 
irrespective of TDP-43 inclusions. 
 
These findings show the tau exon 10 alternative splicing and total tau 
profile in brain regions affected in AD. Taken together these results reveal 
aberrant splicing of tau pre-mRNA in tangle-prone areas of affected AD 
brain. The results suggest that the increase in 4R tau and subsequently 
total tau levels may contribute to the formation of paired helical filaments 
in NFT pathology seen in sporadic AD and not caused exclusively by post-
translational modifications. However the observation that changes are 
found in the cerebellum, a brain region relatively unaffected in AD 
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indicates that the changes in this brain region for tau splicing are not 
directly related to the degree of pathology in the AD samples.  Additional 
work is therefore required to elucidate the relationship between alternative 






4 SR proteins 
 
In this chapter, we describe the expression of SR proteins that regulate tau 
splicing in AD patients with and without TDP-43 inclusions in different brain 
regions with NFTs.  
 
We hypothesise that aberrant expression of splicing factors (SR proteins) 
regulating tau splicing may alter tau splicing and TDP-43 pathology may 
modulate the expression of splicing factors and contribute to pathogenesis of 
disease. SC35, SRp40 and SRp55 are focused on in this Chapter because they 
modulate tau exon 10 splicing in vitro (Kondo et al., 2004; Qian et al., 2011a; 
Wang et al., 2004). Since, SC35 and SRp40 are promoters of tau exon 10 
inclusion in vitro; in brain regions where tau exon 10 splicing is abnormal 
(increase in 4R/3R tau ratio), SC35 and SRp40 expression may be increased while 
SRp55 which inhibits tau exon 10 inclusion in vitro may be decreased in the 
presence of an increased exon 10 inclusion in sporadic AD cases. SC35, SRp40 
and SRp55 were the SR proteins of focus in this thesis because a lot is known 
about their function on tau exon 10 splicing in vitro (Kondo et al., 2004; Qian et 
al., 2011a; Wang et al., 2004). 
 
 
4.1 Characterisation of mAb104 
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Monoclonal antibody 104 (mAb104) binds to a phosphoepitope at the RS domain 
of all SR proteins including SRp20, SRp30, SRp40, SRp55, and SRp75; in 
interphase nuclei of many vertebrates, invertebrates and plants (Manley and 
Tacke, 1996; Roth et al., 1990; Roth et al., 1991; Zahler et al., 1992). 
 
To confirm the recognition of endogenous SR proteins by mAb104 antibody, 
immunocytochemistry was performed with HeLa cells (Figure 4.1). The pan-SR 
protein antibody, mAb104 was produced using hybridoma cells that secrete the 
antibody into the growth medium (detailed in Methods section). mAb104 binds to 
the phosphoepitope in the RS domain of all SR proteins. Nuclear speckles are 
sites for splicing factor storage in the nucleus, from where they are recruited to the 
spliceosome for transcription and RNA processing (Roth et al., 1991). The 
mAb104 detects a nuclear speckled pattern present in the nucleus of HeLa cells 
(Figure 4.1 A and C). We have confirmed that the mAb104 detects endogenous 
SR proteins localized within nuclear speckles, in agreement with previous data on 
the localisation of SR proteins (Caceres et al., 1997). 
 
4.1.1 Characterisation of mAb104 with COS cells transfected with specific SR 
proteins 
 
To verify the reactivity of mAb104, COS cells were transfected with DNA 
constructs encoding specific SR proteins: ASF2, SRp55, Tra2β, SRp40, SRp30 
and SRp20. PTB, a transcriptional splicing repressor was used as a negative 
control to confirm the specificity of mAb104 antibody (Figure 4.2). The 
expression of the transfected SR proteins DNA was determined by western blot 
analysis of whole-cell lysates. mAb104 detects three bands at 75, 55 and 30 kDa 
in the non-transfected COS cells corresponding to SRp75, SRp55 and SRp30 
(Figure 4.2) (Roth et al., 1991; Zahler et al., 1992). In COS cells, transfected with 
SRp55 and SRp40, strong bands are detected by the antibody corresponding to 
their size of 55 and 40 kDa respectively (Figure 4.2). The absence of any band in 
COS cells transfected with PTB confirmed the specificity of mAb104 for SR 
proteins. A 40 kDa band is also detected for the SR-related protein Tra2β (Figure 
4.2).  
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The mAb104 antibody produced recognises exogenous SRp55, Tra2β and SRp40 
in transfected COS cells but not PTB. Thus, the mAb104 antibody produced for 
this study recognises both endogenous and transfected individual SR proteins. 
Therefore, the mAb104 can be used to examine the expression of SR proteins in 






Figure 4.1. Characterisation of the anti-SR protein antibody, mAb104 in 
HeLa cells.  
HeLa cells were fixed and stained with (A) anti-SR protein antibody, mAb104 
and (B) Hoechst 33258 to visualise the nucleus; A and B are merged in (C). Cells 
were imaged by conventional fluorescent microscopy. mAb104 detects 

















Figure 4.2. Characterisation of mAb104 using COS cells transfected with SR 
proteins. 
COS cells were transfected with specific splicing factors: ASF2, PTB, SRp55, 
Tra2β, SRp30, SRp20 and SRp40; cells were harvested 24 h after transfection. 
Western blot analysis with mAb104 detected the presence of individual SR 
proteins; SRp55, Tra2β and SRp40 in transfected COS cells. SRp75, SRp55 and 
SRp30, corresponding to their molecular weights are expressed in the non-
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4.1.2 Characterisation of mAb104 using different cell lines. 
After the characterisation of the mAb104 using transfected COS cells, different 
cell types were used to determine the capability of mAb104 to detect endogenous 
SR proteins by western blot in different cell lines. Cells lysates from HeLa, COS, 
HEK and CHO cells were analysed by western blotting and probed with mAb104. 
The mAb104 detected proteins of molecular weight predicted for the different SR 
proteins; SRp75, SRp55, SRp40, SRp30 and SRp20 in the four cell lines (Figure 
4.3).  However, only COS and HEK cells show expression of SRp20 with a 
molecular weight of 20 kDa (Figure 4.3). Thus, we have demonstrated that the 
mAb104 antibody produced in this study recognises SR proteins, at their predicted 
sizes (although the specific identity of the individual bands requires mass 
spectrometric analysis) in different cell lines similar to that seen in the literature. 
 
4.2 SR proteins expression in adult and foetal rat brain 
 
Adult and foetal rat brain were used to validate the specificity of the mAb104 for 
members of the SR protein family.  The expression of SR proteins in rat brain was 
investigated prior to the use of human brain tissue  having characterised the 
mAb104 with transfected and non-transfected cells. SR proteins are the limiting 
factor in alternative splicing and may show changes in their expression levels 
during development (Stamm et al., 1994; Zahler et al., 1992). A gradual decline of 
the SR protein, SF2/ASF is observed from embryonic stages to adult rat brain 
(Daoud et al., 1999). Adult and foetal rat brain homogenates were prepared for 
western blotting analysis to detect the expression of SR proteins. Here we 
demonstrate that five major SR proteins are expressed in rat brain. Based on their 
molecular weight they are predicted to be SRp20, SRp30, SRp40, SRp55, and 
SRp75 with molecular weights between 20 and 75 kDa (Figure 4.4). The pattern 
of SR protein expression in rat brain is similar to that observed in different cell 
lines (Figure 4.3). However, there is an observable difference in intensity of the 
SR proteins between the adult and foetal brain (Figure 4.4). Although no 
quantitative assessment was done, extreme care was taken to ensure equal 
amounts of tissue was loaded by adding same volume of homogenates (5 ml 1 × 
sample buffer /1g of brain tissue). SR proteins at their predicted sizes (although 
the specific identity of the individual bands requires mass spectrometric analysis) 
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are readily detected in rat brain with mAb104 and a change in abundance during 





Figure 4.3. Characterisation of mAb104 in different cell lines.  
Cell lysates from HeLa, COS, HEK and CHO cells were analysed by western 
blotting and probed with mAb104. Bands corresponding to the molecular weight 
of SR proteins SRp75, SRp55, SRp40, SRp30 and SRp20 are indicated. 


















Figure 4.4. SR proteins expression in adult and foetal rat brain using 
mAb104 antibody.  
Western blot analysis of adult and foetal rat brain homogenates were probed with 
mAb104. SR proteins including bands corresponding to SRp75, SRp55, SRp40, 
SRp30 and SRp20 are observed in both adult and foetal rat brain. Molecular 











   Chapter 4 
 136 
4.3 SR proteins expression in human brain 
 
After the successful detection of SR proteins in rat brain, we analysed the 
expression of SR proteins in normal human brain. Total brain homogenates from 
three normal temporal cortices were analysed by western blotting and probed with 
the mAb104. The antibody detected numerous proteins of molecular weights 
between 30 and 75 kDa. We found that independently of age, post-mortem delay 
and sex, four major bands were detected by mAb104 in all three normal brain 
samples tentatively identified as SRp75, SRp55, SRp40 and SRp30 (Figure 4.5). 
While the “SRp75” and “SRp55” bands were conserved in all three normal brains. 
The densities of the other bands vary between the samples although equal 
amounts of protein were loaded seen from the level of GAPDH (Figure 4.5). The 
mAb104 also detects additional, unexpected bands in the three normal human 
brains that are not found in cell-lines or rodent samples. These may represent 
other members of the SR protein family for example, 9G8 with a molecular 
weight size of 36 kDa (Huang and Steitz, 2001), or may represent non-specific 
binding of antibody under these conditions. 
 
Therefore the pattern of bands seen with is antibody in human brain, is more 
complex than that seen in cell lines (Figure 4.3) and in rat brain (Figure 4.4), 
although SR proteins are conserved from rodents to humans (Figure 4.5) (Roth et 
al., 1991). The specific identity of the individual bands identified in the normal 
human brain samples were not identified in this present study, and may include 
non-specific binding.  Therefore the mAb104 antibody is not suitable for detailed 
analysis of SR protein expression in sporadic AD cases, and is means the human 
tissue western blot analysis results cannot be unequivocally interpreted. The 
specific identity of the individual bands in the normal human brain samples 
requires further analysis, with additional antibodies; the mAb104 antibody is not 
suitable for detailed analysis of predicted SR protein expression in sporadic AD 
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4.3.1 SR protein transcripts expression by RT-PCR in human brain. 
 
After we confirmed the expression of SR proteins in normal human brains using 
mAb104 at the protein level, we next sought to investigate the expression of 
individual SR proteins at the RNA level by RT-PCR. Primers that detect each 
human SR protein transcript including SC35, SRp40 and SRp55 were designed 
(Table 2.1).  
 
Total RNA extracted from three normal brain temporal cortices was reverse 
transcribed and amplified by PCR detailed in the Methods chapter. SC35, SRp40 
and SRp55 expression was assayed by RT-PCR and PCR products visualised 
using ethidium bromide staining (Figure 4.6). RT-PCR analyses showed that SR 
protein members; SC35, SRp40 and SRp55 are expressed in normal brain 
temporal cortices at RNA level (Figure 4.6) and plausibly translated to bona fide 
proteins of molecular weight sizes of 30, 40 and 55 kDa detected at protein level 
(Figure 4.5). These specific SR protein primers are used to determine the 
expression levels of relevant SR proteins by RT-qPCR in brain regions affected in 
AD in the subsequent sections. 
 
4.4 SR proteins expression in the regions affected in AD brain 
 
Here, we investigate the expression levels of SR proteins including SC35, SRp40 
and SRp55; in the amygdala and hippocampus of AD patients as well as other 
brain regions affected in AD including the frontal cortex and temporal cortex. The 
cerebellum was used as a control brain region because it is largely unaffected in 
AD. Total RNA extracted from the frontal cortex, temporal cortex, amygdala, 
hippocampus and cerebellum of fifteen AD cases without TDP-43 inclusions 
(ADTDP43-), eight AD cases with TDP-43 inclusions (ADTDP43+) and eight 
age-matched normal control subjects was analysed by quantitative RT-PCR (RT-
qPCR) explained in the Methods chapter.  
For all subsequent experiments, we considered the following criteria:   
 
 a) Control samples analysed were void of any pathology seen in AD brain such as 
tau aggregates or amyloid plaques. 
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 b) GAPDH and β–actin house-keeping genes were used as reference genes to 
normalise RNA expression of SR proteins; only cases with similar expression of 
GAPDH and β–actin were selected for analysis because of variability between 
samples such as post mortem delay and RNA quality. Samples with a Cycle 
threshold (Ct) value of more than 28 were excluded from the data analysis. Data 






Figure 4.5. SR proteins expression in normal human brain. 
Total brain homogenates from three normal brain temporal cortices were analysed 
by western blotting and probed with the mAb104 antibody. SR proteins of varying 
sizes were detected in human brain with sizes between 30 – 75 kDa. Four major 
SR proteins are expressed in the normal human brain, including: SRp75, SRp55, 
SRp40 and SRp30; indicated on the right. GAPDH (37 kDa) was used as a 
loading control. Molecular weight markers are indicated on the left.  
 














Figure 4.6. Detection of SR protein transcripts in normal human brain.  
The expression of SR proteins SC35, SRp40 and SRp55 was assayed by RT-PCR 
using three primers specific for each human SR protein transcript. GAPDH was 
used as a loading control. PCR products were visualised using ethidium bromide 
staining. Amplicon sizes of 171 bp, 177 bp, 172 bp and 469 bp were detected for 













4.4.1 SR protein expression in the amygdala of AD brain 
 
The amygdala controls many brain functions including emotions, learning and 
memory. It also controls reflective emotions such as fear and anxiety. In the 
previous chapter, we showed that there was an increased expression of 4R tau in 
the amygdala of AD cases without TDP43 inclusions (ADTDP43-) (Figure 3.3).  
 
We analysed the expression levels of SC35, SRp40 and SRp55 in the amygdala of 
ADTDP43-, ADTDP43+ and age-matched controls with the same primers that 
detected their expression in normal human brain (Figure 4.6).  
Some ADTDP43- and ADTDP43+ cases as well as control cases were excluded 
from the data analysis in the amygdala; these include: Control (C) cases, C1 and 
C4 (RIN nos < 5); ADTDP43- (A) cases A2, A8, A11, A12, A13 and A15 (RIN 
nos < 5); A3 and A5 (Ct value > 28) while A12 and A14 (no tissue available); 
ADTDP43+ (T) cases T3, T4, T6 (RIN nos < 5) while T2 and T9 (Ct value > 28).  
 
RT-qPCR revealed that the expression levels of SC35 RNA was not different in 
the amygdala of ADTDP43- and ADTDP43+ cases compared to age-matched 
controls (Figure 4.7). We found a 4-fold increase in the expression SRp55 RNA 
only in ADTDP43- cases compared to controls, (4.91 ± 0.0234 vs. 1.00 ± 0.82, P 
< 0.05) (Figure 4.7). The expression of SRp55 RNA in ADTDP43+ cases was not 
significantly different to that observed in controls (Figure 4.7). Interestingly, we 
found a 9-fold increase in SRp40 RNA expression in ADTDP43- cases compared 
to normal control subjects (10.11 ± 0.24 vs. 1.00 ± 0.84, P < 0.001). However, 
there was no significant difference in the expression of SRp40 RNA in 
ADTDP43+ cases compared to controls (Figure 4.7).  
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4.4.2 SR protein expression in the frontal cortex of AD brain 
 
The frontal cortex, which is involved in the control of skilled movements, mood 
and planning, is one of the brain regions affected in the later stages of AD 
(Tamminga and Buchsbaum, 2004).                
 
We did not find a change in tau exon 10 expression in the frontal cortex of AD 
cases with and without TDP43 inclusions. We analysed the expression levels of 
SC35, SRp40 and SRp55 in the frontal cortex of ADTDP43-, ADTDP43+ and 
age-matched controls with the same primers that detected their expression in 
normal human brain (Figure 4.6). Some ADTDP43- and ADTDP43+ cases as 
well as control cases were excluded from the data analysis in the frontal cortex; 
these include: Control (C) cases, C1 and C7 (RIN nos < 5); ADTDP43- (A) cases 
A7 and A12 (RIN nos < 5); A6, A8, A10, A11, A13, A14 and A15 (Ct value > 
28); ADTDP43+ (T) cases T3 and T4 (RIN nos < 5) while T5, T8 and T9 (Ct 
value > 28).  
 
RT-qPCR revealed that SC35 RNA level of expression was not different in the 
frontal cortex of ADTDP43- and ADTDP43+ cases compared to age-matched 
controls (Figure 4.8). There was no significant difference in the expression level 
of SRp40 RNA compared to age-matched controls (Figure 4.8). Similarly, the 
expression of SRp55 RNA was significantly different in ADTDP43- cases 
compared to age-matched controls (Figure 4.8). Furthermore, SRp55 RNA 
expression in ADTDP43+ cases showed no significant change compared to age-
matched controls (Figure 4.8). 
 
4.4.3 SR protein expression in the temporal cortex of AD brain 
 
The temporal cortex, involved in the control of hearing, memory and language 
functions; is also one of the regions affected in AD brain. In Chapter three, we 
showed that there was an increased expression of tau containing exon 10 (4R) in 
the temporal cortex of AD cases without TDP43 inclusions (ADTDP43-) (Figure 
3.2). Some ADTDP43- and ADTDP43+ cases as well as control cases were 
excluded from the data analysis in the temporal cortex; these include: Control (C) 
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cases, C1 and C7 (RIN nos < 5); C6 (Ct value > 28); ADTDP43- (A) cases A7 
and A13 (RIN nos < 5); A3, A4, A6, A9, A11, A14 and A15 (Ct value > 28); 
ADTDP43+ (T) cases T3, T4 and T5 (RIN nos < 5) while T8  (Ct value > 28).  
 
Figure 4.7. SR proteins expression in the amygdala of Alzheimer’s disease 
brain.  
SR proteins expression in the amygdala of AD brain with (ADTDP43 +) and 
without (ADTDP43 -) TDP-43 inclusions and age-matched controls were 
analysed. SR protein (SC35, SRp40 and SRp55) expression was assayed by RT-
qPCR and normalised to β-actin and GAPDH. RT-qPCR showed that there was 
no significant difference in the expression of SC35 RNA in ADTDP43- and 
ADTDP43+ cases compared to controls. However, SRp55 RNA expression was 
significantly increased only in ADTDP43- cases compared to controls. Compared 
to controls, the expression of SRp40 RNA in the amygdala of ADTDP43- cases 
was significantly increased. One-way ANOVA *, P<0.05; ***, P<0.001 (Tukey’s 
test). n, control = 6, ADTDP43- = 5, ADTDP43+ = 3.  
 




Figure 4.8. SR protein expression in the frontal cortex of Alzheimer’s disease 
brain.  
SR proteins expression in the frontal cortex of AD brain with (ADTDP43 +) and 
without (ADTDP43 -) TDP-43 inclusions and age-matched controls were 
analysed. SR protein expression was assayed by quantitative RT-PCR and 
normalised to GAPDH and β-actin. SC35, SRp40 and SRp55 expression did not 
show any significant changes in ADTDP43- and ADTDP43+ cases compared to 
controls. Significance was set at P<0.05, One-way ANOVA (Tukey’s test); n, 
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Using the same primers that detect their expression in normal brain (Figure 4.6), 
we analysed the expression levels of SC35, SRp40 and SRp55 in the temporal 
cortex of ADTDP43+, ADTDP43- and age-matched controls. In the temporal 
cortex of ADTDP43- and ADTDP43+ cases there was no significant difference in 
the expression levels of SC35 and SRp55 RNA compared to age-matched controls 
(Figure 4.9). Likewise, we did not find any difference in the expression of SRp40 
RNA in ADTDP43- cases compared to controls (Figure 4.9). 
 
4.4.4 SR protein expression in the hippocampus of AD brain 
 
One of the brain areas first affected in AD is the hippocampus which is involved 
in the formation of long term memory; as the disease progresses, pathology 
spreads to other lobes. In Chapter three, we showed that there was an increased 
expression of tau containing exon 10 (4R) in the hippocampus of ADTDP43- and 
ADTDP43+ cases compared to age-matched controls (Figure 3.4).  
 
We analysed the expression levels of SC35, SRp40 and SRp55 RNA in the 
hippocampus of ADTDP43-, ADTDP43+ and age-matched controls with the same 
primers that detected their expression in normal human brain (Figure 4.6). Some 
ADTDP43- and ADTDP43+ cases as well as control cases were excluded from 
the data analysis in the hippocampus; these include: Control (C) cases, C1, C4 and 
C7 (RIN nos < 5); ADTDP43- (A) cases A1, A2, A4, A7, A10, A11 and A14 
(RIN nos < 5);ADTDP43+ (T) cases T3, T4, T6 and T8 (RIN nos < 5). 
 
 RT-qPCR revealed that in the hippocampus of ADTDP43- and ADTDP43+ cases 
there was no significant difference in the expression levels of SC35 and SRp55 
RNA compared to age-matched controls (Figure 4.10). Similarly, the expression 
of SRp40 RNA was not different in ADTDP43- and ADTDP43+ cases compared 
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Figure 4.9. SR proteins expression in the temporal cortex of Alzheimer’s 
disease brain.  
SR proteins expression in the temporal cortex of AD brain with (ADTDP43 +) 
and without (ADTDP43 -) TDP-43 inclusions and age-matched controls were 
analysed. SR proteins expression was assayed by quantitative RT-PCR and 
normalised to β-actin and GAPDH. The expression of SC35, SRp40 and SRp55 in 
the temporal cortex did not show any significant changes in ADTDP43- and 
ADTDP43+ cases, compared to controls.  Significance was set at P<0.05 One 
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Figure 4.10. SR proteins expression in the hippocampus of Alzheimer’s 
disease brain.  
SR proteins expression in the hippocampus of AD brain with (ADTDP43 +) and 
without (ADTDP43 -) TDP-43 inclusions and age-matched controls were 
analysed. SR proteins expression was assayed by quantitative RT-PCR and 
normalised to β-actin and GAPDH. The expression of SC35, SRp40 and SRp55 in 
the hippocampus did not show any changes in ADTDP43- and ADTDP43+ cases, 
compared to controls.  Significance was set at P<0.05 One way ANOVA. n, 
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4.4.5 SR protein expression in the cerebellum of AD brain 
 
The cerebellum is involved in the control of movement and posture and is mostly 
unaffected in AD; hence, it was used as the control brain region in this study. The 
expression levels of SC35, SRp40 and SRp55 was next investigated.  
 
We analysed the expression levels of SC35, SRp40 and SRp55 in the cerebellum 
of ADTDP43-, ADTDP43+ and age-matched controls with the same primers that 
detected their expression in normal human brain (Figure 4.6) by RT-qPCR. Some 
ADTDP43- and ADTDP43+ cases as well as control cases were excluded from 
the data analysis in the cerebellum; these include: Control (C) cases, C1, C6 and 
C7 (RIN nos < 5); ADTDP43- (A) cases A8 (RIN nos < 5); A1, A4, A7, A9, A12 
and A13 (Ct value > 28); ADTDP43+ (T) cases T3 (RIN nos < 5),  T4 and T7 (Ct 
value > 28).  
 
RT-qPCR revealed that in the cerebellum of ADTDP43- and ADTDP43+ cases 
there was no significant difference in the expression levels of SC35, SRp40 and 
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Figure 4.11. SR proteins expression in the cerebellum of Alzheimer’s disease 
brain.  
SR proteins expression in the cerebellum of AD brain with (ADTDP43 +) and 
without (ADTDP43 -) TDP-43 inclusions and age-matched controls were 
analysed. SR proteins expression was assayed by quantitative RT-PCR and 
normalised to β-actin and GAPDH. The expression of SC35, SRp40 and SRp55 in 
the cerebellum did not show any significant changes in ADTDP43- and 
ADTDP43+ cases, compared to controls.  Significance was set at P<0.05 One way 
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A summary of the RT-qPCR analysis for SC35, SRp40 and SRp55 is shown in 
Figure 4.12. RT-qPCR showed that the expression level of SC35 was not different 
in all five brain regions of ADTDP43- and ADTDP43+ cases compared to age-
matched controls. However, SRp55 expression was significantly increased only in 
the amygdala of ADTDP43- cases compared to controls. There was no significant 
difference in the expression of SRp55 in ADTDP43- and ADTDP43+ cases 
compared to controls in the frontal cortex, temporal cortex, hippocampus and 
cerebellum. SRp40 showed a significant increase in expression in the amygdala of 
ADTDP43- cases compared to controls. Nevertheless, there was no significant 
differece in the expression of SRp40 in the frontal cortex, temporal cortex, 
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Figure 4.12. SR proteins expression in brain regions of AD brain.  
SR proteins expression in AD brain with (ADTDP43+) and without (ADTDP43-) 
TDP-43 inclusions of four brain regions affected in AD (frontal cortex, temporal 
cortex, amygdala and hippocampus) and one region largely unaffected in AD, the 
cerebellum; was assayed by quantitative RT-PCR and normalised to GAPDH and 
β-actin. Data are normalised mean values with error bars indicating ± SEM. One-
way ANOVA *, P<0.05; ***, P<0.001 (Tukey’s test) 




The results presented in this chapter have demonstrated that: 
 
• SR protein transcripts implicated in tau exon 10 splicing regulation 
including; SC35, SRp40, and SRp55 are expressed at the RNA level in 
normal human brain. Expression of these SR proteins do not correlate 
with pathology in AD. 
 
• The mAb104 antibody was unsuitable for detection of SR proteins in 
human brain. 
 
• The mRNA encoding SR proteins SRp40 and SRp55 are increased in the 
amygdala of AD cases without TDP-43 inclusions (ADTDP43-).  The 
increased expression of SRp40 in the amygdala of ADTDP43- cases 
compared to controls but not in ADTDP43+ cases suggest that in the 
presence of TDP-43 inclusions, SRp40 does not change.  
 
Taken together, these findings show the expression profile of mRNAs 
encoding SR proteins in normal human brain as well as in brain regions 
affected in AD.  The increase in expression of SRp40 and SRp55 mRNAs 
only in the amygdala of ADTDP-43- confirms our hypothesis that splicing 
factors can be misregulated in sporadic AD brain.  However, since the 
amygdala is a brain region which is not the most affected in AD, we note 
that the change in SRp40 and SRp55 does not correlate with extent of 
pathology 





5 CELF proteins 
 
In this chapter, we demonstrate the expression levels of CELF proteins that 
regulate tau exon 10 splicing in AD patients with and without TDP43 inclusions; 
particularly in different parts of the brain with NFT pathology.  
 
We hypothesise that aberrant expression of splicing factors (CELF proteins) 
regulating tau splicing may alter tau splicing and TDP-43 pathology may 
modulate the expression of splicing factors and contribute to pathogenesis of 
disease. CELF1, CELF3 and CELF4 are focused on in this Chapter because they 
modulate tau exon 10 splicing in vitro (Chapple et al., 2007; Wang et al., 2004) 
Since, CELF3 and CELF4 are promoters of tau exon 10 inclusion in vitro; in brain 
regions where tau exon 10 splicing is abnormal (increase in 4R/3R tau ratio in the 
amygdale and hippocampus of ADTDP43- cases); it is likely that CELF3 and 
CELF4 expression will be increased in sporadic AD cases. 
 
5.1 Characterisation of 3B1 
 
To confirm that the anti-CELF1 protein antibody, 3B1 monoclonal antibody 
recognises endogenous CELF proteins, immunocytochemistry was performed 
with HeLa cells (Jiang et al., 2004; Timchenko et al., 1996). 
  
The 3B1 antibody recognises a conserved epitope at the C-terminus RNA 
recognition motif (RRM3) in all members of the CELF family of proteins (Good 
et al., 2000).  
CELF proteins are important during post-transcriptional events such as mRNA 
stability, alternative splicing, and translational control (Jiang et al., 2004; Ladd et 
al., 2001). We show that the 3B1 antibody detects CELF proteins localised 
diffusely in the cytoplasm and nucleus (Figure 5.1A and C); consistent with their 
involvement as multifunctional proteins.  







Figure 5.1. Characterisation of the anti-CELF antibody, 3B1 using in HeLa 
cells.   
HeLa cells were fixed and stained with (A) 3B1 antibody and (B) Hoechst 33258 
to visualise the nucleus; A and B are merged in (C). Cells were imaged by 
conventional fluorescent microscopy. CELF proteins are localised in the nucleus 
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5.1.1 Characterisation of 3B1 using different cell lines 
After the characterisation of anti-CELF antibody, 3B1 using HeLa cells; cell 
lysates from HeLa and SH-SY5Y cells were analysed by western blotting and 
probed with 3B1 to confirm the capacity of 3B1 to detect endogenous CELF 
proteins in the different cell lines. The 3B1 antibody detected CELF proteins as 
doublet bands with molecular weight predicted for CELF proteins at 50 kDa in the 
two cell lines (Figure 5.2). We have demonstrated that the 3B1 antibody 
recognises CELF proteins in the two cell lines similar to that seen in the literature 
(Ladd et al., 2001). 
 
5.2 CELF proteins expression in adult and foetal rat brain 
 
The expression of CELF proteins is developmentally regulated in the brain (Ladd 
et al., 2001). We therefore wanted to determine the developmental profile of 
CELF proteins in rat brain after characterisation of the 3B1 antibody with HeLa 
and SH-SY5Y cells. This would further characterise the ability of the 3B1 
antibody to detect CELF proteins in rodents although mouse brain could have 
been used. 
 
Adult and foetal rat brain homogenates were prepared for western blotting 
analysis to detect the expression of CELF proteins. Here, we show that CELF 
proteins are expressed in rat brain based on their molecular weight at 50 kDa with 
3B1 antibody (Figure 5.3). Interestingly, we observe a difference in intensity of 
CELF proteins between adult and foetal rat brain (Figure 5.3), similar to that seen 
with the expression of SR proteins between adult and foetal rat brain (Figure 4.4). 
Although no quantitative assessment was done, extreme care was taken to ensure 
equal amounts of tissue was loaded by adding same volume of homogenates (5 ml 
1 × sample buffer /1g of brain tissue). CELF proteins are readily detected in rat 












Figure 5.2. Characterisation of the anti-CELF antibody, 3B1 in different 
cells.   
Total cell lysates extracted from HeLa and SH-SY5Y cells were analysed by 
western blotting and probed with the 3B1 antibody. The CELF proteins detected 
in both HeLa and SH-SY5Y cells appear as doublets at 50kDa. Molecular weight 

















Figure 5.3. CELF proteins expression in adult and foetal rat brain.  
Western blot analysis of adult and foetal rat brain homogenates were probed with 
the 3B1 antibody. CELF proteins are detected at 50 kDa in adult and foetal rat 
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5.3 CELF proteins expression in human brain 
To confirm the expression of CELF proteins in normal human brain, after their 
detection in rat brain, we performed a western blot analysis of homogenised 
normal human brain with 3B1 antibody.  The monoclonal antibody, 3B1 binds to 
an epitope at the third RRM (RNA recognition motif) domain of all CELF 
proteins, detecting members of the CELF family of proteins such as CELF1, 
CELF3 and CELF4) (Good et al., 2000). 
 
Total brain homogenates from three normal brain temporal cortices analysed by 
western blotting were probed with 3B1 antibody. Although the 3B1 antibody 
detects all members of the CELF family of proteins; we found that, independent 
of age, sex and postmortem delay, a single band of CELF proteins was present in 
the temporal cortex of all the normal human brain analysed (Figure 5.4). CELF 
proteins were detected at approximately 50 kDa when equal amounts of proteins 
are loaded, seen from the level of GAPDH (Figure 5.4). We therefore confirm that 
the 3B1 antibody recognises CELF proteins in normal human brain.  
 
In subsequent experiments the 3B1 antibody will be used to compare the 
expression levels of CELF proteins in AD cases compared to age-matched control 
human brain. 
 
5.3.1 Detection of CELF transcripts by RT-PCR 
 
After verification of CELF proteins expression in cell lines, rat brain and normal 
human brain at the protein level using the 3B1 antibody, we wanted to investigate 
the expression of individual CELF proteins at the RNA level by RT-PCR. This 
was done because the 3B1 antibody detects all members of the CELF family of 
proteins. To determine the expression of individual CELF proteins at RNA level 
by RT-PCR, primers that detect each human CELF protein transcript including 
CELF1, CELF3 and CELF4 were designed. CELF 5 which is expressed 
predominantly in the brain was not studied because very little is known about it 
and its influence on tau exon 10 splicing is unknown at the moment.  
 
 








Figure 5.4. CELF proteins expression in normal human brain. 
Total brain homogenates from three normal brain temporal cortices were analysed 
by western blotting and probed with the 3B1 antibody. CELF proteins were 
detected in normal human brain at 50kDa. GAPDH (37kDa) was used as a loading 
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5.3.1.1 Detection of CELF transcripts in transfected cells by RT-PCR 
 
Total RNA was extracted from HeLa cells co-transfected with CELF1, CELF3 
and CELF4 cDNA.  
 
With CELF1 primers, CELF1 amplicon with a size of 236bp was detected in 
HeLa cells transfected with CELF1 cDNA (Figure 5.5A). Likewise, in HeLa cells 
transfected with CELF3 cDNA, a 209bp CELF3 amplicon was detected (Figure 
5.5B).  With CELF4 cDNA, a 236bp amplicon was detected with CELF4 primers 
after RT-PCR (Figure 5.5C).  
 
In non-transfected HeLa cells, no amplicon was detected as expected because a 
higher number of PCR cycles are required to amplify endogenous CELF 
transcripts. GAPDH primers were used to detect endogenous GAPDH with a PCR 
product size of 496bp (Figure 5.5D). We show that the designed CELF primers 
are specific, only detecting their corresponding CELF transcripts in the 
transfected HeLa cells (Figure 5.5).  
 
5.3.1.2 Detection of CELF1 transcripts in SH-SY5Y cells 
 
To confirm endogenous expression of CELF1 transcripts in SH-SY5Y cells, total 
RNA extracted from these cells was reverse transcribed and PCR products 
amplified to detect CELF1 transcripts. CELF1 amplicons with a size of 236bp are 
detected in SH-SY5Y cells after RT-PCR analysis (Figure 5.6). This confirms 
















Figure 5.5. Detection of CELF protein transcripts in transfected cells.  
HeLa cells were transfected with CELF1, CELF3 and CELF4 cDNA for 24 h. 
RNA extracted from non-transfected and transfected HeLa cells was reverse 

















Figure 5.6. Detection of CELF1 in SH-SY5Y cells. 
CELF1 is present in SH-SY5Y cells shown by the distinct amplicons in the three 
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5.3.1.3 CELF protein transcripts expression by RT-PCR in human brain. 
 
Total RNA extracted from three normal brain temporal cortices was reverse 
transcribed and amplified using specific CELF protein primers as detailed in the 
Methods chapter. The expression of CELF proteins including CELF1, CELF3 and 
CELF4 was assayed by RT-PCR and PCR products visualised using ethidium 
bromide (Figure 5.7).  
 
RT-PCR analysis showed that CELF protein members; CELF1, CELF3 and 
CELF4 are expressed in the temporal cortices of normal human brain (Figure 5.7).  
These specific CELF protein primers will be used to determine the expression 
levels of relevant CELF proteins in brain regions affected in AD by RT-qPCR in 
subsequent sections. 
 
5.4 CELF proteins expression in the regions affected in AD brain 
 
Here, we investigate the expression levels of CELF proteins including CELF1, 
CELF3 and CELF4 in the amygdala and hippocampus of AD patients as well as 
other brain regions affected in AD including the frontal cortex and temporal 
cortex characteristically known to have a high ratio of neurofibrillary tangles in 
AD patient’s brain (Braak and Braak, 1992). CELF5 was not included in this 
study because very little is kown about its function in relation to tau splicing and 
splicing in general. The cerebellum was used as a control brain region because it 
is largely unaffected in AD. Total RNA extracted from the frontal cortex, 
temporal cortex, amygdala, hippocampus and cerebellum of fifteen AD cases 
without TDP-43 inclusions (ADTDP43-), eight AD cases with TDP43- inclusions 
(ADTDP43+) and eight age-matched normal control subjects was analysed by 















Figure 5.7. Expression of CELF transcripts in normal human brain.  
The expression of CELF proteins (CELF1, CELF3 and CELF4) was assayed by 
RT-PCR using primers specific for each human SR protein transcript; GAPDH 
was used as a loading control. PCR products were visualised using ethidium 
bromide staining. Amplicon sizes of 236 bp, 209 bp, 236 bp and 469 bp were 














For all subsequent experiments, we considered the following criteria:    
 
a) Control samples analysed were void of any pathology seen in AD brain such as 
tau aggregates or amyloid plaques. 
 
b) GAPDH and β–actin house-keeping genes were used as reference genes to 
normalise RNA expression of CELF proteins; only cases with similar expression 
of GAPDH and β–actin were selected for analysis because of variability between 
samples such as post mortem delay and RNA quality. Data are normalized means 
with error bars indicating ± SEM of two independent experiments. 
 
Total brain homogenates from the frontal cortex, temporal cortex, amygdala, 
hippocampus and cerebellum of three ADTDP43-, ADTDP43+ and age-matched 
normal control subjects were analysed by western blotting and probed with the 
3B1 antibody. Throughout these experiments, the house-keeping gene used as a 
loading control was β-actin detected at 42 kDa.  3B1 antibody was used to 
determine the relative level of expression of CELF proteins at protein level. CELF 
protein expression is determined as a ratio of CELF protein and β-actin (CELF/β-
actin). 
5.4.1 CELF protein expression in the amygdala of AD brain 
 
In Chapter three, we showed by RT-PCR that there was an increased expression 
of tau containing exon 10 (4R) in the amygdala of ADTDP43- compared to age-
matched controls (Figure 3.3). By RT-qPCR, we found an increased expression of 
total tau levels only in the amygdala of ADTDP43- and ADTDP43+ cases 
compared to age-matched controls (Figure 3.6).  
 
Here, we investigate by RT-qPCR the expression levels of CELF1, CELF3 and 
CELF4 RNA with the same primers that detected their expression in normal 
brains (Figure 5.7) in the amygdala.  
Some ADTDP43- and ADTDP43+ cases as well as control cases were excluded 
from the data analysis in the amygdala. These include: control (C) cases, C1 and 
   Chapter 5 
 165 
C4 (RIN nos < 5); ADTDP43- (A) cases A2, A8, A11, A12, A13 and A15 (RIN 
nos < 5); A6 and A9 (Ct value > 28) while A12 and A14 (no tissue available); 
ADTDP43+ (T) cases T3, T4, T6 (RIN nos < 5) while T5 and T9 (Ct value > 28).  
 
We found that the expression levels of CELF1 RNA did not change in the 
amygdala of ADTDP43- and ADTDP43+ cases compared to controls (Figure 
5.8A). There was a significant 3.4-fold increase in CELF4 RNA expression in 
ADTDP43- cases compared to age-matched controls (4.43 ± 1.19 vs. 1.00 ± 0.83, 
P < 0.05). However, in ADTDP43+ cases, the expression of CELF4 RNA was not 
significantly different to that observed in controls (2.47 ± 0.76 vs. 1.00 ± 0.83) 
(Figure 5.8A). Interestingly, we found a 5.3-fold and 8-fold increase in the 
expression CELF3 RNA in ADTDP43- (6.32 ± 0.65 vs. 1.00 ± 1.18, P < 0.05) and 
ADTDP43+ (8.98 ± 0.24 vs. 1.00 ± 1.18, P < 0.05) cases respectively compared 
to age-matched controls (Figure 5.8A). In ADTDP43+ cases, the increase in 
CELF3 RNA was more prominent than that observed in ADTDP43- cases 
compared to age-matched controls. However, this increase was not significantly 
different when ADTDP43- and ADTDP43+ cases are compared (Figure 5.8A). 
 
To determine whether these changes in CELF3 and CELF4 RNA are translated at 
protein level, we analysed brain homogenates from amygdala of three ADTDP43-
, ADTDP43+ and age-matched controls by western blotting with the 3B1 
antibody. We found the expression of CELF proteins at 50 kDa in all groups 
analysed when equal amounts of proteins were loaded seen from the levels of β-
actin (Figure 5.8B). Measurement of the intensity of the CELF protein bands at  
50 kDa relative to the amount of protein loaded (β-actin) was not different in 
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Figure 5.8. CELF proteins expression in the amygdala of AD human brain. 
(A) CELF proteins expression in the amygdala of AD brain with (ADTDP43+) 
and without (ADTDP43-) TDP-43 inclusions and age-matched controls were 
analysed. CELF protein (CELF1, CELF3 and CELF4) expression was assayed by 
RT-qPCR and normalised to β-actin and GAPDH. RT-qPCR showed that there 
was no significant difference in the expression of CELF1 RNA in ADTDP43- and 
ADTDP43+ cases compared to controls. However, CELF4 RNA expression was 
significantly increased only in ADTDP43- cases compared to age-matched 
controls. There was a significant increase in CELF3 RNA expression in 
ADTDP43- and ADTDP43+ cases compared to age-matched controls. One-way 
ANOVA *, P<0.05; (Tukey’s test). n, control = 6, ADTDP43- = 5, ADTDP43+ = 
3. (B) Total brain homogenates from the amygdala of AD (ADTDP43- and 
ADTDP43+ cases) brain and controls were analysed by western blotting and 
probed with the 3B1 antibody. (C) Optical density measurements of the western 
blots showed that CELF proteins are expressed at similar levels in the amygdala 
of ADTDP43-, ADTDP43+ cases as well as controls with no significant 
differences. Significance was set at P <0.05, One way ANOVA. 
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5.4.2 CELF protein expression in the frontal cortex of AD brain 
 
In Chapter three, we investigated the alternative splicing pattern of tau containing 
exon 10 in the frontal cortex of ADTDP43- and ADTDP43+ cases compared to 
age-matched controls by RT-PCR. We did not find any significant difference in 
the percentage of 4R tau in frontal cortex of ADTDP43- and ADTDP43+ cases 
compared to age-matched controls (Figure 3.1). Similarly, there was no 
significant difference in total tau RNA expression in the frontal cortex of 
ADTDP43- and ADTDP43+ cases compared to age-matched controls (Figure 
3.6).  
Here, we investigated the expression levels of CELF1, CELF3 and CELF4 RNA 
in the frontal cortex by RT-qPCR. We found that the expression levels of CELF1 
RNA did not show any significant difference in the frontal cortex of ADTDP43- 
and ADTDP43+ cases compared to age-matched controls (Figure 5.9A). Some 
ADTDP43- and ADTDP43+ cases as well as control cases were excluded from 
the data analysis in the frontal cortex. These include: control (C) cases, C1 and C7 
(RIN nos < 5); ADTDP43- (A) cases A7 and A12 (RIN nos < 5); A2, A6, A8, 
A10, A11, A13, A14 and A15 (Ct value > 28); ADTDP43+ (T) cases T3 and T4 
(RIN nos < 5) while T5, T6 and T8 (Ct value > 28).  
 
There was a significant 1.3-fold increase in CELF3 RNA expression in 
ADTDP43- cases compared to age-matched controls (2.26 ± 0.18 vs. 1.00 ± 0.22, 
P < 0.05) (Figure 5.9A). Interestingly, we also found a 1.5-fold increase in the 
expression of CELF3 RNA in ADTDP43+ (2.52 ± 0.19 vs. 1.00 ± 0.22, P < 0.01) 
cases compared to age-matched controls (Figure 5.9A). We investigated whether 
the increase in CELF3 RNA expression is translated at protein level in the frontal 
cortex. Brain homogenates from the frontal cortex of three ADTDP43-, 
ADTDP43+ cases and age-matched controls were analysed by western blotting 
and probed with 3B1 antibody. We show expression of varying amounts of CELF 
proteins at 50 kDa in all three groups analysed when equal amounts of proteins 
was loaded seen from the levels of β-actin (Figure 5.9B). However, there was no 
significant difference in the expression of CELF proteins at protein level in 
ADTDP43- and ADTDP43+ cases compared to age-matched controls (Figure 
5.9C).  
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Figure 5.9. CELF proteins expression in the frontal cortex of control and 
Alzheimer’s disease (AD) brain.  
(A) CELF proteins expression in the frontal cortex of AD brain with 
(ADTDP43+) and without (ADTDP43-) TDP-43 inclusions and age-matched 
controls were analysed. CELF protein (CELF1, CELF3 and CELF4) expression 
was assayed by RT-qPCR and normalised to β-actin and GAPDH. RT-qPCR 
showed that there was no significant difference in the expression of CELF1 and 
CELF4 RNA in ADTDP43- and ADTDP43+ cases compared to controls. 
However, there was a significant increase in CELF3 RNA expression in 
ADTDP43- and ADTDP43+ cases compared to control subjects.                      
One-way ANOVA; *, P<0.05; **, P<0.01; (Tukey’s test). n, control = 6, 
ADTDP43- = 5, ADTDP43+ = 3. (B) Total brain homogenates from the frontal 
cortices of ADTDP43- and ADTDP43+ cases and controls were analysed by 
western blotting and probed with 3B1 antibody. (C) Optical density measurements 
of the western blots showed that CELF proteins are expressed at similar levels in 
the frontal cortex of ADTDP43-, ADTDP43+ cases as well as controls with no 
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5.4.3 CELF protein expression in the temporal cortex of AD brain 
 
In the Chapter three, we investigated the alternative splicing pattern of tau 
containing exon 10 in the temporal cortex of ADTDP43- and ADTDP43+ cases 
compared to age-matched controls by RT-PCR. We found that there was an 
increased expression of 4R tau in the temporal cortex of ADTDP43- compared to 
age-matched controls but not in ADTDP43+ cases (Figure 3.2). However, the 
total tau level in the temporal cortex of ADTDP43- and ADTDP43+ cases was not 
significantly different when compared to age-matched controls (Figure 3.6). 
 
Some ADTDP43- and ADTDP43+ cases as well as control cases were excluded 
from the data analysis in the temporal cortex; these include: Control (C) cases, C1 
and C7 (RIN nos < 5); ADTDP43- (A) cases A7 and A13 (RIN nos < 5); A2, A4, 
A6, A9, A12, A14 and A15 (Ct value > 28); ADTDP43+ (T) cases T3, T4 and T5 
(RIN nos < 5) while T9  (Ct value > 28).  
 
Analysis of the temporal cortex by RT-qPCR showed that there was no significant 
difference in the expression levels of CELF1, CELF3 and CELF4 RNA in 
ADTDP43- and ADTDP43+ cases compared to age-matched controls (Figure 
5.10A).  
 
Western blot analysis of brain homogenates from the temporal cortex of  
ADTDP43-, ADTDP43+ and age-matched controls with the 3B1 antibody showed 
varying amounts of CELF proteins expression at 50 kDa in all three groups 
analysed when equal amounts of proteins was loaded seen from the levels of       
β-actin (Figure 5.10B). In the controls subjects, CELF protein expression was 
variable although there were relatively equal amounts of protein in each lane. We 
observed a consistent expression of CELF proteins in ADTDP43- cases compared 
to controls (Figure 5.10B). Interestingly, one of the ADTDP43+ cases showed a 
prominent increase in CELF protein expression (Figure 5.10B). However, 
statistical analysis did not show any difference in CELF proteins expression at 
protein level in ADTDP43- cases compared to age-matched controls (Figure 
5.10C). The increase in CELF protein expression observed in ADTDP43+ cases 
compared to age-matched controls was not significantly different (Figure 5.10C). 
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Figure 5.10. CELF proteins expression in the temporal cortex of control and 
Alzheimer’s disease (AD) brain.  
(A) CELF proteins expression in the temporal cortex of AD brain with 
(ADTDP43+) and without (ADTDP43-) TDP-43 inclusions and age-matched 
controls were analysed. CELF protein (CELF1, CELF3 and CELF4) expression 
was assayed by RT-qPCR and normalised to β-actin and GAPDH. RT-qPCR 
showed that there was no significant difference in the expression of CELF1, 
CELF3 and CELF4 RNA in the temporal cortex of ADTDP43- and ADTDP43+ 
cases compared to control. Significance was set at P<0.05 One way ANOVA. n, 
control = 6, ADTDP43- = 5, ADTDP43+ = 4. (B) Total brain homogenates from 
three temporal cortices of ADTDP43- and ADTDP43+ cases and controls were 
analysed by western blotting and probed with 3B1 antibody. A single band of 
CELF proteins was detected at 50 kDa with the 3B1 antibody. (C) Optical density 
measurements of the western blots showed that CELF proteins are expressed at 
similar levels in the temporal cortex of ADTDP43-, ADTDP43+ cases as well as 
controls with no significant differences. Significance was set at P <0.05, One way 
ANOVA.  
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5.4.4 CELF protein expression in the hippocampus of AD brain 
 
In Chapter three, we investigated the alternative splicing pattern of tau containing 
exon 10 (4R) in the hippocampus of ADTDP43- and ADTDP43+ cases compared 
to age-matched controls by RT-PCR. We found that there was an increased 
expression of 4R tau in the hippocampus of ADTDP43- and ADTDP43+ cases 
compared to age-matched controls (Figure 3.4). Conversely, the total tau level in 
the hippocampus of ADTDP43- and ADTDP43+ cases did not show any 
significant difference when compared to age-matched controls (Figure 3.6). 
 
We investigated the expression levels of CELF1, CELF3 and CELF4 RNA in the 
hippocampus by RT-qPCR. Some ADTDP43- and ADTDP43+ cases as well as 
control cases were excluded from the data analysis in the hippocampus; these 
include: Control (C) cases, C1 and C7 (RIN nos < 5); ADTDP43- (A) cases A1, 
A2, A4, A7, A10, A11 and A14 (RIN nos < 5); ADTDP43+ (T) cases T3, T4, T6 
and T8 (RIN nos < 5); T2 (Ct value > 28). 
RT-qPCR  revealed that the expression levels of CELF1 RNA was not different in 
the hippocampus of ADTDP43- and ADTDP43+ cases compared to age-matched 
controls (Figure 5.11A). Similarly, there was no significant difference in the 
expression levels of CELF3 and CELF4 RNA in ADTDP43- and ADTDP43+ 
cases compared to age-matched controls (Figure 5.11A). 
 
Western blot analysis of brain homogenates from the hippocampus of    
ADTDP43-, ADTDP43+ and age-matched controls with 3B1 antibody showed 
varying expression of CELF proteins at 50 kDa in all three groups analysed     
(Figure 5.11B). Although there were relatively equal amounts of protein in each 
lane, we observed variability in the expression of CELF proteins (Figure 5.11B). 
Statistical analysis did not show any difference in the expression of CELF 
proteins at protein level in ADTDP43- and ADTDP43+ cases compared to age-
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Figure 5.11. CELF proteins expression in the hippocampus of control and 
Alzheimer’s disease (AD) brain.  
(A) CELF proteins expression in the hippocampus of AD brain with 
(ADTDP43+) and without (ADTDP43-) TDP-43 inclusions and age-matched 
controls were analysed. CELF protein (CELF1, CELF3 and CELF4) expression 
was assayed by RT-qPCR and normalised to β-actin and GAPDH. RT-qPCR 
showed that there was no significant difference in the expression of CELF1, 
CELF3 and CELF4 RNA in the hippocampus of ADTDP43- and ADTDP43+ 
cases compared to control. Significance was set at P<0.05 One way ANOVA. n, 
control = 6, ADTDP43- = 5, ADTDP43+ = 3. (B) Total brain homogenates from 
the hippocampus of ADTDP43- and ADTDP43+ cases and controls were 
analysed by western blotting and probed with 3B1 antibody. A single band of 
CELF proteins was detected at 50 kDa with the 3B1 antibody. (C) Optical density 
measurements of the western blots showed that CELF proteins are expressed at 
similar levels in the hippocampus of ADTDP43-, ADTDP43+ cases as well as 
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5.4.5 CELF protein expression in the cerebellum of AD brain 
 
We examined the expression levels of CELF1, CELF3 and CELF4 RNA in the 
cerebellum by RT-qPCR. Some ADTDP43- and ADTDP43+ cases as well as 
control cases were excluded from the data analysis in the cerebellum. These 
include: control (C) cases, C1, C6 and C7 (RIN nos < 5); ADTDP43- (A) cases 
A8 (RIN nos < 5); A1, A4, A7, A9, A12 and A13 (Ct value > 28); ADTDP43+ 
(T) cases T3 (RIN nos < 5), T4, T5, T7 and T9 (Ct value > 28).  
We found that the expression levels of CELF1, CELF3 and CELF4 RNA did not 
show any significant difference in the cerebellum of ADTDP43- and ADTDP43+ 
cases compared to age-matched controls (Figure 5.12A).  
 
Western blot analysis of brain homogenates from the cerebellum of  ADTDP43-, 
ADTDP43+ and age-matched controls with 3B1 antibody showed consistent 
expression of CELF proteins at 50 kDa in the cerebellum of ADTDP43-, 
ADTDP43+ and age-matched controls when equal amounts of proteins were 
loaded seen from the levels of β-actin (Figure 5.12B). In the three controls with 
equal amounts of protein loaded, CELF proteins expression was variable in one of 
the control subjects (Figure 5.12B). Statistical analysis of CELF protein 
expression was not different in ADTDP43-, ADTDP43+ and age-matched 
controls (Figure 5.12C).  
 
A summary of the RT-qPCR analysis for CELF1, CELF3 and CELF4 is shown in 
Figure 5.13. RT-qPCR showed that the expression level of CELF1 RNA was not 
different in all five brain regions of ADTDP43- and ADTDP43+ cases compared 
to age-matched controls. However, CELF4 RNA expression was significantly 
increased only in the amygdala of ADTDP43- cases compared to controls. There 
was no significant difference in the expression of CELF4 RNA in ADTDP43- and 
ADTDP43+ cases compared to controls in the frontal cortex, temporal cortex, 
hippocampus and cerebellum. CELF3 RNA expression was significantly 
increased in the frontal cortex and amygdala of ADTDP43- and ADTDP43+ cases 
compared to controls. There was no significant difference in the expression of 
CELF3 RNA in the temporal cortex, hippocampus and cerebellum of ADTDP43- 
and ADTDP43+ cases compared to controls. 
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Figure 5.12. CELF proteins expression in the cerebellum of control and 
Alzheimer’s disease (AD) brain. 
(A) CELF proteins expression in the cerebellum of AD brain with (ADTDP43+) 
and without (ADTDP43-) TDP-43 inclusions and age-matched controls were 
analysed. CELF protein (CELF1, CELF3 and CELF4) expression was assayed by 
RT-qPCR and normalised to β-actin and GAPDH. RT-qPCR showed that there 
was no significant difference in the expression of CELF1, CELF3 and CELF4 
RNA in the cerebellum of ADTDP43- and ADTDP43+ cases compared to control. 
Significance was set at P<0.05 One way ANOVA. n, control = 6, ADTDP43- = 5, 
ADTDP43+ = 3. (B) Total brain homogenates from the cerebellum of ADTDP43- 
and ADTDP43+ cases and controls were analysed by western blotting and probed 
with 3B1 antibody. A single band of CELF proteins was detected at 50 kDa with 
3B1 antibody (C) Optical density measurements of the western blots showed that 
CELF proteins are expressed at similar levels in the cerebellum of ADTDP43-, 
ADTDP43+ cases as well as controls with no significant differences. Significance 
was set at P <0.05, One way ANOVA.  
 













Figure 5.13. CELF proteins expression in brain regions of AD brain.  
CELF proteins expression in AD brain with (ADTDP43+) and without 
(ADTDP43-) TDP-43 inclusions of four brain regions affecte d in AD (frontal 
cortex, temporal cortex, amygdala and hippocampus) and one region largely 
unaffected in AD, the cerebellum; was assayed by quantitative RT-PCR and 
normalised to GAPDH and β-actin. Data are normalised mean values with error 
bars indicating ± SEM. One-way ANOVA *, P<0.05; **, P<0.01; (Tukey’s test) 
 




The results presented in this chapter demonstrate that: 
 
• CELF protein transcripts regulating tau exon 10 splicing including; 
CELF1, CELF3 and CELF4 are expressed at the RNA level in normal 
human brain. 
 
• One band at 50 kDa corresponding to CELF1 or other members of the 
CELF family of proteins is expressed at the protein level in normal human 
brain detected with 3B1 antibody. 
 
• CELF4 is increased in the amygdala of AD cases without TDP-43 
inclusions (ADTDP43-). 
 
• There is an increased expression of CELF3 in the amygdala and frontal 
cortex of AD cases irrespective of the presence of TDP-43 inclusions 
compared to controls which suggest that in the presence of TDP-43 
inclusions, CELF3 RNA expression is increased. 
 
Taken together, these findings show the expression profile of CELF proteins in 
normal human brain and as well as brain regions affected in AD (Figure 5.13). We 
show that the expression levels of CELF proteins (CELF3 and CELF4) that 
regulate tau splicing is altered in brain regions affected in AD. Taken together, 
our data confirms our hypothesis that the expression levels of splicing factors such 
as CELF3 and CELF4 may be altered, resulting in abnormal splicing activity in 








6  Discussion 
 
Mutations in the MAPT gene cause FTDP-17 due to abnormal tau exon 10 
splicing (Hutton et al., 1998). Additionally, the presence of tau exon 10 
missplicing in sporadic tauopathies such as PiD (3R tau overexpression), CBD 
and PSP (4R tau overexpresssion) suggests that splicing factors that regulate tau 
exon 10 splicing may contribute to the pathogenesis of these diseases. 
Furthermore, it indicates that neurodegeneration can be driven in humans 
regardless of which tau isoform is favoured. Elucidation of the underlying 
mechanisms by which these changes in tau alternative splicing affect tau’s cellular 
function and result in neurodegeneration is a focus of scientific interest. 
 
Understanding the exact function of RNA-binding proteins in tauopathies may be 
central to elucidating their role in the pathogenesis of sporadic tauopathies. RNA-
binding proteins play an essential role in splicing and their aberrant expression 
and/or activity leads to several neurological disorders as seen in myotonic 
dystrophy (Ladd et al., 2001). Whether the abnormal expression and/or activity of 
splicing factors in tauopathies are decisive to tau splicing deficit remains elusive. 
The expression levels of CELF proteins and SR proteins involved in regulation of 
tau splicing has not been studied in sporadic tauopathies. This thesis has 
characterised the alternative splicing pattern of tau exon 10 as well as the 
expression profile of members of two families of RNA-binding proteins; SR 
proteins and CELF proteins in sporadic AD cases with and without TDP-43 
inclusions (ADTDP43+ and ADTDP43-). 
 
6.1 Aberrant tau splicing in AD human brain 
 
Aberrant tau exon 10 splicing had been previously described in brain regions of 
sporadic tauopathies including CBD, PSP, PiD and AD (Chambers et al., 1999; 
Takanashi et al., 2002; Umeda et al., 2004; Yasojima et al., 1999); (Connell et al., 
2005). We have now analysed the tau exon 10 splicing pattern in sporadic AD 
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cases with and without TDP-43 inclusions. We found a significant increase in 4R 
tau in vulnerable brain regions affected in AD. Specifically, in the amygdala of 
ADTDP43- cases where there is extensive NFT pathology, we found an increase 
in 4R/3R tau ratio by approximately 78.8 % compared to age-matched controls. 
Our findings are supported by increased 4R tau observed in the temporal cortex of 
sporadic AD cases previously determined by Glatz et al. (Glatz et al., 2006).  In 
the frontal cortex, a region that is heavily affected with NFT pathology during the 
late stages of AD, we found that the percentage of 4R tau in AD cases irrespective 
of TDP-43 pathology was similar to that expressed in normal human adult brain. 
In addition, in the hippocampus, one of the brain regions first affected in AD, we 
found that 4R/3R tau ratio in AD cases without TDP-43 pathology was 
significantly increased by approximately 73 %.  
 
This disturbance of the tau 4R/3R expression from the normal approximate ratio 
of 1:1 results in enhanced NFT formation and neurodegeneration (Andreadis, 
2005). The pathological consequence of disturbed 4R/3R ratio where more 4R is 
favoured often alters tau function resulting in several pathogenic mechanisms. 
Hence, the equal expression of 4R tau and 3R tau in normal adult human brain is 
essential to maintain normal neuronal tau functions (Adams et al., 2010). These 
findings propose that altering the normal equimolar 4R/3R tau ratio may 
contribute to tau pathology in sporadic AD. The splicing pattern expression of the 
tau isoforms is regulated by RNA-binding proteins which are vital in determining 
the equimolar 4R/3R tau ratios. 
 
The RT-PCR technique used in this study to determine the 4R/3R tau ratios does 
not indicate which cell types possess this increased expression of 4R tau. 
However, Goedert et al. showed that hippocampal pyramidal neurons and granule 
cells of the hippocampus, a region with early tau pathology, are vulnerable in AD 
brain (Goedert et al., 1989a; Goedert et al., 1989b). Interestingly, in the 
cerebellum, one of the brain regions spared in AD, we observed that 4R tau 
expression in ADTDP43- pathology was significantly increased. It is possible that 
the mechanism of tau missplicing is not specific to brain regions susceptible to 
NFT pathology only or that the changes observed in the cerebellum are very 
subtle and not sufficient to cause NFT pathology in the convoluted brain region. 
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The reason why NFT pathology develops in specific brain areas is not yet 
understood.  
 
The intensities of the 4R tau and 3R tau isoform bands obtained within the AD 
groups (ADTDP43- and ADTDP43+ cases) varied greatly probably due to 
severity of symptoms and/or variation between individual AD patients as well as 
brain areas. This could be because AD cases with more severe NFT pathology 
show dramatic increase in the percentage 4R tau (Figures 3.2, 3.3, 3.4 and 3.5). 
The study of tau exon 10 splicing in sporadic AD has revealed conflicting results 
probably due to variability between studies and AD subjects used. For instance, 
some studies do not show any differences in exon 10 splicing in AD 
(Boutajangout et al., 2004; Chambers et al., 1999; Connell et al., 2005; Ingelsson 
et al., 2006). Although we did not determine whether the increase in 4R tau 
isoforms was translated to the protein level, we wanted to elucidate whether the 
expression of splicing factors regulating tau exon 10 splicing are altered at the 
RNA level in AD brain. 
 
As predicted in the hypothesis, there was an increase in the expression of exon 10 
in the amygdala and hippocampus, regions shown to possess extensive 
neuropathology (Appendix 1.1). We have now discerned using this RT-PCR 
approach that tau splicing is infact aberrant in these ADTDP43- cases. The 
possible explanation for this abnormal tau exon 10 splicing in brain regions 
(amygdala and hippocampus) affected by AD is that there is abnormal regulation 
of the splicing mechanism in brain regions with NFT pathology of AD patients. 
However, the change in transcript levels in the cerebellum in the absence of 
pathology in most AD cases casts doubt on the relevance of the approach to 
disease. Although the cerebellum is considered as a region without any pathology 
in AD patients yet, the reason for this an increase in the 4R/3R tau ratio in 
ADTDP43- cases is unknown. 
  
 Moreover, tangle development is unlikely to drive the shift in increased 4R tau 
expression in the amygdala and hippocampus because the cerebellum which is not 
normally associated with NFT pathology also showed an increased expression of 
4R tau. The fact that mutations in the MAPT gene have not been associated with 
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AD (Poorkaj et al., 2001) suggests that other factors involved in the regulation of 
tau exon 10 splicing may disrupt tau splicing and contributes to the pathogenesis 
of AD. Hence, splicing factors may be genetic modifiers of disease pathology 
through their influence and control of tau exon 10 splicing (Nissim-Rafinia and 
Kerem, 2002). Our data suggest that abnormal splicing regulation of tau exon 10 
splicing results in favourable expression of 4R tau which may subsequently 
promote tangle formation.  
 
6.2 RNA-binding proteins in human brain. 
 
The processes of RNA metabolism involves several proteins that mediate and 
regulate all aspects of RNA processing. RNA-binding proteins themselves are 
subject to post-transcriptional and post-translational modifications such as 
alternative splicing and phosphorylation respectively. They are also involved in 
RNA processing, mRNA transport, mRNA stability and mRNA translation 
(Anthony and Gallo, 2010). Tau exon 10 splicing is under the synergistic control 
of cis-acting elements and trans-acting factors. As seen in sporadic tauopathies, in 
the absence of mutations within the MAPT gene and predisposing haplotypes, tau 
pathology still develops. RNA-binding proteins involved in the regulation of tau 
exon 10 alternative splicing may contribute to pathogenesis of sporadic AD due to 
altered expression or activity. Furthermore, the expression profiling of RNA-
binding proteins involved in tau alternative splicing in AD brain is important to 
elucidate a potential mechanism by which tau splicing is misregulated. This is 
because the expression level of splicing factors including SR proteins is closely 
related to their regulatory activity in specific adult brain tissues (Grabowski and 
Black, 2001) (Hsu et al., 2011). However, the activity of most splicing factors is 
not solely dependent on their abundance, but also regulated by their 
phosphorylation state (Nissim-Rafinia and Kerem, 2002).  We characterised the 
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6.2.1 Expression of SR proteins in human brain 
 
SR proteins have previously been detected in cell lines and rat brain at the RNA 
and protein level (Daoud et al., 1999; Zahler et al., 1992). We have shown in 
normal human brain that SR proteins including SC35, SRp40 and SRp55 are 
expressed at RNA level as well as the presence of bona fide members of the SR 
protein family in normal human brain using mAb104. The mAb104 detects a 
phosphoepitope in the RS domain of all SR proteins (Zahler et al., 1992). This 
antibody was used to show expression of SR proteins in normal human brain. 
 
We showed that the mAb104 antibody recognises SR proteins in different cell 
lines and rat brain similar to that seen in the literature (Delacourte et al., 1998; 
Gui et al., 1994b). The variation we observed in the expression of SR proteins at 
protein level in normal human brain could be due to posttranslational 
modifications such as phosphorylation (Hanamura et al., 1998). mAb104 also 
detects other bands in the three normal brain; these may represent other members 
of the SR protein family for example, 9G8 with a molecular weight size of 36 kDa 
(Huang and Steitz, 2001). Hence, we show the expression of SR proteins at the 
RNA and protein level in normal human brain before investigating by RT-qPCR, 
the RNA levels of specific SR proteins involved in the regulation of tau exon 10 
splicing in brain regions of sporadic AD patients. 
 
6.2.2 CELF proteins expression in human brain 
 
All members of the CELF proteins family are expressed at RNA level in the 
human brain (Ladd et al., 2001; Ladd et al., 2004). Our findings confirm this by 
showing the expression of CELF1, CELF3 and CELF4 at RNA level in normal 
human brain. Some CELF proteins are involved in the regulation of tau splicing 
including CELF3 and CELF4 in vitro (Chapple et al., 2007; Dhaenens et al., 
2011; Wang et al., 2004). The 3B1 antibody detects several members of the CELF 
family of proteins in cell lines, rat brain and human brain at the same size of 50 
kDa. Hence, to determine specific members of the CELF family at protein level, 
in normal human brain, specific antibodies for each CELF protein will be required 
which are not readily available at present. The ability of CELF protein antibodies, 
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originally raised against one specific family member (CELF1), to identify 
multiple CELF proteins, is due to the sequence homology that exists between 
CELF proteins. Although there is not much similarity between CELF family 
members in the divergent domain, RRMs are well conserved across the protein 
family especially at RRM3 which is recognised by the 3B1 antibody. 
 
The fact that only a single band is detected in normal human brain may be due to 
the relative expression of different CELF proteins. Consequently, it is difficult to 
ascertain which specific CELF proteins are expressed in the human brain. In 
humans, CELF4 is ubiquitously expressed but enriched in the hippocampus 
relative to the other members of the CELF family including the brain-specific 
CELF3 and CELF5 (Ladd et al., 2001; Ladd et al., 2004).  
 
The expression of individual CELF proteins at the RNA as well as the detection of 
CELF proteins at the protein level in normal human brain allowed us to further 
investigate by RT-qPCR, the RNA levels of specific CELF proteins involved in 
the regulation of tau exon 10 splicing in brain regions of sporadic AD. 
 
6.3 Up-regulation of RNA-binding proteins in AD brain 
 
We used RT-qPCR to investigate the expression levels of members of the SR 
proteins and CELF proteins transcripts in AD brain. Comparisons between the 
expression levels of CELF proteins (CELF1, CELF3 and CELF4) and SR proteins 
(SC35, SRp40 and SRp55) in AD brain regions and controls were made.   
 
The results obtained were independent of postmortem delay of the postmortem 
brain tissue showing no statistical correlation. The quantity and quality of RNA 
produced from each individual subject as well as the regions in AD and normal 
brain was very variable. However, most of the brain samples used had good RNA 
integrity number (RIN) number (≥ 5) and we used more than one house keeping 
gene for data normalisation. After data analysis, three genes (CELF4, SRp40 and 
SRp55) were differentially expressed only in the amygdala of AD brain although 
one gene (CELF3) out of the six genes was differentially expressed in the 
amygdala and frontal cortex of AD irrespective of TDP-43 inclusions. Since the 
   Chapter 6.  
 188 
amygdala is the most prominent region with differential expression, it is possible 
that there is a specific role for RNA-binding proteins in the amygdala that is not 
found in other brain regions.  
 
 
6.3.1 Expression profile of some SR proteins in the amygdala of AD brain  
 
Enhancer elements (such as SC35-like enhancer, PPE and ACE) present within 
tau exon 10 are recognised by SR proteins which promote tau exon inclusion (Fu, 
1995; Stamm et al., 1994). Moreover, SR proteins modulate alternative splicing 
both in vitro and in vivo in a concentration dependent manner (Caceres et al., 
1994; Fischer et al., 2004). Hence, SR proteins are an appealing target in the 
analysis of molecular changes that cause discrepancies in alternative splicing. 
 
Earlier, we described marked changes in tau exon 10 alternative splicing in 
sporadic AD cases with and without TDP-43 inclusions. In the Chapter four we 
focussed our studies on the expression profiles of SR proteins splicing factors, 
including SC35, SRp40 and SRp55 in affected brain regions with known NFT 
pathology in sporadic AD cases. Evaluation of their expression pattern by RT-
qPCR showed that in ADTDP43- brain, there were increased RNA levels of 
SRp40 and SRp55.   
 
One of the aims of this study was to examine the expression pattern of different 
nuclear SR proteins in sporadic AD cases and to compare these with 
physiologically normal human brain. SR proteins are known to be potential 
regulators of several pre-mRNA processing including tau thereby influencing 
their cellular behaviour (Fischer et al., 2004). SC35 RNA, which promotes tau 
exon 10 inclusion through the SC35-like enhancer (Qian et al., 2011b) showed no 
significant difference in expression in all four brain regions affected in AD 
whereas a highly significant increase in the expression of SRp40 and SRp55 RNA 
was seen in the amygdala of ADTDP43- cases. SRp40 promotes tau exon 10 
inclusion in vitro through its binding to an ESE within tau exon 10 (Kondo et al., 
2004; Wang et al., 2005) while SRp55 inhibits tau exon 10 inclusion in vitro 
   Chapter 6.  
 189 
through its activity on an ESS within tau exon 10 (Glatz et al., 2006; Kondo et al., 
2004; Wang et al., 2005).  
 
Consistent with this, we found an increase in 4R/3R tau ratio in the amygdala of 
sporadic ADTDP43- patients that also showed a significant increase in SRp40 
RNA. However, we anticipated that if SR proteins that promote tau exon 10 
inclusion (for instance SRp40) were increased in the amygdala of ADTDP43- 
brain, then SR proteins such as SRp55 which inhibits tau exon 10 inclusion would 
be decreased in the amygdala. However, we did not find this in our study as there 
is no clear correlation of the 4R/3R tau ratio with the increased expression of SR 
proteins in the amygdala or with any pathology. In addition, based on the fact that 
the changes seen in these brain regions show no correlation with the increase in 
4R/3R tau ratios or any pathology, the changes seen may be global. It is not clear 
whether SRp55 inhibits tau exon 10 inclusion in vivo because data obtained from 
minigene studies must be interpreted cautiously since transcripts derived from 
minigenes may not act in the same manner as the full-length pre-mRNA. The 
increased tau exon 10 inclusion in the amygdala of ADTDP43- cases may be a 
consequence of the increased expression of SRp40 and SRp55 either individually 
or combined, by promoting the recognition of exon 10 as well as recruiting other 
splicing factors to tau pre-mRNA during splicing regulation. The fact that SC35 
did not show a marked increase in the amygdala of ADTDP43- brain suggests that 
there are gene-specific alterations as well as brain region-specific alterations 
rather than a non-specific increase of the general RNA processing machinery. 
Interestingly, in ovarian cancer, the expression levels of SRp40 and SRp55 
mRNA remained constant while SC35 mRNA was significantly increased 
(Fischer et al., 2004). Nevertheless, additional studies are required to clarify the 
comprehensive mechanism behind tau splicing regulation. 
 
SR proteins play a vital role during spliceosome assembly and splicing, 
particularly in tau splicing. However, the aberrant increase in these SR proteins 
expressions was specific to the amygdala of ADTDP43- cases which suggests a 
special role for SR proteins within this brain region. It is possible that this is a 
secondary effect due to a general up-regulation of RNA-binding proteins when 
there is an abnormal environment or recruitment from nuclear speckles is initiated 
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but if this were the case, we would expect to see the same effect within other brain 
regions affected in AD. At this point, we can only speculate that changes in the 
abundance of SR proteins may cause abnormal splicing of other pre-mRNA 
transcripts modulated by these specific SR proteins. Since alternative splicing of 
individual pre-mRNA is regulated by a myriad of other splicing (often 
antagonistic) factors; we did not study the expression levels of other mRNAs 
regulated by SRp40 and SRp55 in the amygdala of our cohort AD cases. This 
combined control of splicing factors may explain why we found alterations in tau 
exon 10 splicing in the cerebellum since other splicing factors may modulate tau 
exon 10 inclusion in this brain area.  
 
In addition to the analysis of tau exon 10 splicing in this study, these findings 
support the hypothesis that alterations in the expression of SR proteins splicing 
factors may cause changes in tau exon 10 splicing and contribute to the 
pathogenesis of AD. Furthermore, this may be crucial to the development of tau 
pathology in other sporadic tauopathies as well as AD. It would be essential to 
determine the expression levels of these SR proteins (SRp40 and SRp55) at 
protein level in the amygdala of AD cases to establish whether their expression is 
up-regulated due to amplification of their genes in ADTDP43- cases. 
 
Although we did not find any significant difference in SR protein expression in 
the frontal cortex, temporal cortex and hippocampus of sporadic AD cases when 
compared to age-matched controls, our results provide evidence that SR protein 
expression is altered in ADTDP43- cases and may contribute to the altered tau 
exon 10 splicing observed in sporadic AD cases. Even though we found a 
significant increase in the expression of 4R tau in the cerebellum of AD cases 
irrespective of TDP-43 inclusions, we did not find a significant difference in the 
expression of any SR protein that promotes tau exon 10 inclusion.  
 
Nissim-Rafinia et al. suggested that, during changes to the physiological 
conditions and/or the stage of cell development in normal tissues, differences in 
the levels of alternatively spliced transcripts arise due to modifications in the 
system regulating alternative splicing (Nissim-Rafinia and Kerem, 2002). Specific 
tissues show relative differences in the abundance of splicing factors in vivo. 
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These include SR proteins and hnRNP families which regulate tissue specific 
differences in splicing patterns (Hsu et al., 2011). Indeed, overexpression of 
splicing factors regulates the splicing pattern of alternatively spliced exons. 
Another level of regulation of splicing factors is their subcellular distribution 
which also controls splicing efficiency (Nissim-Rafinia and Kerem, 2002). It 
remains to be determined, whether the subcellular localisation of SR proteins are 
misregulated from nuclear speckles in the nucleus to the cytoplasm during 
aberrant cellular conditions in AD.  
 
Altered tau exon 10 splicing causes a change in expression of tau isoforms (4R 
and 3R tau) in some FTDP-17 cases. Similarly, other disorders such as breast and 
colon cancers show changes in expression of some mRNA transcripts due to 
aberrant alternative splicing mechanism. The CD44 family are surface 
glycoproteins involved in cell migration and cell-matrix interactions (He et al., 
2004). The CD44 gene contains ten alternative exons, alternatively spliced into 
several CD44 isoforms (Nissim-Rafinia and Kerem, 2002). Alternative splicing of 
the CD44 pre-mRNA has been implicated as central in a number of human 
cancers, such as breast cancer (Stickeler et al., 1999). Other cancers that show 
high expression of alternatively spliced CD44 variants include colon and ovarian 
cancers while normal tissues only express standard version of CD44 (Fischer et 
al., 2004; He et al., 2004). The fact that changes in regulation of alternative 
splicing are due to altered SR proteins expression during breast cancer 
development was studied in a mouse model for mammary tumourigenesis. During 
tumourigenesis, there were prominent increases in the levels of CD44 transcripts 
as well as the expression levels of individual SR proteins (Stickeler et al., 1999). 
Only two SR proteins were prominently expressed in normal mature epithelial 
cells SRp75 and SRp55 while SRp40 and SRp30 showed a small increase during 
different stages of tumour development. In contrast, adenocarcinoma cells as well 
as lung and liver metastases, showed high expression levels of SR proteins 
suggesting that aberrant expression of SR proteins was induced during 
tumourigenesis (Stickeler et al., 1999). Furthermore, the multidrug resistance 
protein 1 (MRP1) is highly expressed in the ovarian tumour cells compared to 
matched normal tissues and correlates with increased expression of SRp20 (He et 
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al., 2004). Hence, alternations in splicing regulation play a role as a genetic 




6.3.2 Aberrant expression of CELF proteins in AD brain 
 
Another aim of this study was to examine the expression patterns of different 
CELF proteins in sporadic AD cases and to compare these with physiologically 
normal human brain. CELF proteins are known to be potential regulators of 
several pre-mRNA processing including tau (Ladd et al., 2004). In DM1 patients, 
up-regulation of CELF1 and sequestration of MBNL1 are implicated as the major 
contributors to DM pathogenesis which also possess tau pathology in the brain. 
Hence, CELF proteins, which are modulators of tau alternative splicing, are 
interesting targets in the quest to determine the molecular changes that result in 
aberrant tau splicing in sporadic AD. Several CELF proteins that regulate tau 
exon 10 inclusion in vitro include CELF3 and CELF4 (Chapple et al., 2007; 
Wang et al., 2004). We evaluated their expression by RT-qPCR.  We found that in 
the amygdala and frontal cortex of AD brain (regardless of TDP43 inclusions) 
there were increased RNA levels of CELF3 as well as CELF4 in the amygdala of 
ADTDP43- cases.   
 
6.3.2.1. The expression of CELF4 proteins in the amygdala of AD brain is 
misregulated 
 
The amygdala is primarily responsible for controlling emotions, learning and 
memory particularly reflective emotions such as fear and anxiety. The amygdala 
is one of the brain regions affected during mild to moderate AD and coincides 
with the period of anxiety and depression in AD patients when they are unaware 
of their surroundings and sometimes forget family members. In Chapter three, we 
showed that there was a significant increase in the expression of tau containing 
exon 10 in the amygdala of ADTDP43- cases. Consistent with this, we showed 
that CELF4 was increased in the amygdala (30 %) of ADTDP43- patients. Studies 
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investigating the regulation of tau splicing show the involvement of CELF4 as a 
promoter of tau exon 10 inclusion in vitro (Andreadis, 2005; Ladd et al., 2004; 
Wang et al., 2004). This increase correlates with a possible influence of CELF4 
on tau containing exon 10 in the amygdala. In addition, CELF2 which promotes 
tau exon 2 inclusion in vitro (Leroy et al., 2006) was shown to be decreased in the 
cortical neurons of DM1 patients  together with tau isoforms containing exon 2 
(Sergeant et al., 2001). Hence, it is possible that the increased tau exon 10 
inclusion in the amygdala of ADTDP43- cases is a consequence of the increased 
expression of CELF4 by promoting the recognition of exon 10 and/or recruiting 
other splicing factors to tau pre-mRNA during splicing regulation. 
 
Similar to SC35 RNA, CELF1 RNA showed no significant difference in 
expression in all four brain regions affected in AD whereas we found a significant 
increase in the expression of CELF4 RNA in the amygdala of ADTDP43- cases, 
like SRp40 and SRp55 RNA.  
 
The splicing activity of CELF4 was analysed by deletion analysis to be mediated 
through its divergent domain including its first 66 residues, in the presence of 
RRM1 and RRM2 or RRM2 alone (Singh et al., 2004). For example, in cTNT 
exon 5 alternative splicing, substitution analysis demonstrated that the divergent 
domain of CELF4 alone consists of 20 residues that are necessary and sufficient 
for cTNT exon 5 activation. This proposed that the splicing activity of CELF4 is 
through protein-protein interactions (Han and Cooper, 2005). Although all 
members of the CELF protein family are expressed in the brain, CELF4 showed 
an essential role in neuronal viability in the Frequent flier (Ff) mouse model of 
epilepsy (Yang et al., 2007). However, the increase in CELF4 expression was 
specific to the amygdala of ADTDP43- cases which suggests a special role for 
CELF4 within this brain region. 
 
6.3.2.2. CELF3 is differentially expressed in the frontal cortex and amygdala of 
AD brain  
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The brain-specific CELF protein, CELF3, previously reported to be expressed in 
human brain at RNA (Good et al., 2000; Ladd et al., 2001; Ladd et al., 2004) and 
protein level (Chapple et al., 2007) showed significant increase in RNA 
expression in the amygdala (50 %) and frontal cortex (80 %) of AD brain 
independent of TDP43 inclusions in comparison to normal brain. However, at 
protein level, the 3B1 antibody did not show any change in expression of CELF 
proteins. Although the 3B1 antibody was raised against full length CELF1, it also 
detects other members of the CELF proteins family. We were therefore unable to 
identify individual CELF proteins expressed in the human brain. Hence, 
antibodies specific for each individual CELF protein are required to elucidate the 
particular expression pattern in AD brain. At this point, we cannot conclude 
whether this increase in CELF3 RNA results in increased CELF3 protein 
expression in the amygdala and frontal cortex of AD cases. In contrast, increased 
tau exon 10 skipping correlates with increased CELF2 in DM1 patients (Dhaenens 
et al., 2011). Although we cannot rule out the possibility that abnormalities unique 
to AD independently influence CELF3 and CELF4 expression and tau splicing 
pattern, we propose that the increased levels of CELF3 and CELF4 RNA may 
contribute to altered tau exon 10 splicing observed in the amygdala of ADTDP43- 
patients. 
 
CELF proteins play a vital role in alternative splicing regulation by binding to 
intronic sequences whereas, in the cytoplasm, they mediate their other functions 
in mRNA processing (for example deadenylation, stability and translation) 
through their binding to 5’- and 3’-UTR and are implicated in DM with tau 
pathology (Gallo and Spickett, 2010). Furthermore, in DM1 patients, these 
functions of CELF proteins are altered. For instance, CELF1 is a splicing 
modulator in alternative splicing as well as being involved in translation initiation; 
both of which are altered in DM1 cells in accordance with the changed expression 
of CELF1 in DM1 cells (Savkur et al., 2004). In DM1, CELF1 protein is highly 
expressed in the heart and skeletal muscle (Ladd et al., 2001; Ladd et al., 2004; 
Timchenko et al., 1996). However, DM1 patients also show symptoms that affect 
the brain including impaired cognition (Wheeler, 2008). Hence, the identification 
of differential expression of some CELF proteins involved in tau splicing in 
ADTDP43- cases is consistent with the reports of altered tau splicing in AD brain.  
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Savkur et al. proposed a model where an increased expression of CELF1 causes 
insulin resistance in the skeletal muscle of DM1 patients (Savkur et al., 2001). 
This is due to disruption insulin receptor (IR) pre-mRNA splicing generating a 
non-muscle IR isoforms that lacks exon 11 (IRA) (Savkur et al., 2001). However, 
in brain regions affected in AD patients including the frontal cortex, temporal 
cortex and hippocampus, CELF1 did not show any difference in expression 
relative to normal controls.  
 
Altered expression of CELF3 and CELF4 RNA may cause misregulation of their 
specific pre-mRNA target such as tau exon 10. This could result in increased tau 
exon 10 inclusion in the amygdala of ADTDP43- patients. Moreover, these CELF 
proteins regulate tau exon 10 splicing by binding to intronic sequences around 
exon 10. For instance, CELF1 mediated a switch from the active IRB isoform 
(inclusion of exon 11) to the production of the inactive IRA isoforms (exclusion 
of exon 11) in DM1 muscle cultured cells through specific binding to intronic 
elements in intron 10 (Savkur et al., 2001). Furthermore, it is possible that CELF3 
and CELF4 mediate their splicing activity on tau exon 10 splicing through binding 
to intronic sequences in intron 9 or intron 10 (Chapple et al., 2007; Wang et al., 
2004). It is imperative to determine precisely either through SELEX (systemic 
evolution of ligands by exponential enrichment) or CLIP techniques, how the 
brain-specific CELF3; and CELF4 control tau exon 10 splicing. These CELF 
proteins can modulate tau splicing in two ways; either by directly binding to 
intronic sequences in tau pre-mRNA and/or indirectly modulating its splicing 
activity through interaction with other proteins.  
 
For instance, CELF2 binds preferably to UG and UGUU repeat motifs (Faustino 
and Cooper, 2005) and promotes tau exon 10 skipping when overexpressed 
(Dhaenens et al., 2011) while CELF6 mediates splicing activity without the 
presence of such consensus sequences (Gromak et al., 2003; Ladd et al., 2004). 
Chapple et al. reported the influence of CELF3 on tau exon 10 inclusion in vitro 
mediated through CELF3’s binding to tau pre-mRNA by its RRM2 domain 
(Chapple et al., 2007). In accordance with this, most of the RNA-binding activity 
of CELF2 is credited to its RRM2 shown through mutations at the RNP motif 
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(Good et al., 2000). In addition, the divergent domain (between residues 312 and 
335) of CELF3 is sufficient to promote tau exon 10 inclusion in vitro; described 
through deletion mutant analysis (Chapple et al., 2007). Hence, regulation of tau 
exon 10 splicing may be mediated through interaction with other proteins since 
the divergent domain modulates the splicing activity of different pre-mRNA 
targets.  
 
Our results suggest a specific induction of distinct splicing factors in sporadic AD 
cases. The involvement of CELF3 and CELF4 in alternative splicing may be 
important for regulation of alternatively spliced transcripts of the MAPT with 
potential functional consequences in expression of alternative tau exon 10 and its 
contribution to NFT pathology in sporadic AD and other tauopathies. However, 
we did not obseve any clear correlation of the 4R/3R tau ratio with the increased 
expression of CELF proteins in the amygdale or with any pathology. Furthermore, 
increased activity of these CELF proteins in AD patients may be due to the 
increased expression of CEFL3 and CELF4 in the amygdala. We therefore 
propose that altered expression of splicing factors may be a contributing factor to 
tau pathogenesis in sporadic AD. Whether these CELF proteins are differentially 
expressed at the protein level, in different brain regions affected in sporadic AD is 
unknown. However, at RNA level CELF3 seem to be regulated in specific manner 
especially in the frontal cortex and amygdala where its expression was 
significantly increased regardless of TDP-43 inclusions.  
                       
Another level of regulation of CELF protein activity is through their 
phosphorylation state. Consistent with this, CELF1 is hyperphosphorylated in the 
tissues and cells of DM1 patients by PKC which stabilises it and causes an 
increase in its activity (Kuyumcu-Martinez et al., 2007).  
 
Our data suggest that SR proteins and CELF proteins play a role in pathogenesis 
of AD. Other diseases that show aberrant alternative splicing mechanism include 
ovarian, breast and colon cancer. In a mouse model for mammary tumourigenesis, 
abnormal SR protein expression (increased expression of SRp40 mRNA) was 
observed during tumourigenesis (Stickeler et al., 1999) as well as DM1 where 
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CELF1 and CELF2 protein expression are decreased in the brain (Dhaenens et al., 
2008; Dhaenens et al., 2011).  
 
 
6.4 Correlation of splicing factors expression in AD brain and in vitro studies  
 
An important question outstanding before this study was whether the splicing 
factors that modulate tau exon 10 inclusion in vitro do so in vivo. We showed that 
tau exon 10 inclusion was increased in the amygdala of ADTDP43- cases but 
whether this increase is due to the increase observed in the amygdala of splicing 
factors that modulate tau exon 10 inclusion is unknown. Statistical correlation 
analysis did not show a connection between the increase in expression of SRp40, 
SRp55 CELF3 and CELF4 RNA in ADTDP43- patients and the percentage of 4R 
tau increase in the amygdala of these patients (Figure 6.1, 6.2, 6.3, and 6.4). 
However, it is likely that the aberrant increase in tau exon 10 inclusion is due to 
abnormal splicing factor expression (and/or activity) in the amygdala of these AD 
patients and may contribute to the pathogenesis.  In addition to what was reported 
in the literature, that CELF3, CELF4 and SRp40 promote tau exon 10 inclusion in 
vitro (Table 6.1), we show corresponding increase in the expression of these 
splicing factors in the amygdala of ADTDP43- patients as well as tau exon 10 
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Figure 6.1. Correlation between CELF3 and percentage 4R tau in the 
amygdala of AD brain. 
The brain specific CELF3 protein promotes tau exon 10 inclusion in vitro 
(Chapple et al., 2007); (Wang et al., 2004). We examined the correlation between 
relative CELF3 RNA expression and the percentage of 4R tau expressed in the 
same control and AD cases to determine if there is any link between them. The 
Pearson correlation, r in controls (r = -0.2520), ADTDP43- cases (r = 0.4290) and 
ADTDP43+ cases (r = 0.8821) showed no overall correlation between CELF3 and 



















Figure 6.2. Correlation between CELF4 and percentage 4R tau in the 
amygdala of AD brain. 
CELF4 also promotes exon 10 inclusion in vitro (Dhaenens et al., 2011; Wang et 
al., 2004). To determine if there is any link between CELF4 RNA expression and 
the percentage of 4R tau expressed in the same control and AD cases, we 
examined the correlation between them. The Pearson correlation, r in controls (r = 
0.6062), ADTDP43- cases (r = 0.6852) and ADTDP43+ cases (r = 0.5533) 














Figure 6.3. Correlation between SRp40 and percentage 4R tau in the 
amygdala of AD brain. 
SRp40 promotes tau exon 10 inclusion in vitro by binding to an ESE sequence in 
exon 10 (Kondo et al., 2004; Wang et al., 2004). We therefore examined the 
correlation between relative SRp40 RNA expression and the percentage of 4R tau 
expressed in the same control and AD cases to determine if there is any link 
between them.  The Pearson correlation, r in controls (r = 0.5685), ADTDP43- 
cases (r = 0.7716) and ADTDP43+ cases (r = 0.1106) showed no overall 











Figure 6.4. Correlation between SRp55 and percentage 4R tau in the 
amygdala of AD brain. 
SRp55 inhibits tau exon 10 in vitro by binding to an ESS sequence within exon 10 
(Kondo et al., 2004; Wang et al., 2004). We examined the correlation between 
relative SRp55 RNA expression and the percentage 4R tau expressed in the same 
control and AD cases to determine if there is any link between them.  The Pearson 
correlation, r in controls (r = 0.4011), ADTDP43- cases (r = 0.3844) and 
ADTDP43+ cases (r = 0.8020) showed no overall correlation between SRp55 and 
the percentage of 4R tau expressed. 
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6.5 TDP-43 may modulate expression of splicing factors in AD 
 
The identification of TDP-43 pathology in AD suggests that TDP-43 is not an 
exclusive marker for FTLD-U and ALS (Wilson et al., 2011). 
Immunohistochemical analysis was used to reveal that TDP-43 pathology co-
occurred with some NFTs in AD brain, a subset of coil like structures in CBD and 
Pick bodies observed in PiD (Arai et al., 2006; Rohn, 2008). Approximately 30 % 
of AD cases have TDP-43 pathology and are associated with severe clinical 
symptoms including severe cognitive and functional impairment (Josephs, 2008) 
as well as longer disease duration (Uryu et al., 2008). TDP-43 pathology in these 
AD cases is limited to the limbic system including the hippocampus and amygdala 
as well as the temporal lobe where it is mislocalised from the nucleus to the 
cytoplasm as seen in all TDP-43 proteinopathies (Amador-Ortiz et al., 2007b; Hu 
et al., 2008; Josephs, 2008). Furthermore, immunohistochemical studies show that 
TDP-43 pathology is present in the hippocampus and entorhinal cortex, in a 
minority of normal elderly subjects (Wilson et al., 2011). 
 
The final aim of this thesis was to determine whether TDP-43 pathology in a 
subset of our sample cohort (ADTDP43+) modulates the expression of CELF 
proteins and SR protein family members that show altered expression in AD brain 
without TDP-43 pathology. We found that the altered SR protein expression in 
ADTDP43- cases was absent in ADTDP43+ cases (Table 6.1). SRp40 and SRp55 
both showed prominent increase in expression, in the amygdala of ADTDP43- 
cases, a region with characteristic TDP-43 pathology that also showed increased 
tau exon 10 inclusion. In contrast, in ADTDP43+ cases, the expression of SRp40 
and SRp55 was at similar levels with controls showing no significant difference 
(Table 6.1). Consistent with this, the increased expression of CELF4 in the 
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A possible explanation for this is that TDP-43 may be protective of the increase in 
tau exon 10 inclusion through its suppression of SR proteins that modulate tau 
exon 10 splicing probably through sequestration the splicing factors (that promote 
tau exon 10 inclusion) in its nuclear cluster (for example SRp55). However, the 
presence of TDP-43 inclusions is correlated with sever clinical symptoms in 
ADTDP43+ cases (Josephs et al., 2008). Interestingly, in addition to the increased 
expression of CELF3 in ADTDP43- cases both in the amygdala and frontal 
cortex, we found a slightly more pronounced increased in CELF3 expression in 
ADTDP43+ cases in both brain regions (Table 6.1).  It is yet to be determined 
whether there are any interactions between these splicing factors and TDP-43 
except for SRp55 which was found in a nuclear cluster of TDP-43 interacting 
proteins (Freibaum et al., 2010). 
 
Recently, Polymenidou et al. reported that TDP-43 modulated the expression 
levels of gene transcripts implicated in ALS using adult mouse brain 
(Polymenidou et al., 2011). They demonstrated by CLIP that TDP-43 protein 
directly binds to FUS/TLS mRNA (at the 3’UTR as well as intron 6 and 7) which 
encodes for FUS/TLS mutations that result in ALS. RT-qPCR showed that 
FUS/TLS mRNA and protein levels were significantly decreased by roughly 40 % 
of their normal levels after TDP-43 depletion (Polymenidou et al., 2011). In 
contrast, TDP-43 protein binding to GRN mRNA (encodes for progranulin 
mutations in FTLD) was significantly increased by up to six-fold compared to 
controls (Polymenidou et al., 2011). 
 
Another mRNA associated with TDP-43 is the histone deacetylase 6 (HDAC6) 
mRNA, whose expression was decreased in the absence of TDP-43 using 
antisense oligonucleotides in mouse brain (Polymenidou et al., 2011). HDAC6 is 
crucial for protein aggregate degradation (Fiesel et al., 2009). HDAC6 has two 
deacetylase domains; a dyenin motor protein domain which transports cargo to the 
autophagic pathway for degradation; and a zinc finger domain that binds to 
polyubiquitin (Kawaguchi et al., 2003). Hence, HDAC6 through its binding to 
poly-ubiquitinated misfolded proteins as well as the dynein motor protein may be 
transported to an aggresome for degradation (Kawaguchi et al., 2003). In 
neurodegeneration, pathological aggregates consist of misfolded proteins such as 
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Aβ, tau and TDP-43. Interestingly, although there are several binding sites for 
TDP-43 in tau pre-mRNA there was no significant difference in tau splicing 
pattern or levels of tau mRNA when TDP-43 was depleted in mouse brain 
(Polymenidou et al., 2011).  
 
Buratti et al. demonstrated that TDP-43 distinctively binds to a (UG)n element 
near the 3’ splice site of CFTR exon 9 to promote its skipping (Buratti and 
Baralle, 2001). In contrast, TDP-43 activates SMN exon 7 inclusion, which 
contributes to SMA pathogenesis (Bose et al., 2008). There are a group of splicing 
factor families such as hnRNP and SR proteins that can either promote or repress 
inclusion of alternative exons (Douglas and Wood, 2011). In addition, members of 
the CELF protein family bind to UG or UGUU intronic elements and mediate 
their splicing activity as either repressors or activators of splicing (Chapple et al., 
2007; Gromak et al., 2003). We therefore propose that TDP-43 promotes or 
represses splicing activity depending on the target or its influence on a splicing 
regulator. For instance, TDP-43 can influence tau exon 10 splicing indirectly by 
binding to another splicing factor such as hnRNP or to an element upstream or 
downstream of exon 10. Indeed, the C-terminus of TDP-43 interacts with 
members of hnRNP protein family, crucial for the formation of an hnRNP 
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6.6 Future work 
 
6.6.1 Expression levels of splicing factor pre-mRNA targets in AD 
 
An important question highlighted from this study is whether the altered 
expression of SR proteins and CELF proteins affects other pre-mRNA targets also 
regulated by the specific members of splicing factor families that show altered 
expression in AD patients. This will elucidate whether the aberrant activity of 
CELF and SR proteins in AD results in altered splicing pattern of their other pre-
mRNA targets. For instance in the temporal cortex of AD patients with aberrant 
tau exon 10 splicing, tra2B1 (htra2β), the SR-related protein which promotes tau 
exon 10 inclusion (Jiang et al., 2003; Kondo et al., 2004) showed alteration in its 
splicing pattern (Glatz et al., 2006).   
 
It is also crucial to determine if the altered expression and/or activity of the 
SRp40, SRp55, CELF3 and CELF4 shown in this study is disrupted in other brain 
regions affected in AD patients such as the transentorhinal and entorhinal cortex 
of AD brain from which tau pathology begins (Braak and Braak, 1992). Because 
AD arise from the transentorhinal cortex we need to compare the splicing pattern 
of tau exon 10 and expression of splicing factors in AD brain with that of normal 
age-matched controls in order to confirm our findings. Also, the role specific SR 
proteins play during tau alternative splicing in vivo should be investigated. In 
addition, it is likely that different human brain regions express different subsets of 
splicing factors.  However, to study the individual SR proteins and CELF 
proteins, it is vital to develop an antibody to recognise the specific splicing 
factors. 
 
6.6.2 Expression levels of SR proteins and CELF proteins in other sporadic 
tauopathies. 
 
Aberrant tau exon 10 splicing has been reported for other tauopathies including 
CBD, PSP and PiD. In CBD and PSP tauopathies, there is increased expression of 
tau containing exon 10 transcripts in the brain. We proposed from this study that 
aberrant tau exon 10 splicing due to altered expression and activity of splicing 
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factors can contribute to AD pathogenesis. Whether these SR proteins and CELF 
proteins expression is altered in these other tauopathies is unknown. It would be 
interesting to determine whether these SR proteins (SRp40) and CELF proteins 
(CELF3 and CELF4) that regulate tau exon 10 splicing have increased expression 
in PSP and CBD. In PiD, there is an increase in the expression of 3R tau, 
however, we do not know whether the expression of CELF proteins and SR 
proteins promoting tau exon 10 splicing are decreased in this tauopathy. Similar to 
how we determined the expression levels of SR proteins and CELF protein 
transcripts in AD brain, we can use RT-qPCR to determine the expression levels 
of the specific splicing factors in the brain compared to normal control 
individuals. 
 
6.6.3 Identification of phosphorylation state of SR proteins and CELF proteins in 
AD brain compared to normal human brain 
 
Analysis of the phosphorylation state of the different splicing factors in AD brain 
can be attempted by mass spectrometry. Immunoprecipitation of specific splicing 
factors can be enriched from human brain using specific SR protein antibody prior 
to mass spectrometry analysis.  For example, protein bands corresponding to AD-
SRp40 (and control-SRp40) from corresponding brain can be excised from 
Coomassie blue-stained gels and subject to mass spectrometric analysis. The 
excised bands will be reduced, alkylated and digested with trypsin or Asp-N and 
the resultant peptides separated by reversed-phase chromatography. 
 
Mass spectral data can then be searched against a database containing all isoforms 
of human SRp40 using the Mascot searching algorithm (Matrix Science). This 
will determine the phosphorylation state of SR proteins which should have higher 
masses compared to their normal molecular weight. A similar analysis was 
reported for PHF-tau form AD brain (Hanger et al., 2007). This would elucidate 
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6.6.4 Splicing factors in tauopathies 
 
This study used gene expression analysis to elucidate the possible level of activity 
of splicing factors/RNA-binding proteins in sporadic AD. The importance of 
accurate alternative splicing of tau during RNA metabolism is well established 
and our results implicate specific members of CELF proteins and SR proteins in 
brain regions affected in AD, particularly, the amygdala and frontal cortex (Table 
6.1). For the first time, we show that aberrant expression of splicing factors in AD 
brain regions may play a role during pathogenesis. We observed an increase in tau 
exon 10 containing transcripts in the amygdala and hippocampus of AD patients 
and consistent with this, found that specific CELF and SR proteins are up-
regulated in these brain regions (Figure 6.5). Given the ability of SR proteins and 
CELF proteins to influence RNA processing events, our results suggest that a 
number of pre-mRNAs may undergo changes in alternative splicing in different 
brain regions of AD pathogenesis. Together with previously performed functional 
analysis of SR proteins and CELF proteins in tau splicing in vitro, these findings 
implicate that the altered expression profile of SRp40, SRp55, CELF3 and CELF4 
might be responsible for changes in tau alternative splicing in sporadic AD 
(Figure 6.5).  These splicing factors can thus be therapeutic targets to correct 
abnormal tau exon 10 splicing. Future investigation into the relationship among 
specific members of the CELF and SR protein families and their roles during tau 
splicing in vivo is essential. Also, the level of activity of these CELF and SR 
protein families in different brain regions especially in AD brain will provide 
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Figure 6.5.  SRp40, SRp55, CELF3 and CELF4 misregulation may cause tau 
pathology in AD brain. 
Members of SR protein and CELF protein families; SRp40, SRp55, CELF3 and 
CELF4 are modulators of tau exon 10 inclusion in vitro. Their altered expression 
in brain regions affected in AD may lead to an increase in tau exon 10 inclusion 
due to increased activity. Hence, misregulation of target pre-mRNA including tau 
causing mis-regulation of tau transcripts and contribute to NFT pathology with 
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Pathological information for AD cases 
Case Pathology 
A249/07 Braak stage 
VI with amyloid 
angiopathy  
FC This region showed numerous neuropil threads, 
many neurofibrillary tangles and frequent neuritic 
plaques. Also, there were numerous amyloid 
plaques. 
TC The middle temporal gyrus shows moderate 
neuronal loss with superficial spongiosus. Frequent 
neuritic plaques are demonstrated by Tau and 
Bielschowsky in the middle temporal gyrus. TDP-
43 shows no specific MND-type inclusions. 
A The amygdala showed severely affected by neuronal 
loss. 
H The hippocampus shows of pyramidal neurones 
with many ghost tangles in CA1 segment, 
amounting to hippocampal sclerosis. Tau shows 
numerous neuropil threads and many neurofibrillary 
tangles in the hippocampus 
C No pathological information available 
A205/07 
Braak stage VI with 
amyloid angiopathy 
and  additional TDP-
43 positive 
 
FC Sections of the frontal lobe show large numbers of 
neuritic plaques, neurofibrillary tangles and neuropil 
threads. The Aβ immunohistochemistry reveals 
extensive deposition mainly in the form of cored 
and diffuse plaques. TDP-43 does reveal very 
occasional neuronal inclusions within the frontal 
neocortex 
TC There is extensive tau deposition in the form of 
tangles and plaques and neuropil threads within the 
cortex. The Aβ again shows extensive deposition in 
the form of cored and diffuse plaques and amyloid 
angiopathy. 
A Sections from the amygdala show large numbers of 
tangles and neuropil threads in tau 
immunohistochemistry.Aβ immunohistochemistry 
showed large numbers of plaques within the 
amygdala. The amygdala also contains very mild, 
occasional neuropil threads. TDP-43 inclusions 
predominantly neuronal cytoplasmic inclusions. 
H Presence of large numbers of neuritic plaques in the 
hippocampus associated with neuropil threads and 
neurofibrillary tangles. Also, extensive Aβ 
deposition in the form of cored and diffuse plaques. 
A number of cytoplasmic TDP-43 inclusions are 
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also persent. 
C Tau is negative. The Aβ does reveal some plaques 
mainly in the molecular layer. There are occasional 
inclusions within the molecular layer, which appear 
mainly to be neuropil thread-like structures as well 
as occasional dystrophic neurites extending from the 
Purkinje cell layer. 
A349/08 
Braak stage VI with 
amyloid angiopathy 
and limbic TDP43 
pathology 
 
FC The tau immunohistochemistry in this region 
showed high density of neuropil threads with 
neurofibrillary tangles and dystrophic neurites and 
scattered neuritic plaques. The Aβ, showed a high 
density of plaques which were predominantly 
diffuse. Also, a number of cored plaques were seen 
within the cortex. 
TC The temporal neocortex showed moderate density of 
neuropil threads and moderate numbers of 
neurofibrillary tangles with mild to moderate 
numbers of plaques in the middle temporal gyrus. 
The superior temporal gyrus contains occasional 
neuropil threads and tangles. 
A Sections from the amygdala showed scattered 
neuritic plaques. Tau immunohistochemistry 
highlights large numbers of neurofibrillary tangles 
and a high density of neuropil threads and scattered 
neuritic plaques. 
The TDP43 reveals positivity in a number of 
neurones in the form of neuronal cytoplasmic 
inclusions, some being tangle-like, and some being 
more crescent-like. There are a number of neuropil 
threads identified also.  
 
H Marked neuronal loss. Large numbers of 
neurofibrillary tangles and high density of neuropil 
threads. Moderate to large numbers of neuritic 
plaques. The Aβ reveals large numbers of cored and 
diffuse plaques in the hippocampus 
C No pathology 
 
A348/07 Braak IV 
with focal amyloid 
angiopathy 
FC Sections from the frontal lobe reveal no neuritic 
plaques but very occasional  neurofibrillary tangles 
The TDP-43 is negative. The Aβ reveals a number 
of cored and diffuse plaques in the cortex. 
 
TC Sections from the temporal neocortex show only 
very occasional neurofibrillary tangles and No 
neuritic plaques are seen. The Aβ reveals deposition 
in the form of cored and diffuse plaques within the 
cortex. 
A Sections from the amygdala do show large numbers 
of neuritic plaques and neurofibrillary tangles and 
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neuropil threads and occasional grain-like 
structures. 
H Tau immunohistochemistry reveals a number of 
neurofibrillary tangles within the pyramidal cell 
layer. There is a moderate density of neuropil 
threads. The TDP-43 reveals very occasional 
cytoplasmic neuronal inclusions and the neurites. 
C TDP-43 and tau are negative. Sections from the 
cerebellum show good preservation of the Purkinje 
cell layer. 






FC Tau reveals many tangles, threads, and dystrophic 
neurites. A4 for β-amyloid shows severe cortical 
capillary amyloid angiopathy; high numbers of 
diffuse plaques and up to frequent neuritic plaques. 
TC Occasional cytoplasmic TDP-43 inclusions are 
noted in the cortical neurones. 
A There is significant neuronal loss in the amygdala. 
Tau reveals high density of neuropil threads, tangles 
and also scattered neuritic plaques 
There are numerous TDP-43 positive neuronal 
cytoplasmic inclusions in the amygdala and adjacent 
limbic areas.  
H There is severe tau pathology with high density of 
neuropil threads, dystrophic neurites and tangles. 
TDP-43 few inclusions are noted 
C No significant pathologies are noted. 
A037/04 
Braak stage IV 
FC There are frequent neuritic plaques in the cortex and 
large amounts of A4 protein deposits. Only a few 
neurofibrillary tangles are seen. 
 TC There are frequent neuritic plaques and neuropil 
threads and a large number of primitive plaques in 
the cortex. A few tangles are also seen. 
 A No pathological information available 
 H There are a few neuritic plaques and many 
neurofibrillary tangles in the pyramidal cell layer. 
Granulo-vascular degeneration and neuropil threads 
are also present. 
 C There is mild to moderate loss of Purkinje cells and 
increased cellularity of the molecular layer. 
A039/02 
Braak stage IV 
FC The frontal cortex shows some superficial 
spongiform change.  There are large numbers of 
neuritic plaques and neurofibrillary tangles present.  
 
TC The temporal neocortex contains large numbers of 
neurofibrillary tangles and there are also focally 
large numbers of neuritic plaques. 
 
A No pathological information available 
H Sections from the hippocampus show neuronal loss, 
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most notably in the pyramidal cell layer, CA1.  
There are very large numbers of neurofibrillary 
tangles present within the hippocampus.  There are 
moderate numbers of neuritic plaques and large 
numbers of dystrophic neurites present.   
C Sections from the cerebellum show a well-preserved 
Purkinje cell layer.  No abnormality is seen. 
A331/07 
Braak stage V with 
mild amyloid 
angiopathy.   
FC This region showed numerous neuropil threads and 
neurofibrillary tangles and neuritic plaques as well 
as numerous amyloid plaques. 
TC The neuronal loss in this region was mild in the 
middle temporal gyrus and showed moderate 
neuritic plaques. 
A The amygdala showed prominent neuronal loss with 
spongiosus. 
H The hippocampus also showed prominent neuronal 
loss with spongiosus and numerous amyloid plaques 
C No pathological information available 
 
A098/04  
Braak stage VI with 
mild amyloid 
angiopathy 
FC There is mild neuronal loss in the cortex. Tau 
demonstrates moderate to numerous neurofibrillary 
tangles and neuropil threads with moderate numbers 
of neuritic plaques. 
TC numerous amyloid plaques are present, both diffuse 
and mature types, in the rest of the temporal cortex. 
There are numerous neurofibrillary tangles and 
neuropil threads with moderate to frequent neuritic 
plaques. 
A No pathological information available 
 
H There is mild to moderate neuronal loss in the 
hippocampus with some ghost tangles. Also, there 
were many amyloid plaques in the hippocampus.  
C No pathological information available 
 
A191/07 
Braak stage VI. No 
amyloid angiopathy 
was identified. 
FC There are large numbers of neuritic plaques and 
neurofibrillary tangles. There was extensive 
deposition of cored and diffused plaques.  
 
TC The temporal neocortex reveals large numbers of 
neuritic plaques and neurofibrillary tangles 
There is also a high density of neuropil threads 
within the cortex of these regions. The Aβ reveals 
extensive deposition of the protein in the form of 
cored and diffuse plaques. There is no evidence of 
amyloid angiopathy. 
A Sections from the amygdala reveal large numbers of 
neurofibrillary tangles and a high density of 
neuropil threads identified. Large numbers of 
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neuritic plaques are also seen. The Aβ reveals 
extensive deposition mainly in the form of diffuse 
plaques but also a number of cored plaques are 
present. 
 
H There are moderate numbers of neurofibrillary 
tangles and neuritic plaques within the 
hippocampus. Also there were large numbers of 
neuropil threads and extensive deposition of the 
protein in the form of cored plaques and diffuse 
plaques. 
C No pathological information available 
A192/07 




FC In the middle frontal cortex there is severe neuronal 
loss with superficial spongiosis. Numerous tau 
positive tangles and threads are noted as well as 
high density of plaques many of which were 
‘mature’ neuritic. Diffuse plaques were also 
numerous.  
TC There is severe amyloid angiopathy in the temporal 
lobe sections. There are distended perivascular 
spaces around parenchymalblood vessels, 
predominantly in the white matter. There is patchy 
pallor of the white matter. TDP-43 reveals diffuse 
cytoplasmic staining in neurons. 
A In the amygdala severe pathology is seen in forms 
of numerous threads, tangles and plaques. 
H The hippocampus is atrophic with severe neuronal 
loss in the CA1, CA3 and 4 segments. Tangles, 
ghost tangles were numerous and few plaques were 
seen. 
C No pathological information available 
A210/05 




FC Neurofibrillary tangles were numerous both in the 
superficial and deeper cortical layers. Neuropil 
threads and tau-positive dystrophic neurites 
contributing to plaque formation were also frequent. 
TC Moderate neuronal loss with superficial spongiosis. 
Also, there were a high number of plaques and 
tangles. 
A The amygdala contained numerous tau-positive 
tangles as well as moderate amyloid angiopathy. 
H In the hippocampus, there were numerous tangles 
and moderate numbers plaques in the posterior part 
of the hippocampus. 
C Mild, patchy Purkinje cell loss is noted. The dentate 
nucleus is well populated by neurones. Tau is 
immuno-negative. 
A240/06 
Braak stage V with 
mild amyloid 
angiopathy 
FC Sections from the frontal lobe showed scattered 
moderate numbers of neuritic plaques and 
occasional neurofibrillary tangles and neuropil 
threads. Extensive deposition of diffuse and cored 
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 plaques. 
TC The temporal neocortex showed some superficial 
spongiform change. There were scattered neuritic 
plaques and large numbers of neurofibrillary tangles 
and neuropil threads. Extensive deposition of 
amyloid plaques and diffuse plaques. 
A Tau-positive tangleswere evident. 
H Sections from the hippocampus showed evidence of 
loss of neurons within the pyramidal cell layer.  
Within the hippocampus there were large numbers 
of neurofibrillary tangles and neuropil threads as 
well as occasional neuritic plaques. Moderate 
deposition of amyloid plaques within the 
hippocampus. 
C No pathological information available 
A141/07 
Braak stage VI with 
amyloid angiopathy 
 
FC There was moderate neuronal loss as well as high 
numbers of tau positive tangles and threads. Also, 
there were numerous and many amyloid plaques. 
TC Severe neuronal loss was seen, with superficial 
spongiosis. Numerous neurofibrillary tangles and 
neuropil threads as well as high numbers of plaques 
many of them were neuritic. 
A Severe pathology was seen in the amygdala in forms 
of numerous threads, tangles and plaques. 
H Tangles, ghost tangles were numerous with 
occasional plaques. 
C No pathological information available 
A050/04 
Braak stage V 
FC There were a few plaques in the cortex but a large 
number of neurofibrillary tangles and neuropil 
threads were seen. 
TC There were frequent neuritic plaques, tangles and 
neuropil threads as well as evidence of amyloid 
angiopathy. Also, loss of neurones. 
A No pathological information available 
H There is loss of neurones in CA1 region and 
subiculum. There are many tangles and plaques in 
all layers of the hippocampus 
C No pathological information available 
A058/07 
Braak stage VI 
FC Sections from the frontal lobe reveal large numbers 
of neuritic plaques and neurofibrillary tangles 
within the cortex. Confirmed large numbers of 
cored and diffuse plaques and amyloid angiopathy, 
both within the cortical vessels and leptomeningeal 
vessels. The amyloid angiopathy was very 
extensive. 
TC Large numbers of neuritic plaques and 
neurofibrillary tangles were observed. There was 
also a high density of neuropil threads within the 
cortex. There was extensive deposition of the Aβ 
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within the cortex in the form of cored and diffuse 
plaques. There was also amyloid angiopathy  
 
A The sections of the amygdala show focally large 
numbers of neuritic plaques and neurofibrillary 
tangles and a very dense collection of neuropil 
threads. 
H Sections from the hippocampus reveal some mild 
loss of neurons in the pyramidal cell layer.  
There were large numbers of neuritic plaques and 
neurofibrillary tangles, very high density of neuropil 
threads/dystrophic neurites. Also, there were large 
numbers of cored and diffuse plaques and evidence 
of amyloid angiopathy. 
C Sections from the cerebellum showed good 
preservation of the Purkinje cell layer. No other 
abnormality was seen. 
A160/06 
Braak stage VI 
FC Moderate numbers of neuritic plaques and 
numerous neurofibrillary tangles and neuropil 
threads were observed. 
TC There were numerous tau-positive neurofibrillary 
tangles and neuropil threads and numerous amyloid 
plaques. 
A In the amygdala, there was mild neuronal loss with 
moderate neurofibrillary tangles, frequent neuritic 
plaques and neuropil threads. 
H The hippocampus showed prominent loss of 
pyramidal neurones, with many ghost tangles. Also, 
numerous neurofibrillary tangles and frequent senile 
plaques were demonstrated. A4 demonstrates 
numerous amyloid plaques and mild amyloid  
angiopathy.   
C There was mild Purkinje cell loss 
A187/07 
Braak stage V 
with mild amyloid 
angiopathy 
 
FC Moderate neuropil threads, sparse neurofibrillary 
tangles and neuritic plaques were observed. 
numerous amyloid plaques, mainly of diffuse type, 
TC Moderate to frequent neuritic plaques were noted 
A Numerous neuropil threads and many 
neurofibrillary tangles were observed. 
H The hippocampus showed mild loss of pyramidal 
cells, numerous neuropil threads and many 
neurofibrillary tangles as well as numerous amyloid 
plaques. Also, numerous diffuse and moderate cored 
plaques were observed. 
C There was an old cystic infarct in the cerebellar 
cortex. 
A122/04 
Braak stage V 
with moderate 
FC Moderate numbers of neurofibrillary tangles and 
neuropil threads with only occasional neuritic 
plaques were observed. There was also some Tau 




positive astrocytes in places. 
TC The temporal cortex showed moderate amyloid 
angiopathy, numerous tau-positive neurofibrillary 
tangles and neuropil threads. 
A Neurofibrillary tangles and neuropil threads were 
moderately frequent. 
H There was moderate loss of pyramidal neurons in 
the hippocampus as well as neurofibrillary tangles 
and numerous amyloid plaques, mainly of diffuse 
type. 
C There was mild Purkinje cell loss.  
A065/04 




FC Numerous neurofibrillary tangles, including some 
ghost tangles and neurophil threads, were seen in 
the frontal cortex. 
TC There were numerous amyloid plaques, both diffuse 
and mature type; numerous neurofibrillary tangles 
and neurophil threads and also frequent neuritic 
plaques in temporal lobe areas. 
A The amygdala showed frequent neurofibrillary 
tangles. 
H There was mild to moderate loss of pyramidal 
neurons of the hippocampus. Neurofibrillary and 
ghost tangles and some amyloid plaques were 
obvious. 
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